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Chapter 1
General introduction and aims and outline of this 
thesis
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CANCER, CANCER SURvIvAL, AND LONG-TERM CONSEQUENCES OF CANCER 
SURvIvAL
Cancer: an important public health concern
Cancer is one of the most important public health concerns of today. In 2012, worldwide, 
approximately 14.1 million individuals were diagnosed with cancer, and approximately 
32.6 million people lived with cancer.1 Cancer affects both children and adults. Approxi-
mately 1% of all cancers occur in children.2 Leukaemia, brain cancer, and lymphoma are 
the most common malignancies in children.3 Adults predominantly present with lung 
cancer, breast cancer, and colorectal cancer (Figure 1.1).4 In children, solid tumours are 
typically derived from embryonal tissues (i.e. blastomas); adults predominantly manifest 
solid tumours from epithelial tissues (i.e. carcinomas).5 Cancer development depends 
on several factors, including host factors (e.g. genetics, epigenetics, aging), lifestyle 
factors (e.g. tobacco use, alcohol consumption, unhealthy diet, physical inactivity), 
environmental factors (e.g. asbestos, pesticides, air pollution), and infectious agents 
(e.g. Helicobacter pylori, Epstein-Barr virus, human papillomavirus, hepatitis B and C).6 
In 2012, approximately 8.2 million individuals died from cancer worldwide.1 Globally, 
cancer is the fifth leading cause of death in children and the second leading cause of 
death in adults.7
Cancer survival and long-term consequences of cancer survival
During the past decades, cancer mortality has declined substantially in both children 
and adults (Figure 1.2).8 This is due to several factors, including primary and secondary 
prevention efforts (e.g. tobacco discouragement policies, cancer screening practices), 
as well as improvements in cancer treatment and care (e.g. multi-agent chemotherapy, 
combined-modality treatment, enhanced treatment stratification, advances in support-
ive care).9-12 The decrease in cancer mortality is accompanied by an increase in long-term 
cancer survival.13-16 To date, in Europe, approximately 78% of children and 58% of adults 
survive at least five years after cancer diagnosis.14, 15 Accordingly, awareness of and 
insight in long-term health effects of cancer and its treatment have become increasingly 
important.17-22 Most knowledge on long-term complications of cancer and its treatment 
has been gained from studies in survivors of childhood, adolescent, and young adult 
cancer. Reports on late effects in older adults with cancer are limited.
Studies on the health status of survivors of childhood cancer report a high prevalence 
of chronic health conditions. At an attained age of 45 years, approximately 95% of child-
hood cancer survivors suffer from at least one chronic health condition; in approximately 
80%, this concerns a serious/disabling or life-threatening condition.23 Chronic health 
conditions are significantly more common in childhood cancer survivors compared 
to control subjects not treated for cancer. A recent report from the Childhood Cancer 
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Figure 1.1. Global cancer incidence
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Survivor Study found survivors of childhood cancer to be four times more likely to be 
diagnosed with a severe, disabling, life-threatening, or fatal health condition compared 
to their siblings.24 Studies in survivors of adult cancer report a health status more or less 
similar to control subjects not treated for cancer.25-27 This seems to be due to a coincident 
high prevalence of chronic health conditions in elderly individuals not treated for cancer, 
as well as to a survivorship bias in cancer survivors participating in the available studies. 
Smith et al. reported that at an attained age of 75 years, approximately 85% of adult 
cancer survivors compared to 84% of non-cancer control subjects suffer from at least 
one chronic health condition.28 However, some specific chronic health conditions, like 
cardiovascular disease, type 2 diabetes mellitus, and osteoporosis occur significantly 
more often in survivors of adult cancer compared to elderly individuals not treated for 
cancer.28-31
Both survivors of childhood and adult cancer are at increased risk for premature mor-
tality.32-38 In childhood cancer survivors, excessive mortality is mainly due to secondary 
malignancies, as well as circulatory and respiratory diseases.32, 33 Adult cancer survivors 
mainly die from secondary malignancies, digestive diseases, and suicide.34-38
Long-term endocrine and metabolic consequences of cancer and its treatment
Endocrine and metabolic conditions are among the most frequent long-term sequelae 
of both childhood and adult cancer (Figure 1.3). At an attained age of 35 years, approxi-
mately 60% of childhood cancer survivors are diagnosed with an endocrine condition.23 
In adult cancer survivors, nearly 85% suffers from an endocrine morbidity by the age of 60 
years.31 Hypopituitarism, gonadal dysfunction, and hypothyroidism have been reported to 
be the most frequent endocrinopathies in childhood cancer survivors;39 adult cancer sur-
Figure 1.2. Cancer mortality in the Netherlands (1950-2013)
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Figure 1.3. Endocrine conditions in cancer survivors
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vivors predominantly present gonadal dysfunction, type 2 diabetes mellitus, and thyroid 
nodules.31 In childhood cancer survivors, the highest risks for endocrine disorders have 
been reported in patients treated for brain cancer, leukaemia, Hodgkin lymphoma, non-
Hodgkin lymphoma, and neuroblastoma.39 In adult cancer survivors, most studies focused 
on patients treated for breast cancer, prostate cancer, testicular cancer, lymphoma, and 
brain cancer.40 The increased risk for endocrine conditions in cancer survivors is related to 
administered treatment modalities, like radiotherapy and chemotherapy (Table 1.1).41, 42
Among the most important long-term health effects in cancer survivors are subsequent 
neoplasms. After 30 years of follow-up since primary cancer diagnosis, approximately 
21% of childhood cancer survivors and 19% of adult cancer survivors are diagnosed 
with a second tumour.43 Endocrine-related cancers, including tumours of the breast and 
thyroid, are among the most frequent secondary neoplasms.16, 44
Many endocrine conditions adversely affect metabolism. Accordingly, several studies 
investigated metabolic risk factors in cancer survivors.45, 46 In both childhood and adult 
cancer survivors an increased incidence of obesity, insulin resistance, dyslipidaemia, 
and elevated blood pressure has been reported.47-50 The clustering of these related risk 
factors is referred to as the metabolic syndrome.51 The metabolic syndrome has been 
reported in 6-39% and 8-49% of childhood and adult cancer survivors, respectively.48-50 
The metabolic syndrome has been associated with a two-fold increased risk for cardio- 
and cerebrovascular disease, as well as a five-fold increased risk for type 2 diabetes 
mellitus.52 An unhealthy lifestyle with insufficient physical activity has been proposed as 
an important risk factor for the metabolic syndrome.53, 54 To date, several reports evalu-
ated physical activity in cancer survivors.55, 56 However, most were limited by the use of 
a non-validated questionnaire that did not assess daily life physical activity. In addition, 
many lacked comparison to a non-cancer control group.
With more than 32.5 million long-term cancer survivors worldwide,57 the study and 
follow-up care of this patient population is crucial. Most studies that investigated long-
term consequences of cancer and its treatment focused on individuals with a malignant 
tumour. However, some benign neoplasms may also cause substantial long-term health 
effects. This is not only because of a destructive tumour behaviour, but also due to a 
critical localization and need for local aggressive therapy. An important example is 
craniopharyngioma.
CRANIOPHARYNGIOMA
Background and epidemiology
Craniopharyngiomas are benign intracranial tumours that often contain calcifications 
and fluid-filled cysts. From a treatment perspective, their locally aggressive behaviour 
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Table 1.1. Treatment-related risk factors for endocrine and metabolic disorders in cancer survivors
Organ system Morbidity Treatment-related risk factors
Hypothalamic-pituitary Hypopituitarism (GH, FSH/LH, ACTH, 
TSH, ADH deficiency)
Cranial radiotherapy
Total body irradiation
Neurosurgery
Hyperprolactinemia Cranial radiotherapy
Growth failure Antimetabolites
Glucocorticoids
Cranial radiotherapy
Precocious puberty Cranial radiotherapy
Delayed puberty Cranial radiotherapy
Pelvic radiotherapy
Glucocorticoids
Thyroid Primary hypothyroidism Neck, mantle, spine radiotherapy
Total body irradiation
Primary hyperthyroidism Neck, mantle, spine radiotherapy
Thyroid nodules and secondary 
neoplasms
Neck, mantle, spine radiotherapy
Anthracyclines
Breast Secondary neoplasms Neck, mantle, chest, abdominal radiotherapy
Total body irradiation
Anthracyclines
Gonad Acute ovarian failure and premature 
ovarian insufficiency
Alkylating agents
Pelvic radiotherapy
Total body irradiation
Oestrogen deprivation
Leydig and germ cell dysfunction Alkylating agents
Pelvic radiotherapy
Total body irradiation
Androgen deprivation therapy
Bone Osteoporosis Glucocorticoids
Antimetabolites
Aromatase inhibitors
Tamoxifen (premenopausal women only)
Androgen deprivation therapy
Metabolism Obesity Cranial radiotherapy
Glucocorticoids
Oestrogen deprivation
Androgen deprivation therapy
Metabolic syndrome and type 2 
diabetes mellitus
Cranial radiotherapy
Abdominal radiotherapy
Total body irradiation
Glucocorticoids
Oestrogen deprivation
Androgen deprivation therapy
ACTH = adrenocorticotropic hormone; ADH = antidiuretic hormone; FSH/LH = follicle stimulating hor-
mone/luteinizing hormone; GH = growth hormone; TSH = thyroid stimulating hormone. Data from Rose 
et al.41 and Shahrokni et al.42
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and proximity to critical neurovascular structures (e.g. hypothalamus, pituitary, optic 
nerves, carotid arteries) make them challenging tumours (Figure 1.4A).58 Craniopharyn-
giomas were already described in 1857 by Von Zenker.59 In 1904, Erdheim was the first to 
describe their histopathological features.60 Halstead performed the first craniopharyn-
gioma resection in 1909.61 Of note, this was a transsphenoidal resection. In 1910, the first 
transcranial resection was performed by Lewis.62 At that time, different terminologies 
were used to describe these tumours. In 1931, Frazier named them craniopharyngio-
mas,63 which was further popularized by Cushing in 1932.64
Craniopharyngiomas are rare with an estimated incidence rate of 1.34 per million 
person-years. They affect children and adults, and present with peak incidences between 
5-9 and 40-44 years of age.65 Craniopharyngiomas account for 3% of all intracranial 
tumours in children and 0.6% of all intracranial neoplasms adults.66 Approximately 30% 
of all craniopharyngiomas present in children.67
Location, pathology, and pathogenesis
Craniopharyngiomas arise from remnants of the craniopharyngeal duct, which is an 
embryonic structure formed during pituitary development (Figure 1.4B).68 Most cranio-
pharyngiomas have a suprasellar origin with an intrasellar extension (75%); some re-
main suprasellar (20%). Entirely intrasellar craniopharyngiomas are less common (5%).69 
There are two histological subtypes of craniopharyngioma (i.e. adamantinomatous and 
papillary) (Figure 1.5). The adamantinomatous subtype contains calcifications and cysts 
filled with a cholesterol-rich machinery oil-like fluid. The papillary subtype is solid or 
unicystic without calcifications.70 Approximately all craniopharyngiomas in children are 
adamantinomatous. In adults, papillary craniopharyngiomas are more frequent (65%).71
The pathogenesis of craniopharyngiomas remains poorly understood. There are 
two theories on their development. The first is the embryogenetic theory, which sug-
gests that craniopharyngiomas arise from mutated cell rests of the (in those cases) 
not entirely involuted craniopharyngeal duct.72 The second is the metaplastic theory, 
which implies that craniopharyngiomas develop from metaplastic cells of the anterior 
pituitary.73 Over the past years, significant progress has been made in understanding 
the genetic mechanisms underlying craniopharyngioma development. In the adaman-
tinomatous subtype, activating somatic mutations in CTNNB1 have been found, which 
result in β-catenin-accumulating cell clusters with over-activation of the Wnt/β-catenin 
pathway.74 Recently, Andoniadou et al. demonstrated that these cell clusters promote 
craniopharyngioma tumorigenesis by autocrine and paracrine mechanisms.75 In the 
papillary subtype, BRAF p.V600E mutations have been reported.76 Four families with 
multiple craniopharyngioma cases have been reported.77-80 However, an underlying 
genetic predisposition has never been verified.
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Figure 1.4. Neuroanatomy and pituitary development
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Presenting symptoms and imaging modalities
In children, craniopharyngiomas often present with growth failure, headaches, and vi-
sual impairment. In adults, the most common presenting features are hypogonadotropic 
hypogonadism, growth hormone deficiency, and visual field defects (Table 1.2).81-83 
In both children and adults, the duration from symptom onset to craniopharyngioma 
diagnosis has been reported to be approximately 12 months.81 However, Müller et al. 
observed that most children with craniopharyngioma already show a reduced growth 
rate 7.5 years before diagnosis. In their study, concomitant weight gain was a late mani-
festation.84
Magnetic resonance imaging with and without gadolinium contrast enhancement 
and unenhanced computed tomography are the imaging modalities of choice for the 
detection and characterization of craniopharyngiomas. Computed tomography is par-
ticularly important for visualizing calcifications (Figure 1.6).85
Craniopharyngioma treatment
Craniopharyngiomas are generally treated with neurosurgical resection, followed by 
radiotherapy in case of residual or progressive disease. Alternative treatment options 
include primary cyst drainage, intracystic appliance of β-emitting isotopes (e.g. 90Yt-
trium) or chemotherapeutic substances (i.e. bleomycin or interferon-α), and stereotactic 
radiosurgery.86 Neurosurgical resection can be performed either transcranial or trans-
Table 1.2. Manifestations of craniopharyngiomas
Presenting features All patients (%) Children (%) Adults (%)
Headaches 49-64 46-78 50-59
Visual acuity disorder 39-78 39-66 40-83
Visual field defect 55-72 46 60-77
Hydrocephalus 16-25 34-47 7-19
Neurological deficits 3-18 4-34 2-10
Epilepsy 2-4 2-3 3-5
Cognitive impairment 14-23 5-10 17-27
Behaviour changes 8-11 5-10 8-13
Altered level of consciousness 3-6 3-10 3-4
Anorexia or weight loss 10-12 10-20 8-10
Obesity or weight gain 10-15 5-8 13-17
Growth hormone deficiency 52-95 56-100 51-86
Hypogonadotropic hypogonadism 74-82 NA 74-82
Secondary adrenal insufficiency 34-62 40-68 33-58
Secondary hypothyroidism 26-36 25-26 26-42
Diabetes insipidus 14-18 6-22 15-17
NA = not accessible. Data from Karavitaki et al.81, Nielsen et al.82, and Du et al.83
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Figure 1.5. Histological subtypes of craniopharyngioma
A: High magnification micrograph of an adamantinomatous craniopharyngioma (haematoxylin phloxine 
saffron [HPS] stain). Copyright © 2010 Michael Bonert. 
B: High magnification micrograph of a papillary craniopharyngioma (HPS stain). Copyright © 2011 Michael 
Bonert. Both figures can be found at https://commons.wikimedia.org/wiki/User:Nephron and are distribut-
ed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/
by-sa/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium. The 
full text of this license can be found in this thesis at page 200.
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sphenoidal (Figure 1.4C). The transsphenoidal approach is preferred for favourably 
localized, predominantly intrasellar, tumours, but requires an adequate pneumatization 
of the sphenoidal sinus. Otherwise, a transcranial resection may be carried out using 
a pterional, subfrontal, transcallosal, or transcortical-transventricular route.87 In case 
radiotherapy is applied, the total recommended dose is 50-54 Gy, delivered in fractions 
of 1.8-2 Gy.88 Craniopharyngioma treatment aims to provide long-term survival and 
disease control, while preserving quality of life by minimizing tumour- and treatment-
related morbidity.
Although craniopharyngioma treatment is predominantly individualized based on 
tumour and patient characteristics, the preferred treatment strategy varies from centre 
to centre depending on local surgical and radiotherapeutic expertise.87 Some centres 
favour initial gross total resection whereby preserving hypothalamic and optic func-
tions,83, 89-96 while other centres prefer subtotal resection or primary cyst drainage.97-101 
Gross total resection and subtotal resection with radiotherapy result in similar 5-year 
overall and recurrence-free survival rates. Overall and recurrence-free survival rates 
after subtotal resection without radiotherapy have been reported to be lower (Table 
1.3).81, 98, 102
Treatment of recurrent craniopharyngioma is complicated by scarring from preceding 
surgery and radiotherapy, and depends on therapy previously administered.103 The costs 
associated with a hospital admission for craniopharyngioma resection in the United 
States are estimated to be approximately $90 000.104
Figure 1.6. Unenhanced computed tomogra-
phy of a craniopharyngioma
A calcified cystic structure can be seen in the 
suprasellar area, together with hydrocephalus. 
Reproduced from Garnett et al. Orphanet Journal 
of Rare Diseases Vol. 2(18), 2007.160 Copyright © 
2007 BioMed Central Ltd. This figure is distribut-
ed under the terms of the Creative Commons At-
tribution License (https://creativecommons.org/
licenses/by/2.0), which permits unrestricted use, 
distribution, and reproduction in any medium.
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Survival and long-term consequences of craniopharyngioma
Recent studies in patients with craniopharyngioma reported 10-year overall and 
recurrence-free survival rates between 40-95% and 44-76%, respectively.83, 105-111 
Despite these relatively encouraging survival rates, long-term tumour- and treatment-
related health conditions are frequent,83, 101, 106, 108, 110-116 and significantly impair quality of 
life.112, 117-121 Pituitary hormone deficiencies, visual impairment, and obesity are the most 
common long-term health effects (Table 1.4).101, 106, 111-116 In addition, neurocognitive and 
neurobehavioral deficits occur frequently, especially in patients with childhood-onset 
disease.122-127 Moreover, specific late effects due to hypothalamic dysfunction have been 
reported (e.g. absence of thirst, loss of temperature control, sleep-wake disorders).128-135
Although many groups investigated long-term health conditions in patients with 
craniopharyngioma, most focused on patients treated with neurosurgical resection and 
radiotherapy solely.83, 101, 106, 108-112, 114-116 Long-term sequelae of other treatment modali-
ties, like 90Yttrium brachytherapy and primary cyst drainage, remain largely unknown. In 
addition, nearly all available studies have a relatively short follow-up period of less than 
ten years.81, 83, 101, 107, 108, 110, 111, 113, 114 This precludes the assessment of long-term health 
conditions that require a prolonged time to develop (e.g. radiation-induced pituitary 
dysfunction).136 Moreover, only a few reports evaluated long-term health effects in rela-
tion to the age at craniopharyngioma diagnosis (i.e. childhood- vs. adult-onset).81, 112, 115 
These studies reported inconclusive results.
Most studies on long-term tumour- and treatment-related sequelae in patients with 
craniopharyngioma have directly examined long-term health conditions. Alternatively, 
long-term health effects could be evaluated relative to the general population. To date, 
only few such studies have been performed. One study observed excess morbidity due 
to type 2 diabetes mellitus, fracture, infection, cerebral infarction, and visual impair-
ment.108 Six studies reported excess all-cause mortality.108, 137-141 Three of these studies 
also evaluated cause-specific mortality, and observed a significantly increased risk for 
mortality due to circulatory and respiratory diseases.108, 137, 138 Only a minority of these 
studies examined risk factors for excess morbidity and mortality.108, 137, 139
Obesity due to hypothalamic damage is one of the most important long-term health 
conditions in patients with craniopharyngioma. Hypothalamic damage may result in 
acquired leptin and insulin resistance, as well as autonomic nervous system dysfunc-
Table 1.3. Overall and recurrence-free survival after different craniopharyngioma treatment strategies
Treatment strategy 5-year overall survival (%) 5-year recurrence-free survival (%)
Gross total resection 82-100 60-100
Subtotal resection with radiotherapy 85-100 72-82
Subtotal resection without radiotherapy 75-90 25-47
Data from Karavitaki et al.81, Schoenfeld et al.98, and Rao et al.102
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tion, which may altogether adversely affect food intake, metabolism, and energy 
expenditure.142 Other factors, like a familial predisposition for obesity, physical inactiv-
ity, increased daytime sleepiness, and psychological difficulties may also contribute to 
excessive weight gain.117, 143, 144 Obesity develops predominantly during the first twelve 
years after craniopharyngioma treatment.109 In this twelve years, the most significant 
weight gain occurs during the first year.145 Obesity is the main predictor for a worse 
quality of life in patients with craniopharyngioma.112, 117, 118, 120, 121 
As indicated above, obesity is often associated with other metabolic abnormalities, like 
the components of the metabolic syndrome.52 To date, only a few studies investigated the 
metabolic syndrome and its components in patients with craniopharyngioma.139, 146-150 
Small study populations that mainly consisted of children, a lack of comparison to con-
trol data, and the evaluation of only a few risk factors for the metabolic syndrome and 
its components were major limitations of these studies.
Treatment of obesity in patients with craniopharyngioma is difficult. Lifestyle modifi-
cation and pharmacotherapy have only modest effects.142, 151-153 Therefore, bariatric sur-
gery has been proposed.154 However, there are concerns regarding the safety of bariatric 
procedures in this patient population, since drug absorption and bioavailability may be 
affected.155, 156 To date, only a few studies investigated the efficacy of bariatric surgery 
regarding its effects on weight loss in patients with craniopharyngioma.157-159 However, 
none studied weight loss relatively to matched control subjects. In addition, only one 
study evaluated the effects on hormone replacement therapy requirements.159
In Figure 1.7, current knowledge of long-term endocrine and metabolic consequences 
of cancer treatment in patients with craniopharyngioma is summarized.
Table 1.4. Long-term health conditions in patients with craniopharyngioma
Long-term health conditions All patients (%) Children (%) Adults (%)
Visual acuity disorder 49 52 48
Visual field defect 49 52-58 48-64
Obesity 11-43 11-46 15-52
Epilepsy 19 7-25 16
Neurological deficit 2-9 5-18 2-5
Growth hormone deficiency 66-94 66-94 NA
Hypogonadotropic hypogonadism 95 77-97 68-94
Secondary adrenal insufficiency 46-89 59-94 39-90
Secondary hypothyroidism 55-93 47-99 64-92
Diabetes insipidus 62-76 61-89 64-68
Panhypopituitarism 59 57-58 60
NA = not available. Data from Kendall-Taylor et al.112, Sughrue et al.113, Elliott et al.114, Gautier et al.115, Lopez-
Serna et al.106, Yuen et al.116, Tan et al.101, and Shi et al.111
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AIMS AND OUTLINE OF THIS THESIS
The aim of this thesis was to examine long-term endocrine and metabolic conditions, 
as well as their determinants in patients treated for cancer with a special focus on pa-
tients treated for craniopharyngioma. Chapter 1 provides an introduction into cancer, 
cancer survival, and long-term endocrine and metabolic consequences of cancer and 
its treatment, as well as an overview of craniopharyngioma and its associated long-
term health conditions. In Chapter 2, risk factors for subsequent endocrine-related 
cancer in childhood cancer survivors are reviewed. Thereby, there is a special focus on 
secondary neoplasms of the breast and thyroid. Chapter 3 provides a study on daily 
life physical activity in survivors of nephroblastoma and neuroblastoma relative to a 
socio-demographically similar control group not treated for cancer. In Chapter 4, a large 
single-centre cohort of patients treated for craniopharyngioma is studied for long-term 
health conditions. In this chapter, long-term sequelae are evaluated according to the ini-
tial craniopharyngioma treatment strategy, as well as age group at craniopharyngioma 
diagnosis. Chapter 5 provides a study in which morbidity and mortality in patients with 
craniopharyngioma are investigated relative to the general population. To increase the 
strength of this study and to replicate the findings in two study populations, we collabo-
rated with the Sahlgrenska University Hospital in Gothenburg, Sweden. In Chapter 6, 
the metabolic syndrome and its components are studied in a large cohort of Dutch and 
Swedish patients with craniopharyngioma. Chapter 7 provides a matched case-control 
Figure 1.7. Current knowledge of long-term endocrine and metabolic consequences of cancer treatment 
in patients with craniopharyngioma
Craniopharyngioma
Pituitary damage Hypothalamic damage
ObesityHypopituitarism
Excess mortality
(cardio-/cerebrovascular)
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study in which the efficacy and safety of bariatric surgery in patients with craniopharyn-
gioma are investigated relative to control subjects with common obesity. In Chapter 8, 
general discussion and conclusions of this thesis are presented.
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ABSTRACT
Long-term adverse health conditions, including secondary malignant neoplasms, are 
common in childhood cancer survivors. Although mortality attributable to secondary 
malignancies declined over the past decades, the risk for developing a solid second-
ary malignant neoplasm did not. Endocrine-related malignancies are among the most 
common secondary malignant neoplasms observed in childhood cancer survivors. In 
this systematic review, we describe risk factors for secondary malignant neoplasms of 
the breast and thyroid, since these are the most common secondary endocrine-related 
malignancies in childhood cancer survivors. Radiotherapy is the most important risk 
factor for secondary breast and thyroid cancer in childhood cancer survivors. Breast 
cancer risk is especially increased in survivors of Hodgkin lymphoma who received 
moderate- to high-dosed mantle field irradiation. Recent studies also demonstrated an 
increased risk after lower-dosed irradiation in other radiation fields for other childhood 
cancer subtypes. Premature ovarian insufficiency may protect against radiation-induced 
breast cancer. Although evidence is weak, oestrogen-progestin replacement therapy 
does not seem to be associated with an increased breast cancer risk in premature ovar-
ian insufficient childhood cancer survivors. Radiotherapy involving the thyroid gland 
increases the risk for secondary differentiated thyroid carcinoma, as well as benign 
thyroid nodules. Currently available studies on secondary malignant neoplasms in 
childhood cancer survivors are limited by short follow-up durations and assessed prior 
treatment regimens. In addition, studies on risk-modifying effects of environmental and 
lifestyle factors are lacking. Risk-modifying effects of premature ovarian insufficiency 
and oestrogen-progestin replacement therapy on radiation-induced breast cancer 
require further study.
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INTRODUCTION
Childhood cancer survival has increased substantially over the past five decades due to 
advances in therapy, risk-based treatment stratification, and supportive care.1 To date, 
approximately 80% of children and adolescents survive at least five years following a 
diagnosis of childhood cancer,2, 3 and are thereby subsequently considered childhood 
cancer survivors. This percentage is anticipated to grow due to further improvements in 
childhood cancer care,1 and a slow increase in childhood cancer incidence as reported 
by some investigators.4, 5 Accordingly, awareness of and insight in side effects and 
long-term consequences of childhood cancer treatment have become increasingly 
important.6-11 At an attained age of 45 years, approximately 95% of childhood cancer 
survivors suffer from at least one chronic health condition related to their former cancer 
treatment; in approximately 75% this concerns a serious/disabling or life-threatening 
condition.9 Over the past decades, childhood cancer treatment protocols have been 
modified, aiming to reduce the occurrence and severity of long-term treatment-related 
complications. Recently, Armstrong et al. demonstrated that these efforts resulted in 
improved long-term survival.12 
Secondary neoplasms are among the most serious long-term adverse health con-
ditions in childhood cancer survivors, and can be defined as histologically distinct 
tumours developing after primary cancer therapy. They have been estimated to affect 
approximately 21% of childhood cancer survivors after 30 years of follow-up since pri-
mary cancer diagnosis.13 This estimation includes both benign and malignant second-
ary neoplasms. The 30-year cumulative incidence of secondary malignant neoplasms 
solely is approximately 8%, and represents a six-fold increased risk in comparison to 
the general population.13 The increased risk for secondary malignancies in childhood 
cancer survivors seems to persist even after 40 years of follow-up since primary can-
cer diagnosis.14 At an attained survivor’s age of 60 years, the cumulative incidence of 
secondary malignant neoplasms varies between 14-18%.14, 15 The risk for secondary 
malignant neoplasms in older childhood cancer survivors remains unknown. Although 
most secondary malignant neoplasms are diagnosed during the first 10-20 years fol-
lowing childhood cancer treatment,13, 16 they may present within months to decades 
following the completion of former cancer therapy.16 Risk factors for the development 
of secondary malignancies in childhood cancer survivors include host factors, primary 
cancer diagnosis, types and timing of primary cancer treatment, environmental factors, 
and lifestyle factors.17 Secondary malignant neoplasms appear to be an important cause 
of death in childhood cancer survivors. Recent cohort studies demonstrated that 12-19% 
of mortality in individuals who survived at least five years following a diagnosis of child-
hood cancer was attributable to secondary malignancies.18-20 After 25 years of follow-up 
since primary cancer diagnosis, secondary malignant neoplasms even become the most 
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important cause of death in survivors of childhood cancer.18, 20 Although mortality at-
tributable to secondary malignancies in childhood cancer survivors declined over the 
past treatment eras,12 the risk for developing a solid secondary malignant neoplasm did 
not.21 Endocrine-related cancers are among the most common secondary malignan-
cies in childhood cancer survivors.13-15, 22 In the Childhood Cancer Survivor Study they 
represent 40% of the invasive secondary malignant neoplasms observed (Figure 2.1A).13
In this review, we will discuss risk factors for secondary endocrine-related malignant 
neoplasms in childhood cancer survivors. A special focus will be on breast and thyroid 
cancer, since these are the most common secondary endocrine-related malignancies in 
survivors of childhood cancer.13-15
SEARCH STRATEGY
We systematically searched the MEDLINE-database (United States National Library of 
Medicine, Washington, DC) until January 2016 for relevant articles on secondary cancer 
risk in survivors of paediatric malignancies. The keywords “childhood cancer survi-
vors”, “second malignant neoplasms”, “secondary malignant neoplasms”, “subsequent 
neoplasms”, “endocrine cancers”, “breast cancer”, “thyroid cancer”, “risk factors”, “radio-
therapy”, “radiation”, “irradiation”, “chemotherapy”, “stem cell transplantation”, “total body 
irradiation”, “conformal radiotherapy”, “intensity-modulated radiation therapy”, and 
“proton-beam therapy” were used. Only articles written in English were included in the 
review. Reference lists of included articles were checked for additional relevant publica-
tions. In case two or more articles described the same patient cohort, the most recent or 
relevant article was included.
RISk FACTORS FOR SECONDARY MALIGNANT NEOPLASMS IN CHILDHOOD 
CANCER SURvIvORS
In the Childhood Cancer Survivor Study, host-, disease-, and treatment-related risk fac-
tors for the development of secondary neoplasms in childhood cancer survivors have 
been identified.13 The Childhood Cancer Survivor Study is a multi-institutional study 
conducted in the United States and Canada, and involves 14 363 individuals treated for 
cancer < 21 years of age.23 Female gender and older age at initial cancer diagnosis were 
associated with an increased risk for secondary malignant neoplasms after childhood 
cancer (relative risk [RR] 1.4 [95% confidence interval (CI) 1.2-1.6] for females vs. males; 
RR 1.5 [95% CI 1.2-1.9] for age at diagnosis ≥ 15 years vs. 0-4 years).13 The Surveillance, 
Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) of 
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the United States could not demonstrate this sex difference in the risk for secondary 
malignant neoplasms, but found a somewhat higher risk for secondary malignancies in 
black vs. white people (standardized incidence ratio [SIR] 8.9 vs. SIR 5.5; excess absolute 
risk [EAR] 18.4 vs. 15.0 per 10 000 person-years).22 Genetic susceptibility might contrib-
ute to the development of secondary neoplasms in childhood cancer survivors, which is 
illustrated by high-penetrance genetic cancer predisposition syndromes (Table 2.1).24-27 
However, germline mutations in known moderate- to high-penetrance cancer suscepti-
bility genes are only found in 8.5% of paediatric and adolescent cancer patients.28 Data 
from the Swedish general population suggest less pathogenic low-penetrance familial 
cancer predisposition might be more important in the development of malignancies 
than high-penetrance genetic cancer susceptibility genes.29 This is illustrated by 
Friedman et al., who observed an increased cancer risk in siblings of childhood cancer 
survivors in comparison to the general population (SIR 1.5 [95% CI 1.3-1.7]), even after 
exclusion of families with suspected high-penetrance genetic cancer predisposition 
syndromes (SIR 1.3 [95% CI 1.2-1.5]).30 In their study, siblings and offspring of childhood 
cancer survivors who developed a secondary malignant neoplasm were even at higher 
risk of developing cancer in comparison to relatives of childhood cancer survivors who 
did not develop a secondary malignancy (SIR 2.4 [95% CI 1.5-3.7] for siblings; SIR 15.0 
[95% CI 5.3-42.9] for offspring).30
Childhood cancer survivors at highest risk for secondary malignant neoplasms in-
clude survivors of Hodgkin lymphoma, leukaemia, sarcoma, and central nervous system 
malignancies (Figure 2.1B).13, 15, 22 This seems to be related to administered treatment 
modalities. Radiotherapy is the most important risk factor for the development of 
secondary neoplasms.13, 15, 22 Risk for radiation-induced secondary malignant neoplasms 
depends on cumulative radiation dose, radiotherapy fractionation, radiation field, 
radiosensitivity, radiotherapy technique, quality of radiation, and other confounding 
factors.31 Besides radiotherapy, chemotherapeutic agents (i.e. alkylators, anthracyclines, 
and topoisomerase II inhibitors), as well as hematopoietic stem cell transplantation have 
been associated with an increased risk for secondary malignant neoplasms in childhood 
cancer survivors.16, 32, 33
Besides the factors mentioned above, environmental and lifestyle determinants may 
also be important in secondary tumour development.34-36 However, studies specifically 
addressing the risk-modifying effects of these determinants in childhood cancer survi-
vors have to be performed yet.
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Figure 2.1. Distribution of secondary malignant neoplasms and primary cancer diagnoses among child-
hood cancer survivors who developed a secondary neoplasm as observed in the Childhood Cancer Survi-
vor Study by Friedman et al.13
Leukemia (5%)
Lymphoma (3%)
CNS (8%)
Breast (27%)
Thyroid (13%)
Other solid SMN 
(15%)
Melanoma (6%)
Other (23%)
SUBSEQUENT MALIGNANT NEOPLASMS
A: Secondary malignant neoplasms (non-melanoma skin cancers excluded). 
Leukemia (28%)
CNS (11%)
Hodgkin (32%)
Non-Hodgkin (6%)
Kidney (4%)
Neuroblastoma (3%)
Soft-tissue (8%)
Bone tumors (8%)
PRIMARY	CANCER	DIAGNOSIS
B: Primary cancer diagnoses. CNS = central nervous system; SMN = secondary malignant neoplasm.
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BREAST CANCER
Epidemiology and host-related risk factors
Breast cancer risk in childhood cancer survivors has recently been addressed in several 
large cohort studies (Table 2.2).13-15, 22 After 30 years of follow-up since childhood can-
cer diagnosis, secondary breast cancer affects approximately 5% of childhood cancer 
survivors.13 This represents a standardized incidence ratio of 2.2-9.8 in comparison to 
the general population.13-15, 22 Latency periods for the development of secondary breast 
cancer following childhood cancer vary between 6.7 and 39 years (average 21.8 years) 
(Table 2.3).13, 37-45 This is illustrated by Reulen et al., who observed an increased risk for 
secondary breast cancer in female childhood cancer survivors during the first three 
decades following primary cancer diagnosis, which gradually declined to general popu-
lation norms at an attained survivor’s age of 50 years.46
Table 2.1. High-penetrance genetic cancer predisposition syndromes associated with endocrine-related 
malignancies
Name Genes Associated cancers References
Hereditary Breast and 
Ovarian Cancer Syndrome 
BRCA1
BRCA2
Breast cancer, ovarian cancer, prostate cancer, 
pancreatic cancer, biliary cancer, melanoma
Shiovitz et al.27
Cowden syndrome 
(also known as multiple 
hamartoma syndrome) 
PTEN Breast cancer, non-medullary thyroid cancer, 
endometrial cancer, genitourinary tumours
Pilarski et al.24 
Shiovitz et al.27
Li-Fraumeni syndrome 
(LFS) 
TP53 Breast cancer, sarcoma, brain tumour, adrenocortical 
tumour, leukaemia, lung cancer
Shiovitz et al.27
Hereditary Diffuse Gastric 
Cancer
CDH1 Breast cancer, gastric cancer, colorectal cancer Shiovitz et al.27
Peutz-Jeghers syndrome STK11 Gastro-intestinal cancer, breast cancer, ovarian cancer, 
pancreatic cancer
Strahm et al.25
Shiovitz et al.27
Multiple Endocrine 
Neoplasia type 1 (MEN1) 
MEN1 Parathyroid adenoma, pancreatic endocrine tumours, 
pituitary adenoma
Pilarski et al.24
Strahm et al.25
Multiple Endocrine 
Neoplasia type 2 (MEN2) 
RET Medullary thyroid carcinoma, pheochromocytoma, 
parathyroid hyperplasia
Pilarski et al.24
Strahm et al.25
Succinate Dehydrogenase 
complex (SDHX) 
SDHB
SDHC
SDHD
Paraganglioma, pheochromocytoma Pilarski et al.24
Von-Hippel Lindau 
syndrome (VHL) 
VHL Retinal and central nervous system 
hemangioblastoma, renal cell carcinoma, 
pheochromocytoma, pancreatic islet cell tumour, 
endolymphatic sac tumour
Pilarski et al.24
Adenomatous polyposis 
of the colon 
APC Colon cancer, small intestine cancer, thyroid cancer, 
stomach cancer, hepatoblastoma
Strahm et al.25
Beckwith-Wiedemann 
syndrome 
CDKN1C/
NSD1
Nephroblastoma, hepatoblastoma, adrenal carcinoma, 
rhabdomyosarcoma
Strahm et al.25
DICER1 syndrome DICER1 Pleuropulmonary blastoma, ovarian tumour, cystic 
nephroma, sarcoma, thyroid tumour, pituitary tumour
Foulkes et al.26
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Several studies identified pubertal age at primary cancer diagnosis to be an impor-
tant risk factor for secondary breast cancer.37, 47, 48 In a study by Metayer et al., risk for 
secondary breast cancer was highest in women aged 10-16 years at Hodgkin lymphoma 
diagnosis.47 In addition, 114 of the 120 secondary breast cancers observed in a study by 
Inskip et al. were diagnosed in women aged 10-20 years at childhood cancer diagnosis.48 
Therefore, an increased susceptibility of proliferating breast tissue for carcinogenic fac-
tors in adolescent girls has been suggested.47-49 However, several other studies could not 
confirm a risk-modifying effect of age at childhood cancer diagnosis.46, 50, 51 This incon-
sistency might be explained by shorter follow-up durations since childhood cancer in 
studies reporting an increased secondary breast cancer risk by pubertal age compared 
to studies not reporting such an effect (average 11.0-16.8 vs. 16-25.1 years).37, 46, 47, 50 
Secondary breast cancer risk in childhood cancer survivors by follow-up since childhood 
cancer diagnosis, attained survivor’s age, and at age at childhood cancer diagnosis is 
represented in Table 2.4.22, 46, 50, 52
Genetic susceptibility might contribute to secondary breast cancer development in 
childhood cancer survivors. This is illustrated by studies reporting an increased second-
ary breast cancer risk in survivors of childhood cancer with a positive family history 
for breast and/or ovarian cancer.52, 53 However, germline mutations in known high- to 
moderate-penetrance breast cancer susceptibility genes like BRCA1, BRCA2, TP53, and 
ATM are only found in a minority of childhood cancer survivors who develop a secondary 
breast malignancy.54, 55 Therefore, less pathogenic low-penetrance genetic susceptibility 
might be more important. Recent studies identified allelic variants in PRDM1 and FGFR2 
to predispose Hodgkin lymphoma survivors to radiation-induced breast cancer.56, 57
Noteworthy, Kenney et al. identified presence of thyroid disease to be a risk factor 
for secondary breast cancer in childhood cancer survivors (RR 1.7 [95% CI 1.1-2.6]).52 
An association between thyroid disease and breast cancer has also been observed in 
the general population.58, 59 Although no clear explanations for this finding have been 
found, stimulation of breast cancer cells by deregulated thyroid hormone receptors, 
oestrogen-receptor activation by triiodothyronine, and a potential role of the sodium-
iodide symporter expressed in breast cancer tissue have been proposed.60-62 
Treatment-related risk factors for secondary breast cancer 
Radiotherapy
Chest irradiation is the most important treatment-related risk factor for secondary breast 
cancer in childhood cancer survivors. In a recent review, Henderson et al. summarized 
the risk for secondary breast cancer after treatment with chest irradiation for paediatric 
cancer.63 In the included higher-quality cohort studies, standardized incidence ratios for 
secondary breast cancer varied between 13.3-55.5, excess absolute risks between 18.6-
79.0 per 10 000 person-years, and cumulative incidences between 12-26% at 25-30 years 
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follow-up since childhood cancer.37, 39, 52, 64-66 These risk estimates are comparable to risks 
for breast cancer in women harbouring a germline BRCA1 or BRCA2 gene mutation.67
Radiation fields associated with an increased secondary breast cancer risk in childhood 
cancer survivors include mantle field, whole lung, hemithorax, mediastinum, supra-
diaphragmatic abdomen, axilla, neck and clavicle, as well as total body (Table 2.5).43, 66-68 
Smaller radiation fields seem to be associated with lower risks for radiation-induced breast 
cancer.21, 66, 68 However, despite an increased use of less-extensive supradiaphragmatic 
radiation fields over the past decades, the incidence of radiation-induced breast cancer 
remained stable in Hodgkin lymphoma survivors.21 This may be partly related to an earlier 
detection of secondary breast malignancies by improved screening practices.69 In a recent 
study on secondary breast cancer risk after craniospinal irradiation for paediatric central 
nervous system malignancies and leukaemia, Moskowitz et al. observed an increased risk 
for secondary breast cancer in the subgroup of leukaemia survivors solely (SIR 3.8 [95% CI 
1.2-11.7]).70 This observation might be related to genetic susceptibility, as illustrated by a 
population-based study in Italy that observed an increased standardized mortality ratio 
attributable to breast cancer in mothers of children diagnosed with leukaemia.71 
The relationship between chest radiation dose and breast cancer risk has been inves-
tigated by several studies (Table 2.6).48, 50, 51, 53, 72 A linear dose-response curve has been 
established (Figure 2.2A).48, 73 Risk for radiation-induced breast cancer was traditionally 
studied after moderate- to high-dosed chest irradiation (i.e. ≥ 20 Gy).63 However, recent 
studies also demonstrated an increased secondary breast cancer risk after lower-dosed 
chest irradiation.43, 67 Lange et al. observed an increased breast cancer risk of 14.4% (95% 
CI 7.6-30.1) at an attained survivors’ age of 40 years after 1-12 Gy chest irradiation for 
nephroblastoma.43 In a recent study by Moskowitz et al., breast cancer risk was 30.6-fold 
increased (95% CI 18.4-50.7) in comparison to the United States general population after 
10-19 Gy chest irradiation for various childhood cancer subtypes.67 Currently, there is no 
evidence of a significant effect of radiotherapy fractionation on secondary breast cancer 
risk following childhood cancer.50 
Studies investigating radiation-related secondary cancer risk in childhood cancer 
survivors have predominantly assessed older radiotherapeutic modalities.31 Contem-
porary radiotherapeutic techniques like conformal radiotherapy, intensity-modulated 
radiation therapy, and proton-beam therapy allow for more precise radiation delivery 
to the tumour target, thereby sparing healthy surrounding tissue. Therefore, these tech-
niques may yield lower risks for secondary malignant neoplasm development compared 
to older radiotherapeutic modalities of earlier treatment eras.31, 74 However, there are 
also concerns of a potentially increased secondary cancer risk following modern radio-
therapeutic techniques due to a larger amount of leakage radiation.31 To our knowledge, 
observational studies on secondary breast cancer risk in childhood cancer survivors 
following modern radiotherapeutic techniques have to be performed yet.
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Hematopoietic stem cell transplantation
Childhood cancer survivors who received hematopoietic stem cell transplantation are at 
increased risk for secondary breast cancer.75, 76 Friedman et al. observed a standardized 
incidence ratio of 2.2 (95% CI 1.7-2.9) for secondary breast cancer following allogeneic 
hematopoietic stem cell transplantation. In their study, secondary breast cancer risk was 
associated with total body irradiation, follow-up duration, and age at stem cell trans-
plantation.76 In addition, Danner-Koptik et al. observed a standardized incidence ratio 
of 93 (95% CI 11-336) for secondary breast cancer following autologous hematopoietic 
stem cell transplantation. However, they could not demonstrate an association between 
Figure 2.2. Fitted radiation dose-response relationships for chest irradiation and breast cancer, as well as 
thyroid gland irradiation and thyroid cancer as observed as in the Childhood Cancer Survivors Study by 
Inskip et al.48 and Bhatti et al.102, respectively
A: Fitted dose-response relationship between chest radiation and breast cancer risk by radiation dose to 
the chest and ovaries. Reprinted with kind permission from Inskip et al. J Clin Oncol 27(24), 2009: 3901-7. © 
2009 American Society of Clinical Oncology. All rights reserved. 
B: Fitted dose-response relationship for thyroid gland irradiation and thyroid cancer risk (based on two 
constructed models [model 5 and 10] and adjusted for attained age, gender, and primary childhood cancer 
subtype).102 Reprinted with kind permission from Bhatti et al. Radiat Res 174(6), 2010: 741-752. © 2010 Ra-
diation Research Society. All rights reserved.
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secondary breast cancer risk and age, gender, childhood cancer subtype, follow-up 
duration, response to primary cancer treatment, and use of total body irradiation or 
etoposide as part of pretransplant conditioning regimen.75 Intriguingly, three cases of 
secondary breast cancer in male childhood cancer survivors following total body irradia-
tion and hematopoietic stem cell transplantation have been described.77-79 
Chemotherapy
Although most studies in cohorts of childhood cancer survivors solely and childhood- 
and adult-onset cancer survivors combined did not observe a relationship between 
chemotherapy and secondary breast cancer risk,46, 50, 80, 81 or observed a protective 
effect of certain chemotherapeutic agents on the development of radiation-related 
breast cancer,21, 51, 66, 68, 72, 82 two studies reported an increased risk for secondary breast 
cancer attributable to chemotherapy.42, 83 In a combined cohort of childhood- and 
adult-onset Hodgkin lymphoma survivors, Hancock et al. observed a higher risk for 
secondary breast cancer following treatment with mechlorethamine, vincristine, pro-
carbazine, and prednisone in combination with radiotherapy compared to treatment 
with radiotherapy alone during the first fifteen years following Hodgkin lymphoma (SIR 
6.3 [95% CI 3.1-11.6] for combination chemoradiation therapy vs. SIR 0.8 [95% CI 0.1-
2.5] for radiotherapy alone). After fifteen years of follow-up since Hodgkin lymphoma, 
secondary breast cancer risk became equivalently increased in both treatment groups 
(SIR 14.8 [95% CI 3.7-40.4] for combination chemoradiation therapy vs. SIR 13.0 [95% CI 
6.6-23.1] for radiotherapy alone).83 In addition, in a recent Childhood Cancer Survivor 
Study report by Henderson et al. on the risk for secondary breast cancer in childhood 
cancer survivors not treated with chest irradiation, exposure to anthracyclines and al-
kylating agents was associated with an increased secondary breast cancer risk (relative 
SIR 3.8 [95% CI 1.7-8.3] for anthracyclines dosed ≥ 250 mg/m2, and relative SIR 3.0 [95% 
CI 1.2-7.7] for alkylating agents dosed ≥ 18 000 mg/m2 compared to no treatment with 
anthracyclines or alkylating agents).42 As suggested by Van Leeuwen et al., the observed 
increased risk for secondary breast cancer attributable to anthracyclines and alkylating 
agents in childhood cancer survivors not treated with chest irradiation might be partly 
related to genetic susceptibility.84 
Primary cancer diagnosis and secondary breast cancer risk
In a series of three articles, Maule et al. reported standardized incidence ratios and excess 
absolute risks for secondary malignant neoplasms in childhood cancer survivors derived 
from thirteen population-based cancer registries.85-87 They observed an increased risk for 
secondary breast cancer after several childhood cancer subtypes (Table 2.7). The high-
est risk for secondary breast cancer was observed in survivors of Hodgkin lymphoma,87 
which likely reflect treatment with mantle field irradiation. However, Guibout et al. also 
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observed an increased risk for secondary breast cancer in Hodgkin lymphoma survivors 
after adjustment for chest irradiation and treatment with chemotherapy (RR 7.01 [95% CI 
1.4-30.9] compared to survivors of other childhood cancer subtypes).50 This supports the 
idea that factors other than treatment exposures, like genetic determinants, may also 
contribute to secondary breast cancer development in Hodgkin lymphoma survivors. 
Although Maule et al. did not observe a significantly increased risk for secondary breast 
cancer in survivors of soft-tissue sarcoma, retinoblastoma, nephroblastoma, neuroblas-
toma, germ cell tumours, and non-Hodgkin lymphoma, other studies did.15, 22, 43, 50, 52, 81, 88 
The increased risk for secondary breast cancer in survivors of sarcoma might also be 
partly related to genetic factors. Data from the Childhood Cancer Survivor Study dem-
onstrated an increased standardized incidence ratio for secondary breast cancer in 
sarcoma survivors not treated with chest irradiation (5.3 [95% CI 3.6-7.8]).42 In addition, 
a positive family history for sarcoma was associated with an increased secondary breast 
cancer risk (RR 5.3 [95% CI 1.3-21.5]).52 The increased risk for secondary breast cancer 
after retinoblastoma is observed in both heritable and non-heritable retinoblastoma 
survivors,81 and seems to become apparent after ≥ 40 years of follow-up since primary 
cancer diagnosis in heritable retinoblastoma survivors.88
Hormonal influences on secondary breast cancer risk
In the general population, prolonged exposure to oestrogens has been associated 
with an increased breast cancer risk.89 Therefore, several studies investigated the risk-
modifying effects of age at menarche, menopausal age, and age at first childbirth on 
secondary breast cancer in childhood- and young adult-onset cancer survivors.51-53, 66, 72, 90 
In contrast to observations in the general population, Cooke et al. demonstrated an 
increased risk for secondary breast cancer in Hodgkin lymphoma survivors experiencing 
Table 2.7. Risk for secondary breast cancer by childhood cancer subtype85-87
Primary childhood cancer diagnosis SIR (95% CI) EAR per 100 000 person-years
Leukaemia 2.42 (0.06-13.5) 0.8
Hodgkin lymphoma 20.9 (7.66-45.4) 40.6
Non-Hodgkin lymphoma 0.00 (0.00-0.33) -1.7
Glioma 1.4 (0.2-5.2) 1.3
Other central nervous system tumours 1.3 (0.0-7.4) 2.5
Retinoblastoma 1.5 (< 0.1-8.5) 1.6
Renal tumours 3.0 (0.1-16.7) 2.7
Bone sarcomas 6.8 (1.9-17.5) 26.9
Soft-tissue sarcomas 1.3 (< 0.1-7.4) 1.1
Epithelial tumours 1.8 (0.5-4.6) 8.7
CI = confidence interval; EAR = excess absolute risk; SIR = standardized incidence ratio.
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a late menarche (OR 3.74 [95% CI 1.08-12.98] for age at menarche 17 vs. 13 years).90 In 
addition, they observed a relationship between timing of chest irradiation in relation to 
menarche and secondary breast cancer risk. Secondary breast cancer risk was signifi-
cantly increased in survivors treated with chest irradiation within five years of menarche; 
the smaller the interval between chest irradiation and menarche, the higher the risk for 
secondary breast cancer (P < 0.001 for trend).90 Other studies could not demonstrate an 
association between age at menarche and secondary breast cancer risk.52, 53, 72 In addi-
tion, no studies observed a risk-modifying effect of age at first childbirth on secondary 
breast cancer development in childhood- and young adult-onset cancer survivors.52, 53, 72 
However, Hill et al. demonstrated a relationship between timing of childbirth in relation 
to Hodgkin lymphoma diagnosis and secondary breast cancer risk. Women not treated 
with alkylating agents or ovarian irradiation ≥ 5 Gy who had childbirth within five years 
following Hodgkin lymphoma diagnosis demonstrated an increased secondary breast 
cancer risk compared to women who had childbirth at least five years after Hodgkin lym-
phoma diagnosis (OR 2.6 [95% CI 1.0-6.7]).53 An increased risk for breast cancer shortly 
after childbirth has also been observed in the general population, and is thought to be 
related to gestational hormone exposure, immunosuppressive effects of pregnancy, and 
postpartum breast involution.91
Several studies investigated the risk-modifying effects of age at menopause, pre-
mature ovarian insufficiency, alkylating agents, and ovarian irradiation on radiation-
induced breast cancer in survivors of childhood- and young adult-onset cancer (Table 
2.8).21, 39, 51-53, 66, 72, 90 Studies in combined cohorts of childhood- and adult-onset Hodgkin 
lymphoma survivors consistently reported a protective effect of premature ovarian in-
sufficiency on radiation-induced breast cancer risk.51, 53, 66, 72, 90 Risk for radiation-induced 
breast cancer seems to be lower in women experiencing less premenopausal years fol-
lowing Hodgkin lymphoma treatment.66, 90 Alkylating agent chemotherapy and ovarian 
irradiation are known to potentially induce premature ovarian insufficiency. Therefore, 
several studies investigated the risk-modifying effects of these therapies on radiation-
induced breast cancer development. A protective effect of alkylating agent chemo-
therapy on radiation-induced breast cancer has been observed in combined cohorts of 
childhood- and adult-onset Hodgkin lymphoma survivors.21, 51, 66, 68, 72, 82 In the studies by 
Travis et al. and Van Leeuwen et al., increasing cycles of alkylating agent chemotherapy 
and a high dose of procarbazine were significantly associated with a decreased risk for 
radiation-induced breast cancer.51, 72 Noteworthy, no studies in cohorts of childhood 
cancer survivors solely could demonstrate a beneficial effect of alkylating agents on 
radiation-induced breast cancer risk. In addition, several studies in cohorts of childhood 
cancer survivors solely and childhood- and adult-onset cancer survivors combined 
observed a protective effect of ovarian irradiation on radiation-induced breast cancer 
(Figure 2.2A).37, 48, 52, 67, 68 
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Although the aforementioned studies suggest protective effects of premature 
ovarian insufficiency and gonadotoxic therapies on radiation-induced breast can-
cer development, it is important to keep in mind that most of these studies were 
performed in combined cohorts of childhood- and adult-onset Hodgkin lymphoma 
survivors.21, 51, 53, 66, 68, 72, 82, 90 The beneficial effects of gonadotoxic treatment on radiation-
induced breast cancer risk seem less pronounced in childhood- compared to adult-onset 
cancer survivors. This is underscored by a recent study in survivors of Hodgkin lym-
phoma by Swerdlow et al., which observed a beneficial effect of gonadotoxic therapy on 
radiation-induced breast cancer risk only in women aged ≥ 20 years at primary cancer 
treatment.68 The less pronounced protective effect of gonadotoxic therapy in child-
hood- compared to adult-onset cancer survivors may be explained by a greater reserve 
of follicles in young women, which might be less likely to deplete following ovarian toxic 
treatment.92 Noteworthy, in a recent study in childhood cancer survivors not treated 
with chest irradiation, Henderson et al. could not demonstrate a protective effect of 
ovarian irradiation or alkylating agent chemotherapy on secondary breast cancer risk.42 
This indicates gonadotoxic treatment only protects for radiation-induced breast cancer 
development.
Currently, there is no evidence of a harmful effect of oestrogen-progestin replacement 
therapy on secondary breast cancer risk in premature ovarian insufficient childhood 
cancer survivors.51, 66, 72 However, the number of women using oestrogen-progestin 
replacement therapy in the available studies addressing this issue is too small to reli-
ably evaluate this topic. Only recently, oestrogen-progestin replacement therapy is 
prescribed commonly in premature ovarian insufficient childhood cancer survivors.72 
Since potential benefits of premature ovarian insufficiency on radiation-induced breast 
cancer risk have not been demonstrated in cohorts of childhood cancer survivors solely, 
and harms of oestrogen-progestin replacement therapy on radiation-induced breast 
cancer risk in premature ovarian insufficient childhood cancer survivors have not been 
described thus far, castration of female childhood cancer survivors at high risk for radia-
tion-induced breast cancer should not be performed. This is underscored by the clearly 
demonstrated beneficial effects of oestrogen-progestin replacement therapy on bone 
and cardiovascular health, as well as quality of life in women from the general popula-
tion experiencing premature ovarian insufficiency.93 The effect of oral contraceptives 
on secondary breast cancer risk in childhood cancer survivors has only been studied 
in combined cohorts of childhood- and adult-onset Hodgkin lymphoma survivors. No 
risk-modifying effects have been demonstrated.53, 66, 72
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THYROID CANCER
Epidemiology and host-related risk factors
Several recent large cohort studies in childhood cancer survivors observed significantly 
increased standardized incidence ratios for secondary thyroid carcinoma between 5.4-
18.0 in comparison to the general population.13, 14, 22, 94 This represents a 30-year cumula-
tive incidence of 1.4% (95% CI 1.1-1.6) since childhood cancer diagnosis.13 The increased 
risk for secondary thyroid cancer in childhood cancer survivors involves predominantly 
differentiated thyroid carcinoma (i.e. papillary or follicular thyroid carcinoma).94, 95 La-
tency periods for the development of secondary thyroid carcinoma in childhood cancer 
survivors vary between 0.6-38 years (average 12.3 years) (Table 2.9).37, 40, 45, 75, 94-101 In a 
recent study by Veiga et al., which included pooled data from the Childhood Cancer 
Survivor Study cohort,102 the Late Effects Study Group cohort,103 the Nordic countries 
cohort,104 and a combined French and British cohort,105 female gender (RR 2.0 [95% 
CI 1.5-2.8]), younger age at primary cancer (P < 0.01 for trend), longer follow-up since 
primary cancer (P = 0.01 for trend), older attained survivor’s age (P < 0.01 for trend), 
and treatment with radiotherapy (RR 5.5 [95% CI 3.1-9.7]) were significantly associated 
with secondary thyroid carcinoma risk in childhood cancer survivors.106 A risk-modifying 
effect of gender and age at childhood cancer diagnosis has also been observed in other 
studies,37, 98 but not all.94, 107 A recent study by De Vathaire et al. investigated the influ-
ence of smoking and overweight on secondary thyroid cancer risk in childhood cancer 
survivors, but could not demonstrate a significant effect (RR 0.75 [95% CI 0.32-1.6] for 
smoking; RR 1.4 [95% CI 0.7-2.80 for overweight]).108 Best et al. identified allelic variants 
in PRDM1 to predispose Hodgkin lymphoma survivors to radiation-induced thyroid 
cancer.56 In addition, several studies identified allelic variants in TP53, ATM, and FOXE1 
to be associated with radiation-induced papillary thyroid carcinoma in survivors of the 
Chernobyl nuclear accident.109-111
Treatment-related risk factors for secondary thyroid carcinoma
Radiotherapy involving the thyroid gland is the most important risk factor for secondary 
thyroid carcinoma in childhood cancer survivors, and seems to exert its effect via a sig-
moidal dose-response relationship.106, 108 In the aforementioned pooled study by Veiga 
et al., the dose-response relationship for thyroid carcinoma in survivors of paediatric 
cancer increased linearly until a radiation dose of approximately 10 Gy, levelled off at a 
radiation dose of approximately 10-30 Gy, and declined again at a radiation dose > 30 
Gy. However, the risk for thyroid cancer still remained increased at a radiation dose > 
50 Gy.106 The downturn in the dose-response relationship for radiation-induced thyroid 
carcinoma is thought to be related to a cell-killing effect.112 In Figure 2.2B, the dose-
response curve for secondary thyroid carcinoma following thyroid gland irradiation as 
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reported by Bhatti et al. is shown.102 This study by Bhatti et al. is also included in the 
pooled analysis by Veiga et al.106 Besides increasing the risk for differentiated thyroid 
carcinoma, radiotherapy involving the thyroid gland is also known to promote the oc-
currence of benign thyroid nodules in childhood cancer survivors (Table 2.10). Clinically, 
it may be difficult to distinguish malignant from benign thyroid nodules.96, 99, 107, 113-120 
Studies investigating radiation-related thyroid carcinoma risk after childhood cancer 
treatment have predominantly assessed older radiotherapeutic modalities. To our 
knowledge, observational studies on secondary thyroid carcinoma risk in childhood 
cancer survivors treated with modern radiotherapeutic techniques like conformal ra-
diotherapy, intensity-modulated radiation therapy, and proton-beam therapy have to 
be performed yet.
A few studies demonstrated an increased risk for secondary thyroid carcinoma in 
childhood cancer survivors attributable to chemotherapy.100, 106, 108 Veiga et al. observed 
a 2.4-fold increased risk (95% CI 1.3-4.5) for secondary thyroid cancer in childhood can-
cer survivors treated with a combination of alkylating agents and ≤ 20 Gy thyroid gland 
irradiation; the contribution of chemotherapy to secondary thyroid cancer risk declined 
with increasing thyroid gland irradiation dose (P = 0.03 for trend).100 In another study, 
Veiga et al. observed a 4.5-fold increased risk (95% CI 1.4-17.8) for secondary thyroid 
carcinoma in childhood cancer survivors treated with anthracyclines without thyroid 
gland irradiation.106 A recent study by De Vathaire et al. demonstrated an increased 
secondary thyroid carcinoma risk in childhood cancer survivors treated with nitrosourea 
chemotherapy (RR 6.6 [95% CI 2.5-15.7]).108 Interestingly, in this study by De Vathaire et 
al., childhood cancer treatment with splenectomy was also associated with an increased 
risk for secondary thyroid cancer (RR 2.3 [95% CI 1.3-4.0]); while pituitary irradiation > 
10 Gy decreased secondary thyroid carcinoma risk (RR 0.2 [95% CI 0.1-0.6]).108 In our 
institution, we could not demonstrate an increased risk for secondary thyroid cancer 
in survivors of childhood Hodgkin lymphoma treated with chemotherapy solely.121, 122
Autologous and allogeneic hematopoietic stem cell transplantation are also associated 
with an increased secondary thyroid cancer risk.75, 98, 118, 123 In a cohort of childhood- and 
adult-onset autologous and allogeneic hematopoietic stem cell transplantation survi-
vors, Cohen et al. identified young age at transplantation (RR 24.61 [95% CI 4.45-136.25] 
for age 0-10 vs. > 20 years), pretransplant conditioning with total body irradiation (RR 
3.44 [95% CI 1.41-8.37]), and chronic graft-versus-host disease (RR 2.94 [95% CI 1.21-
7.15]) to increase the risk for secondary thyroid cancer.98 
Primary cancer diagnosis and secondary thyroid carcinoma risk
Several childhood cancer subtypes have been associated with an increased secondary 
thyroid cancer risk (Table 2.11). Particularly high risks for secondary thyroid carcinoma 
have been observed in survivors of neuroblastoma, Hodgkin lymphoma, non-Hodgkin 
Subsequent endocrine-related cancer risk in CCS 61
lymphoma, brain tumours, and leukaemia.85-87 In addition, De Vathaire et al. observed 
an increased risk for secondary thyroid carcinoma in survivors of gonadal tumours (SIR 
16.0 [95% CI 4.0-41.4]) and soft-tissue sarcoma (SIR 8.2 [95% CI 2.0-21.2]).108 Adminis-
tered treatment modalities, like 131I-MIBG (131-iodine metaiodobenzylguanidine) and 
radiotherapy involving the thyroid gland may conceivably explain the increased risks for 
secondary thyroid cancer. 131I-MIBG may be used to treat neuroblastoma, and involves 
administering a radioiodine-labelled guanidine derivate.124 Approximately 2-5% of the 
administered 131I-MIBG enters the circulation as free radioiodine, and may affect thyroid 
functioning and induce thyroid nodules as well as secondary thyroid carcinoma.125
LIMITATIONS OF CURRENTLY AvAILABLE LITERATURE, AND 
RECOMMENDATIONS FOR FUTURE RESEARCH
The currently available literature on secondary endocrine-related cancer risk in child-
hood cancer survivors has some limitations. Follow-up durations since childhood 
cancer are generally too short to assess the risk for secondary malignant neoplasms 
in aging childhood cancer survivors. Average follow-up durations since childhood 
cancer vary between 6.3-27.3 years in studies assessing secondary breast cancer 
risk,15, 21, 22, 37, 40, 44, 47, 50, 64-66, 70, 75, 76, 80, 81, 83, 85, 88, 90 and 5.1-27 years in studies investigating sec-
ondary thyroid carcinoma risk.13, 22, 37, 40, 75, 85, 94, 97-99, 108, 114, 116, 118, 119, 121, 126 Specific subtypes 
of secondary malignant neoplasms and potential risk-modifying factors yet unknown 
may become apparent at an advanced survivor’s age. Therefore, it is important to pro-
spectively evaluate the growing cohort of aging childhood cancer survivors.
Furthermore, a large amount of the evidence on secondary breast cancer risk in child-
hood cancer survivors,13, 40-42, 48, 52, 67, 70, 88 and to a lesser extent on secondary thyroid cancer 
risk in childhood cancer survivors,13, 40, 100, 102, 108, 112 has been derived from retrospective 
cohort studies using self-reported data to ascertain secondary malignant neoplasms, 
which may predispose to selection bias. Another source for selection bias may be the 
nature of the cohort. This is illustrated by Ness et al., who observed an overestimation 
of the prevalence of long-term adverse health conditions by 9.3% (95% CI 7.0-11.6) in 
childhood cancer survivors ascertained in a hospital- compared to a population-based 
setting.127 Future studies on secondary endocrine-related malignancies after childhood 
cancer could be prospective, based on national registries, and use objective methods to 
collect data on secondary malignant neoplasms.
Although several studies reported a protective effect of gonadotoxic therapies and 
premature ovarian insufficiency on radiation-induced breast cancer,21, 37, 48, 51-53, 66, 67, 72, 82, 90 
it is important to consider that most of these studies were performed in combined co-
horts of childhood- and adult-onset Hodgkin lymphoma survivors.21, 51, 53, 66, 72, 82, 90 Since 
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the beneficial effects of gonadotoxic treatments on radiation-induced breast cancer risk 
seem to be less pronounced in childhood- compared to adult-onset cancer survivors,68 
and no studies assessed the risk-modifying effect of a diagnosis of premature ovarian 
insufficiency on radiation-induced breast cancer in childhood cancer survivors solely, 
more studies should be performed. Future studies may also address the potential harms 
and benefits of oestrogen-progestin replacement therapy on radiation-induced breast 
cancer risk in women experiencing childhood cancer treatment-related premature ovar-
ian insufficiency.
Studies on secondary malignant neoplasms after childhood cancer concern pre-
dominantly survivors treated with old-fashioned treatment regimens. Although child-
hood cancer therapy has changed considerably over the past five decades,1, 31 results 
described in this review are still highly valuable for those individuals treated in earlier 
treatment eras. Since the effects of modern radiotherapeutic techniques like conformal 
radiotherapy, intensity-modulated radiation therapy, and proton-beam therapy on sec-
ondary endocrine-related cancer risk remain unknown, future studies should address 
the potential risks and benefits associated with these contemporary radiotherapeutic 
modalities. Risks for radiation-induced malignant neoplasms may be greater in small 
compared to large children due to a more significant contribution of scatter radiation.128 
Currently, no studies on secondary endocrine-related malignancies after childhood 
cancer accounted for this issue. Future studies may investigate radiation-induced cancer 
risks by dosimetry according to body size at cancer treatment.
Finally, there is a lack of studies specifically investigating the influence of environmen-
tal and lifestyle factors on secondary endocrine-related cancer risk in childhood cancer 
survivors. Future studies should address these potentially risk-modifying factors.
Table 2.11. Risk for secondary thyroid cancer by childhood cancer subtype85-87
Primary childhood cancer diagnosis SIR (95% CI) EAR per 100 000 person-years
Leukaemia 18.8 (8.60-35.7) 11.3
Hodgkin lymphoma 52.5 (24.0-99.6) 62.7
Non-Hodgkin lymphoma 40.4 (14.8-88.0) 31.0
Glioma 6.8 (1.9-18.0) 7.2
Embryonal central nervous system tumours 30 (8.2-77) 25
Other central nervous system tumours 7.7 (0.2-43) 8.8
Sympathetic nervous system tumours 143.7 (29.6-419.8) 60.8
Retinoblastoma 5.3 (0.1-29.6) 3.8
Renal tumours 13.9 (2.9-40.5) 11.1
Bone sarcomas 10.8 (1.3-38.9) 14.3
Soft-tissue sarcomas 4.1 (0.1-22.6) 3.6
Epithelial tumours 3.3 (0.1-18.4) 3.4
CI = confidence interval; EAR = excess absolute risk; SIR = standardized incidence ratio.
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CONCLUSION
Secondary malignant neoplasm development in childhood cancer survivors depends 
on host factors, primary cancer diagnosis, and types and timing of primary cancer treat-
ment. In addition, environmental factors and lifestyle factors may play a contributing 
role. Radiotherapy is the most important risk factor for secondary breast and thyroid 
cancer in childhood cancer survivors. Premature ovarian insufficiency may protect 
against radiation-induced breast cancer. Although evidence is weak, there seems to be 
no harmful effect of oestrogen-progestin replacement therapy on radiation-induced 
breast cancer risk in premature ovarian insufficient childhood cancer survivors. Child-
hood cancer survivors at risk for secondary endocrine-related malignancies should be 
regularly screened in a risk-based fashion, preferably by endocrinologists in close col-
laboration with physicians experienced in long-term complications of childhood cancer 
treatment.
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ABSTRACT
The risk of metabolic late effects after childhood cancer, such as obesity, hypertension, 
and diabetes, can be positively influenced by a healthy lifestyle with sufficient physical 
activity. Nevertheless, studies on physical activity in adult survivors of childhood cancer 
are scarce and involve different and often non-validated questionnaires. We used the 
Short Questionnaire to Assess Health-enhancing physical activity (SQUASH), which 
was developed and validated to assess daily life physical activity in the Dutch adult 
population. The aim of the study was to assess daily life physical activity in Dutch adult 
long-term nephroblastoma and neuroblastoma survivors. Sixty-seven nephroblastoma 
and 36 neuroblastoma survivors (median age 30 years; range 18-51) and 60 socio-
demographically similar healthy control subjects (median age 32 years; range 18-62) 
were asked to complete the SQUASH during their regular follow-up visit. The adjusted 
mean physical activity score in male neuroblastoma survivors (mean 7155; P=0.004) was 
significantly lower than in male controls (mean 10574), whereas it was not significantly 
lower in male nephroblastoma survivors (mean 9122; P=0.108). Adjusted means for 
physical activity scores in females were not different from their controls. In conclusion, 
male neuroblastoma survivors were identified as performing less daily physical activity.
Physical activity after nephro- and neuroblastoma 79
INTRODUCTION
Survival of nephroblastoma and neuroblastoma patients has increased significantly dur-
ing the last few decades. The increased survival is due to better stratification, improve-
ments of treatment strategies, and optimized supportive care. With a mean survival rate 
of 92% and 55%, respectively, nephroblastoma and neuroblastoma survivors represent 
a considerable group of childhood cancer survivors.1, 2 
Late effects that occur in these survivors include pulmonary, musculoskeletal, renal, 
and cardiac late effects, second malignant neoplasms, and increased risk of cardiovas-
cular diseases.3-6 Some of these late effects influencing cardiovascular risk, for example 
hypertension, obesity, dyslipidaemia, and insulin resistance, that is, the metabolic syn-
drome, might be positively affected by sufficient physical activity.
According to a recent review, most studies reported less physical activity in child-
hood cancer survivors than in control subjects. In particular, survivors treated with 
cranial radiotherapy or amputation are less physically active.7 Limitations of previously 
performed research on physical activity in childhood cancer survivors are the lack of 
objective physical activity measures, validated questionnaires, non-cancer comparison 
groups, and the heterogeneity of studied diagnostic groups.7
The Short Questionnaire to Assess Health-enhancing physical activity (SQUASH) was 
developed by the Dutch National Institute of Public Health and the Environment to 
assess daily life physical activity in the Dutch adult population.8 The SQUASH contains 
questions about commuting activities, exertion at work or school, household activi-
ties, and leisure time and sports during an average week. Although this questionnaire 
is a subjective measure of physical activity, it has an important advantage over other 
questionnaires as it was validated using an objective measure: a Computer Science and 
Applications activity monitor.
The objective of this study was to assess daily life physical activity using the SQUASH 
and to assess compliance to the Dutch physical activity guidelines in adult long-term 
survivors of nephroblastoma and neuroblastoma, as compared with a non-cancer com-
parison group.
MATERIALS AND METHODS
Participants
All long-term (i.e. ≥5 years after cessation of treatment) adult survivors of childhood 
nephroblastoma and neuroblastoma, treated between 1961-2004 in the Erasmus MC-
Sophia Children’s Hospital and routinely visiting the late effects outpatient clinic were 
invited to participate in this prospective study. A control group, consisting of siblings, 
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friends, or neighbours, preferably of the same sex and within an age range of five years 
of the survivor, was cross-sectionally recruited. This control group was designed as a 
socio-demographically similar comparison population. Informed consent was obtained 
according to the Helsinki declaration9 and the study was approved by the local medi-
cal ethical committee. Adult survivors of neuroblastoma stage 4S who did not receive 
any treatment were excluded from this study. During the regular visit of the survivors, 
history was taken and physical examination, laboratory tests, and imaging studies were 
performed. The study took place from October 2009 to March 2011.
Outcome of interest
Information about daily life physical activity was collected with the SQUASH (Appendix 
A).8 The SQUASH expresses physical activity as a score. Physical activity score is the sum 
of activity scores for each question. A higher physical activity score indicates a higher 
amount of daily physical activity. Questions are prestructured in commuting activities, 
activities at work or school, household activities, and leisure time activities including 
sports. The SQUASH consists of three main queries about physical activity: days per week, 
average time per day, and intensity. Intensity is subdivided in three categories based on 
Ainsworth’s Compendium of Physical Activities.10 The method of Wendel-Vos et al. was 
used for allocating intensity scores to reported activities.8 For determining intensity 
categories of reported sports, the method of Ainsworth et al. was used.10 Mean physical 
activity score using the SQUASH was reported to be 7850 in a study of healthy males 
and females (mean age 44 years; standard deviation [SD] 6). To assess compliance to the 
Dutch guidelines for physical activity,11 the question “How many days a week do you 
bicycle, garden, exercise, or do odd jobs, for at least 30 minutes?” was added. If subjects 
answered this question with ≥5 days, they were considered to adhere to the guideline.11
Data Collection
Information on disease and treatment was obtained from our local database and medi-
cal records. To assess the influence of relevant confounders, the following data were col-
lected: information regarding smoking status and education level was collected using 
a self-designed questionnaire. Smoking status was categorized as non-smoker, former 
smoker, and current smoker. Educational level was defined by the highest level of edu-
cational attainment as selected from three categories based on the Dutch educational 
system. Height was measured to the nearest millimetre using a Harpenden Stadiometer 
and weight was measured to the nearest 0.1kg on a standard clinical balance. Body mass 
index (BMI) was calculated as weight (kg)/height (m2). Spinal deformities were deter-
mined in survivors by physical examination. N-terminal pro-brain natriuretic peptide 
(NT-proBNP) was determined as a marker for heart function in both survivors and con-
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trol subjects and was measured using a validated, commercially available immunoassay 
(Elecsys ProBNP; Roche Diagnostics, Indianapolis, IN), using established methodology.12
Statistics
Statistical analyses were performed with SPSS 18.0 (SPSS Inc., Chicago, IL). Mann-Whit-
ney U-tests were used to compare physical activity scores, BMI, and NT-proBNP between 
survivors and control subjects. Adjusted subgroup-comparisons for sex and diagnosis 
were performed by calculating the estimated marginal means of the factor scores of 
the clusters, with adjustments for the confounders age, sex, smoking, educational level, 
NT-proBNP, and BMI. Multiple linear regression analysis was performed to assess the 
influence of spinal deformities in survivors only. P-values of <0.05 (two-tailed) were 
considered statistically significant.
RESULTS
Patients
One hundred three adult long-term (≥5 years after cessation of treatment) survivors of 
nephroblastoma and 54 adult survivors of neuroblastoma were eligible to participate in 
this study. Out of 103 nephroblastoma survivors, 28 could not be contacted for participa-
tion (six died after having survived at least five years after cessation of treatment, eight 
refused to attend the clinic, five were lost to follow-up, six emigrated, and three visited 
another outpatient clinic). Out of 54 neuroblastoma survivors, 12 could not be contacted 
for participation (three died after having survived for at least five years after cessation 
of treatment, three refused to attend the clinic, five were lost to follow-up, and one emi-
grated). In total, 75 survivors of nephroblastoma and 42 survivors of neuroblastoma were 
contacted for participation. Eight nephroblastoma survivors (two being ill at the time, one 
lost to follow-up, and five refused to participate) and six neuroblastoma survivors (three 
were currently pregnant, two being ill at the time, and one refused to participate) did 
not participate. In total, 103 adult survivors (67 nephroblastoma and 36 neuroblastoma 
survivors) participated in the current study. In addition, 60 healthy control subjects were 
included. The main reason for control subjects not to participate was that they had to take 
a day off work. Ninety-four percent (n=97) of the survivors and 83% (n=50) of the control 
subjects answered all the questions of the SQUASH. Median age of nephroblastoma 
survivors was 30.2 years (range 18.8-50.8), of neuroblastoma survivors 29.6 years (range 
20.4-46.2), and of control subjects 32.1 years (range 18.0-61.7). Median age at diagnosis 
was 2.3 years (range 0.0-12.7) and median follow-up time after cessation of treatment was 
26.2 years (range 6.4-48.9) in nephroblastoma survivors and 27.8 years (range 15.0-44.4) in 
neuroblastoma survivors. Characteristics of the study participants are shown in Table 3.1.
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Outcomes
Physical activity scores in nephroblastoma survivors (n=67, missing n=3) (median 8140; 
P=0.721) were not different from controls (n=60, missing n=10) (median 8080), whereas 
neuroblastoma survivors (n=36, missing n=3) had lower physical activity scores than 
controls (median 6685; P=0.043). Physical activity scores in female survivors of both 
nephroblastoma (n=28, missing n=1) (median 8490; P=0.205) and neuroblastoma (n=21, 
missing n=2) (median 7190; P=0.979) were not significantly different from sex-matched 
controls (n=27, missing n=5) (median 7200). Physical activity score of male nephroblas-
toma survivors (n=39, missing n=2) was not different from controls (n=27, missing n=5) 
(median 8040 vs. 9528; P=0.442). Male survivors of neuroblastoma (n=15, missing n=1), 
Table 3.1. Baseline characteristics 
Nephroblastoma Neuroblastoma Controls
n 67 36 60
Male/female 39/28 15/21 27/33
Age at follow-up (years)a 30.2 (18.8-50.8) 29.6 (20.4-46.2) 32.1 (18.0-61.7)
Age at diagnosis (years)a 3.3 (0.0-12.7) 0.8 (0.0-11.7) NA
Follow-up time (years)a 26.2 (6.4-48.9) 27.8 (15.0-44.4) NA
Stage:
I 32 6 NA 
II 13 17 NA 
III 11 8 NA 
IV 3 2 NA 
V 1 0 NA 
Unknown 7 3 NA 
Surgery (n) 67 36 NA
Radiotherapy (n) 35 12 NA
Cumulative dose (Gy) 25 (15-40) 20 (10-30) NA 
Chemotherapy (n) 59 31 NA
Smoking:
Non-smoking 44 (65.7%) 17 (47.2%) 28 (46.7%) 
Former smoker 8 (11.9%) 8 (22.2%) 10 (16.7%) 
Current smoker 15 (22.4%) 11 (30.6%) 19 (31.7%) 
Missing 0 (0.0%) 0 (0.0%) 3 (5.0%) 
Educational status:
Low 4 (6.0%) 1 (2.8%) 1 (1.7%) 
Intermediate 31 (46.3%) 17 (47.2%) 33 (55.0%) 
High 32 (47.8%) 18 (50.0%) 24 (40.0%) 
Missing 0 (0.0%) 0 (0.0%) 2 (3.3%) 
aData are expressed as median (range) or n. Gy = Gray; n = number; NA = not applicable.
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however, reported a significantly lower physical activity score than male control subjects 
(median 6390 vs. 9528; P=0.031) (Table 3.2).
Female nephroblastoma survivors (n=28, missing n=0) seemed to adhere more of-
ten to the physical activity guidelines (at least 30 minutes of activity per day at least 
5 days a week) than female controls (n=27, missing n=1), however, this difference was 
not significant (64.3% vs. 44.4%, P=0.180). Adherence to the guideline was comparable 
between female neuroblastoma survivors (n=21, missing n=0) and female controls 
(47.6% vs. 44.4%, P=0.920) (Table 3.2). Male survivors of nephroblastoma (n=39, miss-
ing n=0) (35.9%, P=0.066) and male survivors of neuroblastoma (n=15, missing n=0) 
(33.3%, P=0.119) seemed to adhere less frequently to the guidelines than male controls 
(n=33, missing n=0) (57.5%), however, these differences were not significant (Table 3.2). 
There were no differences in median BMI and NT-proBNP between survivors and control 
subjects (Table 3.2), however, both nephroblastoma and neuroblastoma survivors more 
often had high (>13.5pmol/L) NT-proBNP levels (Table 3.2). Spinal deformities were 
present in 43/92 (42%) of assessed survivors.
After correction for the possible confounding effects of age, sex, educational level, 
smoking, NT-proBNP, and BMI, the adjusted mean physical activity scores between female 
Table 3.2. Daily life physical activity scores, body mass index, and NT-proBNP in survivors and controlsa
Control subjects Nephroblastoma P-valued Neuroblastoma P-valuee
Physical activity score
Males 9528 (2835-20640) 8040 (3450-16310) 0.442 6390 (840-21150) 0.031 
Females 7200 (2480-14220) 8490 (2295-16410) 0.205 7190 (3710-14070) 0.979 
Missing 10 (16.7%) 3 (4.5%) 3 (8.3%) 
Adherence to Dutch recommendationsb
Males 19 (57.5%) 14 (35.9%) 0.066 5 (33.3%) 0.119 
Females 12 (44.4%) 18 (64.3%) 0.180 10 (47.6%) 0.920 
Missing 1 (1.7%) 0 (0.0%) 0 (0.0%) 
Body mass index (kg/m2)
Males 23.8 (20.1-35.2) 24.1 (19.1-32.3) 0.755 24.3 (18.8-36.5) 0.864 
Females 25.4 (20.3-41.8) 24.7 (19.4-36.3) 0.680 23.6 (17.5-30.2) 0.145 
Missing 1 (1.7%) 0 (0.0%) 0 (0.0%) 
NT-proBNP (pmol/L) 3.4 (0.5-11.4) 4.3 (0.5-95.6) 0.185 3.9 (0.5-38.0) 0.351
High NT-proBNP (n)c 0 (0.0%) 10 (15.4%) 0.002 3 (8.6%) 0.052 
Missing 3 (5.0%) 2 (3.0%) 1 (2.8%) 
aData are expressed as median (range) or n. bAt least five days a week at least 30 minutes of activity. cDe-
fined as NT-proBNP >13.5pmol/L. dAdult nephroblastoma survivors compared with control subjects. eAdult 
neuroblastoma survivors compared with control subjects. n = number; NT-proBNP = N-terminal pro B-type 
natriuretic peptide.
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controls (8062), female nephroblastoma survivors (9235), and female neuroblastoma 
survivors (7898) were not signifi cantly diff erent (Figure 3.1). The adjusted mean physical 
activity score in male neuroblastoma survivors was signifi cantly lower compared with 
male controls (mean 7155 vs. 10574; P=0.004). The adjusted mean physical activity score 
in male nephroblastoma survivors also seemed to be lower than in controls; however, 
this diff erence was not signifi cant (mean 9122 vs. 10574; P=0.108) (Figure 3.2). Physical 
activity scores in male control subjects were signifi cantly higher compared with female 
control subjects (P=0.015). To assess the infl uence of spinal deformities on the physical 
activity score, we performed a multiple linear regression analysis in survivors only, which 
enabled us to adjust for age, sex, smoking, educational level, NT-proBNP, and BMI. No 
associations between physical activity score and spinal deformities were found (β=1219, 
P=0.116).
Figure 3.1. Adjusted mean physical activity scores in females
Adjusted means are corrected for age, sex, smoking, educational level, NT-proBNP, and BMI. Female control 
subjects n=33, missing n=5. Female nephroblastoma survivors n= 28, missing n=1. Female neuroblastoma 
survivors n=21, missing n=2.
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DISCUSSION
We investigated daily life physical activity in 67 nephroblastoma and 36 neuroblas-
toma survivors compared with 60 socio-demographically comparable healthy control 
subjects. After correction for age, sex, smoking status, educational level, BMI, and NT-
proBNP, male survivors of neuroblastoma reported less daily life physical activity than 
male control subjects.
It is unknown why male neuroblastoma survivors are less physically active than their 
healthy peers. Specifi c late eff ects of cancer treatment could possibly induce such be-
haviour. Cardiac late eff ects and deformities such as scoliosis may infl uence daily life 
physical activity, but in our study, spinal deformities and NT-proBNP did not infl uence 
daily life physical activity.
Physical activity scores in female survivors were not diff erent from female control sub-
jects. It is possible that female survivors are more concerned about their health status 
and therefore commit more often in physical activity. Compared with the male control 
subjects, female control subjects were less physically active. This is consistent with previ-
Figure 3.2. Adjusted mean physical activity scores in males
Adjusted means are corrected for age, sex, smoking, educational level, NT-proBNP, and BMI. Male control 
subjects n=27, missing n=5. Male nephroblastoma survivors n= 39, missing n=2. Male neuroblastoma sur-
vivors n=15, missing n= 1.
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ous reports which showed that healthy males are more physically active than females 
both on a daily basis and based on committing to sports.13, 14 Similarly, the percentage 
of healthy siblings in the Childhood Cancer Survivors Study not meeting the physical 
activity guidelines was also somewhat higher in females than in males.15
Our data concerning male neuroblastoma survivors are in concordance with findings 
of Ness and colleagues. In contrast to our study, they reported that also female survivors 
of nephroblastoma and neuroblastoma were more likely to report an inactive lifestyle 
compared with siblings.15 Differences in the assessment of not only physical activity but 
also in health behaviour and lifestyle between the different countries might contribute 
to these discrepant findings.
Our study has some important strengths. We used a proven reliable and validated 
questionnaire to assess daily life physical activity, developed specifically for the Dutch 
adult population. The relatively complete follow-up of survivors limits the possibility of 
selection bias. Furthermore, we were able to compare physical activity in adult survivors 
of childhood cancer with an age, sex, and socio-demographically similar control group. 
Moreover, we investigated the influence of several potential confounders on daily life 
physical activity. Limitations of our study are the relatively small group of survivors and 
the use of a subjective measurement of physical activity instead of an objective mea-
surement. Studies in larger groups of survivors might reveal more detailed information 
on therapy subgroups and their influence on physical activity.
In conclusion, using the SQUASH we found that male neuroblastoma survivors report 
less daily physical activity than controls. Physical activity in male nephroblastoma 
survivors and female nephroblastoma and neuroblastoma survivors was comparable 
with that in controls. Future research on physical activity in adult survivors of childhood 
cancer should investigate large populations of survivors and focus on all types of child-
hood malignancies.
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Appendix A: Reprinted with kind permission from Wendel-Vos et al. J Clin Epidemiol 56(12), 2003: 1163-9. 
© 2003 Elsevier. All rights reserved.
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ABSTRACT
Objective: Studies investigating long-term health conditions in patients with cranio-
pharyngioma are limited by short follow-up durations and do generally not compare 
long-term health effects according to initial craniopharyngioma treatment approach. In 
addition, studies comparing long-term health conditions between patients with child-
hood- and adult-onset craniopharyngioma report conflicting results. The objective of 
this study was to analyse a full spectrum of long-term health effects in patients with 
craniopharyngioma according to initial treatment approach and age group at cranio-
pharyngioma presentation.
Design: Cross-sectional study based on retrospective data.
Methods: We studied a single-centre cohort of 128 patients with craniopharyngioma 
treated from 1980 onwards (63 patients with childhood-onset disease). Median follow-
up since presentation was 13 years (interquartile range 5-23 years). Initial craniopharyn-
gioma treatment approaches included gross total resection (n=25), subtotal resection 
without radiotherapy (n=44), subtotal resection with radiotherapy (n=25), cyst aspira-
tion without radiotherapy (n=8), and 90Yttrium brachytherapy (n=21).
Results: Pituitary hormone deficiencies (98%), visual disturbances (75%), and obesity 
(56%) were the most common long-term health conditions observed. Different initial 
craniopharyngioma treatment approaches resulted in similar long-term health effects. 
Patients with childhood-onset craniopharyngioma experienced significantly more 
growth hormone deficiency, diabetes insipidus, panhypopituitarism, morbid obesity, 
epilepsy, and psychiatric conditions compared with patients with adult-onset disease. 
Recurrence-/progression-free survival was significantly lower after initial craniopharyn-
gioma treatment with cyst aspiration compared with other therapeutic approaches. Sur-
vival was similar between patients with childhood- and adult-onset craniopharyngioma.
Conclusions: Long-term health conditions were comparable after different initial cra-
niopharyngioma treatment approaches and were generally more frequent in patients 
with childhood- compared with adult-onset disease.
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INTRODUCTION
Craniopharyngiomas are benign (supra)sellar tumours of epithelial histology that often 
exhibit calcifications and fluid-filled cysts.1 They affect both children and adults, and 
have peak incidences between 5-9 and 40-44 years of age.2 Since their discovery in 1857 
by Von Zenker,3 there has been controversy about their aetiology, pathogenesis, and op-
timal therapeutic approach.4 In general, craniopharyngioma treatment aims to provide 
long-term survival and disease control while preserving quality of life by minimizing 
tumour- and treatment-related morbidity. This is challenging due to close proximity of 
the tumour to vital brain structures, like the hypothalamic-pituitary system and visual 
pathways.1 Craniopharyngiomas are generally treated with neurosurgical excision with 
or without postoperative radiotherapy. Alternative treatment options include intra-
cystic appliance of beta-emitting isotopes or chemotherapeutic substances, as well as 
stereotactic radiosurgery.5 Although craniopharyngioma treatment is predominantly 
individualized based on tumour and patient characteristics, the aggressiveness of the 
therapeutic approach varies from centre to centre.6 Some centres favour initial extensive 
excision whereby preserving hypothalamic and optic functions,7-15 while other centres 
prefer a more conservative approach comprising limited resection or cyst decompres-
sion.16-20
Although recent studies on craniopharyngioma report encouraging 10-year overall 
survival rates between 40-95%,10, 21-25 serious long-term health conditions related to tu-
mour and treatment are frequent,10, 20, 22-24, 26-31 and significantly impair quality of life.28, 32 
Most studies assessing long-term health effects in patients with craniopharyngioma 
are limited by short follow-up durations of less than ten years.10, 20, 22-27, 32-34 Furthermore, 
only a few studies compare long-term health conditions according to initial craniopha-
ryngioma treatment approach.17, 35-37 Moreover, studies comparing long-term health 
effects between patients with childhood- and adult-onset craniopharyngioma report 
conflicting results.28, 30, 36
The objective of the present study is to analyse a full spectrum of long-term health 
conditions in patients with craniopharyngioma according to initial treatment approach 
and age group at craniopharyngioma presentation.
SUBjECTS AND METHODS
Participants
Patients who were diagnosed with and/or treated for craniopharyngioma at the Erasmus 
University Medical Centre were eligible for participation in this cross-sectional study 
based on retrospective data. In order to reduce heterogeneity in our study population 
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attributable to time-related differences in craniopharyngioma treatment, neuroimag-
ing, and supportive care, we chose to include only patients with craniopharyngioma 
treated from 1980 onwards. Our local institutional review board approved this study and 
all patients gave their informed consent.
Data collection
Patients were identified by a computer-based search in the electronic patient files. This 
search yielded 145 patients with craniopharyngioma of whom 128 were treated from 
1980 onwards. Of these 128 patients, 63 presented < 18 years of age (i.e. childhood-
onset), and 65 ≥ 18 years of age (i.e. adult-onset). Patients presented between 1978-
2015 and were followed-up for a median 13 years (interquartile range 5-23 years). Diag-
noses of all but three craniopharyngiomas were histologically verified. Data regarding 
baseline characteristics, presenting symptoms, hydrocephalus, tumour localization and 
consistency, treatment, long-term health conditions, and survival were extracted from 
the medical records.
Craniopharyngioma localization and characteristics
Data regarding craniopharyngioma localization and consistency at diagnosis were ob-
tained from neuroimaging and neurosurgery reports. Craniopharyngioma localization 
was defined as intrasellar, suprasellar, or both intra- and suprasellar. Craniopharyngioma 
consistency was characterized as unicystic, multicystic, or solid. Computed tomography 
and magnetic resonance imaging became available in our institution in 1976 and 1990, 
respectively.
Craniopharyngioma treatment
Initial craniopharyngioma treatment approaches were subdivided in gross total resec-
tion (n=25), subtotal resection without radiotherapy (n=44), subtotal resection with 
radiotherapy (n=25), cyst aspiration without radiotherapy (n=8), and 90Yttrium brachy-
therapy (n=21). Three patients were treated with neurosurgical excision but had an 
unknown degree of resection and two patients were treated with other therapeutic ap-
proaches (radiotherapy only [n=1], cyst aspiration with radiotherapy [n=1]). These latter 
five patients were excluded from the analyses according to initial craniopharyngioma 
treatment approach. Gross total resection was defined as complete removal of the 
craniopharyngioma as documented by the neurosurgeon, without residual disease on 
postoperative imaging. In each patient, the initial therapeutic approach was based on 
the treating physicians’ preferences. Since the nineties, all patients were systematically 
discussed in multidisciplinary meetings by specialists in (paediatric) neurosurgery, (pae-
diatric) endocrinology, paediatric neurology, paediatric oncology, radiation-oncology, 
and neuroradiology.
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Long-term health conditions
Visual disturbances, epilepsy requiring treatment, neurological deficits, cognitive impair-
ment, behavioural changes, psychiatric conditions requiring treatment (postoperative 
delirium excluded), weight status, obstructive sleep apnoea, pituitary hormone defi-
ciencies, secondary neoplasms, and cardio- and cerebrovascular events were studied as 
outcomes reflecting long-term health conditions. Visual disturbances were diagnosed 
based on ophthalmic examinations. Visual acuity was determined after correction for 
refraction disorders. Visual field defects were diagnosed with Goldmann perimetry. Neu-
rological deficits were classified into two categories (i.e. mild and severe) based on their 
reported impact on independent daily living. Deficits that had no impact were classified 
as mild; deficits that compromised independent daily living were classified as severe. 
Cognitive impairment and behavioural changes were considered to be present whenev-
er documented in the patient files. Weight status was classified according to body mass 
index. Obstructive sleep apnoea was diagnosed by polysomnography in patients with 
suspected sleep-disordered breathing. Pituitary hormone deficiencies were confirmed 
by formal pituitary function testing in all patients. In ten patients, the pituitary gland 
was completely removed during neurosurgical excision of the craniopharyngioma.
Survival
Overall and recurrence-/progression-free survival were calculated since initial cranio-
pharyngioma treatment. Craniopharyngioma recurrence/progression was diagnosed 
with neuroimaging. Recurrence was defined as reappearance of the craniopharyngioma 
after gross total resection. Progression was defined as re-growth of the craniopharyn-
gioma after subtotal resection, irradiation, cyst aspiration, or 90Yttrium brachytherapy. 
Follow-up neuroimaging was performed regularly, based on physician’s preference and 
clinical judgement. Cause of death was classified as directly related to the craniopharyn-
gioma itself or not.
Statistics
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS 
24, Chicago, IL, USA). Continuous variables were described as median and interquartile 
range; discrete variables as frequencies and percentages. Evaluations were based on 
the number of patients with available data. Comparisons according to initial cranio-
pharyngioma treatment approach were performed by one-way analyses of variance for 
continuous variables and Chi-squared tests for discrete variables. In case assumptions 
were not met, Kruskal-Wallis tests and likelihood ratio statistics were used. Comparisons 
between patients with childhood- and adult-onset craniopharyngioma were made by 
Student’s t-test for continuous variables and Chi-squared tests for discrete variables. 
Mann-Whitney U-tests and likelihood ratio statistics or Fisher’s exact tests were used 
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in case assumptions were not met. Overall and recurrence-/progression-free survival 
were estimated by Kaplan-Meier methods. Log-rank tests were used to compare sur-
vival curves. In case statistical significance was reached in a variable concerning more 
than two groups, Bonferroni-corrected post-hoc analyses were performed to specify 
subgroup-related differences. Because certain long-term health conditions may only 
become apparent after a prolonged follow-up period, and because craniopharyngioma 
management may have evolved over time due to advances in treatment, neuroimaging, 
and supportive care, we investigated the influence of treatment decade and follow-up 
duration since initial craniopharyngioma treatment on the development of long-term 
health effects using multivariable logistic regression models including treatment de-
cade and follow-up duration as independent variables. We investigated the influence of 
treatment decade on survival by log-rank tests for trend. A P-value < 0.05 (two-tailed) 
was considered statistically significant.
RESULTS
Presenting symptoms
Presenting symptoms in patients with craniopharyngioma are shown in Table 4.1. Visual 
disturbances, pituitary hormone deficiencies, and headaches were the most common 
disease manifestations and occurred in 87%, 71%, and 68% of the patients, respectively. 
Hypogonadotropic hypogonadism was the most common pituitary hormone deficiency 
and affected 60% of the patients. Diabetes insipidus was found in 7% of the patients. 
Underweight and obesity affected 10% and 12% of the patients, respectively. Two 
patients (both with childhood-onset craniopharyngioma) presented with blindness. 
Patients with childhood-onset craniopharyngioma presented significantly more growth 
hormone deficiency (53% vs. 27%, P<0.01) compared with patients with adult-onset 
craniopharyngioma. Visual field defects (85% vs. 59%, P<0.01), cognitive impairment 
(16% vs. 3%, P=0.02), overweight (39% vs. 16%, P<0.01), and secondary hypothyroidism 
(56% vs. 32%, P<0.01) were significantly more common in patients with adult- compared 
with childhood-onset craniopharyngioma.
Craniopharyngioma characteristics at diagnosis
Tumour characteristics at diagnosis are depicted in Table 4.1. Tumour consistency 
was significantly different between patients with childhood- and adult-onset cranio-
pharyngioma. Bonferroni-corrected post-hoc analyses revealed a significantly higher 
number of multicystic craniopharyngiomas in patients with childhood- compared with 
adult-onset disease (45% vs. 21%; P=0.02). Hydrocephalus, as well as hypothalamic and/
or third ventricle involvement were also significantly more common in patients with 
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Table 4.1. Baseline characteristics, presenting symptoms, and tumour characteristics at diagnosis
All
craniopharyngiomas
(n=128)
n (%)
Childhood-
onset
(n=63)
n (%)
Adult-
onset
(n=65)
n (%)
Childhood
- vs. adult-
onset
P-value
Baseline characteristics
Gender ♂ 57 (45)
♀ 71 (56)
♂ 25 (40)
♀ 38 (60)
♂ 32 (49)
♀ 33 (51)
0.28
Median age at presentation (yr.) (interquartile 
range)
19 (8-42) 8 (5-12) 41 (29-55) < 0.01
Presenting symptoms
Headaches 83 (68) 42 (71) 41 (65) 0.47
Visual acuity disorders 73 (73) 33 (72) 40 (74) 0.79
Visual field defects 72 (74) 23 (59) 49 (85) < 0.01
Epilepsy 7 (6) 6 (10) 1 (2) 0.06
Neurological deficits 42 (34) 25 (42) 17 (27) 0.07
Altered level of consciousness 26 (21) 15 (25) 11 (18) 0.28
Cognitive impairment 12 (10) 2 (3) 10 (16) 0.02
Behavioural changes 15 (12) 8 (14) 7 (11) 0.68
History of weight change: 0.14
- Increase 13 (11) 3 (5) 10 (16) 
- Decrease 19 (16) 9 (15) 10 (16) 
Weight status (BMI [kg/m2]):
- Underweight (< 18.5) 10 (10) 8 (16) 2 (4) 0.09 
- Normal weight (18.5-24.9) 51 (51) 31 (61) 20 (41) 0.05 
- Overweight (25.0-29.9) 27 (27) 8 (16) 19 (39) < 0.01 
- Class I obesity (30.0-34.9) 7 (7) 2 (4) 5 (10) 0.26 
- Class II obesity (35.0-39.9) 2 (2) 0 (0) 2 (4) 0.24 
- Class III obesity (≥ 40.0) 3 (3) 2 (4) 1 (2) 1.00 
- Class I-III obesity (≥ 30.0) 12 (12) 4 (8) 8 (16) 0.19 
Pituitary hormone deficiencies: 87 (71) 40 (68) 47 (73) 0.49
- GH 48 (40) 31 (53) 17 (27) < 0.01 
- FSH/LH 49 (60) 10 (56) 39 (61) 0.68 
- ACTH 42 (34) 17 (28) 25 (39) 0.21 
- TSH 54 (44) 19 (32) 35 (56) < 0.01 
- ADH 8 (7) 4 (7) 4 (6) 1.00 
- Anterior PH 17 (14) 10 (17) 7 (12) 0.39 
- Complete PH 4 (3) 2 (3) 2 (3) 1.00 
Tumour characteristics
Localization: 0.87
- Intrasellar 5 (4) 3 (5) 2 (3) 
- Suprasellar 48 (39) 23 (38) 25 (40) 
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childhood- compared with adult-onset craniopharyngioma (40% vs. 18%, P<0.01; 66% 
vs. 42%, P=0.01). Patient and tumour characteristics were not significantly different 
between different initial craniopharyngioma treatment approaches (Table 4.2).
Craniopharyngioma treatment
In the patients who were initially treated with neurosurgical excision, the neurosurgical 
approach was transsphenoidal in 35 patients (39%), subfrontal in 31 patients (35%), 
pterional in 20 patients (23%), transcallosal in two patients (2%), and supra-orbital 
in one patient (1%). In five patients (5%) data regarding the neurosurgical approach 
were missing. There were no significant differences in the neurosurgical approaches 
used between patients treated with gross total resection, subtotal resection without 
radiotherapy, and subtotal resection with radiotherapy. Initial craniopharyngioma 
treatment approaches, as well as neurosurgical approaches were not significantly dif-
ferent between patients with childhood- and adult-onset craniopharyngioma. In the 
patients who initially received radiotherapy, conventional external beam radiotherapy 
was applied to eight patients and stereotactic radiotherapy to 16 patients. In four pa-
Table 4.1. Baseline characteristics, presenting symptoms, and tumour characteristics at diagnosis (con-
tinued)
All
craniopharyngiomas
(n=128)
n (%)
Childhood-
onset
(n=63)
n (%)
Adult-
onset
(n=65)
n (%)
Childhood
- vs. adult-
onset
P-value
- Intra-/suprasellar 70 (57) 34 (57) 36 (57) 
Consistency: 0.02
- Unicystic 71 (61) 29 (52) 42 (69) 
- Multicystic 38 (33) 25 (45) 13 (21) 
- Solid 8 (7) 2 (4) 6 (10) 
Presence of hydrocephalus 36 (29) 25 (40) 11 (18) < 0.01
Hypothalamic and/or third ventricle involvement 60 (53) 35 (66) 25 (42) 0.01
Brain stem compression 16 (14) 6 (11) 10 (17) 0.39
Data regarding headaches, epilepsy, neurological deficits, altered level of consciousness, cognitive impair-
ment, behavioural changes, and weight change were missing in six patients. Data regarding visual acuity 
disorders and visual field defects were missing in 28 and 31 patients, respectively. Weight status could not 
be determined in 28 patients. Data regarding pituitary hormone deficiencies were missing in eight patients 
(growth hormone [GH] in seven patients, follicle stimulating hormone/luteinizing hormone [FSH/LH] in 
four patients, adrenocorticotropic hormone [ACTH] in four patients, thyroid stimulating hormone [TSH] in 
five patients, antidiuretic hormone [ADH] in four patients, and anterior and complete panhypopituitarism 
[PH] in eight patients). 42 patients were too young to reliably assess gonadal function (girls < 14 years of 
age; boys < 15 years of age). Data regarding initial craniopharyngioma localization, consistency, hydro-
cephalus, hypothalamic and/or third ventricle involvement, and brain stem compression were missing in 
five, 11, three, 15, and 14 patients, respectively. ♂ = male; ♀ = female; % = percentage; BMI = body mass 
index; kg/m2 = kilograms per square metre; n = number; yr. = years.
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tients, detailed information on the type of radiotherapy was missing. In the patients 
who initially received radiotherapy, the median cumulative radiation dose was 54 Gy 
(interquartile range 54-54 Gy); delivered in a median 30 fractions (interquartile range 
30-30 fractions). The median duration between neurosurgery and radiotherapy was two 
months (interquartile range 1-6 months).
In our institution, initial craniopharyngioma treatment changed over time (Figure 
4.1). The use of gross total resection declined from 22% in 1980-1989 to 12% in ≥2010. 
Meanwhile, the use of subtotal resection (with or without radiotherapy) increased from 
30% in 1980-1989 to 71% in ≥2010. 90Yttrium brachytherapy was predominantly used in 
1980-1989.
Table 4.2. Patient characteristics and tumour characteristics at diagnosis according to initial craniopha-
ryngioma treatment
GTR 
(n=25)
n (%)
STR w/o
RTx
(n=44)
n (%)
STR with
RTx 
(n=25)
n (%)
Cyst
aspiration
(n=8)
n (%)
90Yttrium
(n=21)
n (%)
P-value
Baseline characteristics
Gender ♂ 9 (36)
♀ 16 (64)
♂ 19 (43)
♀ 25 (57)
♂ 11 (44)
♀ 14 (56)
♂ 3 (38)
♀ 5 (63)
♂ 12 (57)
♀ 9 (43)
0.69
Median age at presentation (yr.) 
(interquartile range)
15 (8-37) 26 (9-41) 26 (15-46) 13 (5-71) 11 (6-45) 0.38
Tumour characteristics
Localization: 0.84
- Intrasellar 1 (4) 1 (2) 1 (4) 0 (0) 1 (5) 
- Suprasellar 9 (39) 14 (33) 9 (38) 5 (63) 10 (48) 
- Intra-/suprasellar 13 (57) 28 (65) 14 (58) 3 (38) 10 (48) 
Consistency: 0.81
- Unicystic 15 (65) 23 (58) 15 (65) 5 (63) 13 (65) 
- Multicystic 7 (30) 14 (35) 6 (26) 3 (38) 7 (35) 
- Solid 1 (4) 3 (8) 2 (9) 0 (0) 0 (0) 
Presence of hydrocephalus 6 (25) 10 (23) 5 (21) 5 (63) 7 (33) 0.18
Hypothalamic and/or third ventricle 
involvement
11 (48) 20 (50) 15 (68) 6 (75) 7 (41) 0.28
Brain stem compression 2 (9) 4 (10) 4 (17) 1 (13) 4 (24) 0.65
Data regarding initial craniopharyngioma localization, consistency, hydrocephalus, hypothalamic and/or 
third ventricle involvement, and brain stem compression were missing in four, nine, three, 13, and 12 pa-
tients, respectively. ♂ = male; ♀ = female; % = percentage; 90Yttrium = 90Yttrium brachytherapy; GTR = gross 
total resection; n = number; RTx = radiotherapy; STR = subtotal resection; w/o = without; yr. = years.
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Long-term health conditions
Long-term health conditions in patients with craniopharyngioma are shown in Table 4.3. 
Pituitary hormone deficiencies, visual disturbances, and obesity were the most common 
long-term health effects and affected 98%, 75%, and 56% of the patients, respectively. 
Hypogonadotropic hypogonadism was the most common pituitary hormone deficiency 
and was found in 92% of the patients. Diabetes insipidus was diagnosed in 61% of the 
patients. Five patients demonstrated blindness (four after initial treatment with subtotal 
resection; one after initial treatment with 90Yttrium brachytherapy). Severe neurological 
deficits (i.e. compromising independent daily living) affected 11 patients. In three pa-
tients, severe neurological deficits were directly related to the craniopharyngioma itself. 
One patient developed radiation encephalopathy six years after conventional external 
beam radiotherapy at an age of 41 years. Three patients suffered from radionecrosis 
related to leakage of the installed radio-isotope a median 15 months after 90Yttrium 
brachytherapy at a median age of 54 years. In four patients, cerebrovascular events 
caused severe neurological dysfunction a median seven months after initial craniopha-
ryngioma treatment at a median age of 27 years. This latter group included one child 
who experienced a cerebral infarction of the entire left hemisphere without a known 
cause approximately two years after craniopharyngioma resection.
Long-term health conditions according to initial craniopharyngioma treatment are 
shown in Table 4.4. Initial craniopharyngioma treatment with gross total resection, 
subtotal resection with or without radiotherapy, cyst aspiration, and 90Yttrium brachy-
therapy resulted in a similar pattern of long-term health effects. Long-term health condi-
tions in patients with childhood- compared with adult-onset craniopharyngioma are 
shown in Table 4.3. Patients with childhood-onset craniopharyngioma demonstrated 
significantly more growth hormone deficiency (93% vs. 68%, P<0.01), diabetes insipidus 
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Figure 4.1. Initial craniopharyngioma treatment per decade
% = percentage; 90Yttrium = 90Yttrium brachytherapy; GTR = gross total resection; RTx = radiotherapy; STR 
= subtotal resection; w/o = without.
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Table 4.3. Long-term health conditions in patients with craniopharyngioma
All
craniopharyngiomas 
(n=128)
n (%)
Childhood-
onset
(n=63)
n (%)
Adult-
onset
(n=65)
n (%)
Childhood- 
vs. adult-
onset
P-value
Median follow-up since presentation (yr.) 
(interquartile range)
13 (5-23) 14 (5-23) 11 (6-23) 0.81
Median age at follow-up (yr.) (interquartile 
range)
37 (21-54) 22 (15-31) 54 (44-70) < 0.01
Visual acuity disorders 71 (63) 34 (63) 37 (64) 0.93
Visual field defects 65 (66) 31 (66) 34 (65) 0.95
Epilepsy 30 (23) 20 (32) 10 (15) 0.03
Neurological deficits: 30 (23) 16 (25) 14 (22) 0.61
- Mild 19 (15) 10 (16) 9 (14) 0.75 
- Severe 11 (9) 6 (10) 5 (8) 0.71 
Cognitive impairment 36 (28) 22 (35) 14 (22) 0.09
Behavioural changes 24 (19) 12 (19) 12 (19) 0.93
Psychiatric conditions 50 (39) 35 (56) 15 (23) < 0.01
Weight status (BMI [kg/m2]):
- Underweight (< 18.5) 4 (4) 4 (7) 0 (0) 0.12 
- Normal weight (18.5-24.9) 18 (16) 7 (12) 11 (21) 0.22 
- Overweight (25.0-29.9) 27 (24) 10 (17) 17 (32) 0.07 
- Class I obesity (30.0-34.9) 34 (31) 18 (31) 16 (30) 0.92 
- Class II obesity (35.0-39.9) 11 (10) 5 (9) 6 (11) 0.63 
- Class III obesity (≥ 40.0) 17 (15) 14 (24) 3 (6) < 0.01 
- Class I-III obesity (≥ 30.0) 62 (56) 37 (64) 25 (47) 0.08 
Obstructive sleep apnoea 11 (9) 7 (11) 4 (6) 0.32
Pituitary hormone deficiencies: 125 (98) 61 (97) 64 (99) 0.62
- GH 99 (81) 57 (93) 42 (68) < 0.01 
- FSH/LH 110 (92) 49 (91) 61 (94) 0.73 
- ACTH 111 (87) 54 (86) 57 (88) 0.74 
- TSH 116 (91) 58 (92) 58 (91) 0.77 
- ADH 78 (61) 50 (79) 28 (43) < 0.01 
- Anterior PH 85 (70) 48 (79) 37 (61) 0.03 
- Complete PH 63 (50) 41 (66) 22 (34) < 0.01 
Secondary neoplasmsa 22 (17) 7 (11) 15 (23) 0.07
Cardio- and/or cerebrovascular events 20 (16) 3 (5) 17 (26) < 0.01
Data regarding visual acuity disorders and visual field defects were missing in 16 and 29 patients, respec-
tively. Weight status could not be determined in 17 patients. Data regarding pituitary hormone deficiencies 
were missing in six patients (GH in five patients, FSH/LH in one patient, TSH in one patient, anterior PH in six 
patients, and complete PH in one patient). Eight patients were too young to reliably assess gonadal func-
tion. aSecondary neoplasms included meningioma (n=2), prostate cancer (n=2), breast cancer (n=2), arach-
noid cyst (n=2), thyroglossal duct cyst (n=1), fibroadenoma (n=2), cavernous sinus schwannoma (n=1), 
growth hormone-producing pituitary adenoma (n=1), pineal gland cyst (n=1), pancreatic cancer (n=1), 
lung cancer (n=1), mesothelioma (n=1), bladder cancer (n=1), ovarian cancer (n=1), cervical cancer (n=1), 
calcifying odontogenic cyst (n=1), osteoma of the skull (n=1), haemangioma (n=1), Hodgkin lymphoma 
(n=1), neuro-endocrine tumour of the appendix (n=1). % = percentage; BMI = body mass index; kg/m2 = 
kilograms per square metre; n = number; yr. = years.
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(79% vs. 43%, P<0.01), anterior panhypopituitarism (79% vs. 61%, P=0.03), complete 
panhypopituitarism (66% vs. 34%, P<0.01), morbid obesity (24% vs. 6%, P<0.01), epi-
lepsy (32% vs. 15%, P=0.03), and psychiatric conditions (56% vs. 23%, P<0.01) compared 
with patients with adult-onset craniopharyngioma. Cardio- and cerebrovascular events 
were significantly more common in patients with adult- compared with childhood-onset 
craniopharyngioma (26% vs. 5%, P<0.01).
Initial craniopharyngioma treatment in more recent decades resulted in significant 
reductions of morbid obesity (odds ratio [OR] 0.3, 95% confidence interval [CI] 0.12-
0.86; P=0.02) and severe neurological deficits (OR 0.4, 95% CI 0.21-0.97; P=0.04) after 
adjustment for follow-up duration. In addition, a prolonged follow-up duration after 
craniopharyngioma presentation was associated with a significantly lower risk of severe 
neurological deficits after adjustment for treatment decade (OR 0.9, 95% CI 0.81-0.98; 
P=0.02).
Survival
Overall and recurrence-/progression-free survival after initial craniopharyngioma 
treatment are shown in Figure 4.2 and Figure 4.3. Overall survival was 93%, 85%, and 
77% at 5, 10, and 20 years of follow-up. Recurrence-/progression-free survival was 90%, 
74%, and 52% at 5, 10, and 20 years of follow-up. Although overall survival was com-
parable after initial craniopharyngioma treatment with gross total resection, subtotal 
resection with or without radiotherapy, cyst aspiration, and 90Yttrium brachytherapy, 
recurrence-/progression-free survival was not (P=0.03). Bonferroni-corrected post-hoc 
analyses revealed a significantly lower recurrence-/progression-free survival after initial 
craniopharyngioma treatment with cyst aspiration compared with the other treatment 
approaches (P=0.01). Overall and recurrence-/progression-free survival were similar 
in patients with childhood- and adult-onset craniopharyngioma. Patients with cranio-
pharyngioma recurrence/progression experienced a significantly lower overall survival 
compared with patients without craniopharyngioma recurrence/progression (P<0.01). 
Initial craniopharyngioma treatment in more recent decades resulted in similar overall 
survival (P=0.50 for trend) and lower recurrence-/progression-free survival (P<0.01 
for trend). Overall survival was also similar over time in the subgroup of patients with 
craniopharyngioma recurrence/progression (P=0.46 for trend).
In our study, 22 patients (17%) died during follow-up. In five patients (23%) the cause 
of death was directly related to the craniopharyngioma itself (tumour invading vital 
brain structures [n=4], brain herniation [n=1]). Eleven patients (50%) died of causes not 
directly related to the craniopharyngioma itself (infection [n=4], cardiac arrest [n=2], sec-
ondary malignancies [n=3], cerebrovascular infarction [n=1], radiation encephalopathy 
[n=1]). The cause of death was unknown in six patients (27%). Deaths directly related to 
the craniopharyngioma itself and deaths not directly related to the craniopharyngioma 
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Table 4.4. Long-term health conditions according to initial craniopharyngioma treatment
GTR 
(n=25)
n (%)
STR w/o RTx 
(n=44)
n (%)
STR with RTx 
(n=25)
n (%)
Cyst
aspiration
(n=8)
n (%)
90Yttrium
(n=21)
n (%)
P-value
Median follow-up (yr.) 
(interquartile range)
14 (6-21) 9 (5-23) 10 (6-14) 12 (2-24) 22 (9-29) 0.13
Median age at follow-up (yr.) 
(interquartile range)
30 (18-51) 42 (21-60) 40 (21-65) 37 (18-74) 35 (28-56) 0.72
Visual acuity disorders 10 (50) 24 (63) 14 (58) 5 (71) 16 (84) 0.20
Visual field defects 12 (67) 19 (61) 11 (52) 5 (71) 17 (94) 0.07
Epilepsy 6 (24) 10 (23) 3 (12) 2 (25) 8 (38) 0.36
Neurological deficits: 6 (24) 8 (18) 5 (20) 1 (13) 9 (43) 0.25
- Mild 3 (12) 6 (14) 3 (12) 1 (13) 5 (24) 0.81 
- Severe 3 (12) 2 (5) 2 (8) 0 (0) 4 (19) 0.28 
Cognitive impairment 11 (44) 7 (16) 9 (36) 2 (25) 7 (33) 0.11
Behavioural changes 4 (16) 9 (21) 7 (28) 2 (25) 2 (10) 0.56
Psychiatric conditions 8 (32) 18 (41) 9 (36) 5 (63) 8 (38) 0.65
Weight status (BMI [kg/m2]):
- Underweight (< 18.5) 0 (0) 3 (8) 1 (4) 0 (0) 0 (0) 0.28 
- Normal weight (18.5-24.9) 5 (22) 6 (16) 4 (17) 1 (13) 2 (13) 0.95 
- Overweight (25.0-29.9) 7 (30) 10 (27) 4 (17) 2 (25) 3 (19) 0.82 
- Class I obesity (30.0-34.9) 5 (22) 11 (30) 8 (35) 2 (25) 6 (38) 0.82 
- Class II obesity (35.0-39.9) 2 (9) 2 (5) 3 (13) 2 (25) 2 (13) 0.58 
- Class III obesity (≥ 40.0) 4 (17) 5 (14) 3 (13) 1 (13) 3 (19) 0.98 
- Class I-III obesity (≥ 30.0) 11 (48) 18 (49) 14 (61) 5 (63) 11 (69) 0.58 
Obstructive sleep apnoea 3 (12) 5 (11) 1 (4) 1 (13) 1 (5) 0.71
Pituitary hormone deficiencies: 23 (92) 44 (100) 25 (100) 7 (88) 21 (100) 0.08
- GH 19 (79) 34 (77) 20 (80) 5 (63) 17 (94) 0.33 
- FSH/LH 21 (88) 38 (95) 22 (92) 6 (86) 18 (95) 0.46 
- ACTH 22 (88) 40 (91) 22 (88) 6 (75) 17 (81) 0.71 
- TSH 22 (88) 41 (95) 22 (88) 6 (75) 20 (95) 0.41 
- ADH 17 (68) 30 (68) 13 (52) 4 (50) 10 (48) 0.38 
- Anterior PH 18 (75) 29 (67) 19 (76) 4 (50) 12 (67) 0.66 
- Complete PH 16 (64) 21 (48) 12 (48) 3 (38) 8 (40) 0.49 
Secondary neoplasms 2 (8) 11 (25) 6 (24) 1 (13) 1 (5) 0.12
Cardio- and/or cerebrovascular 
events
2 (8) 8 (18) 4 (16) 2 (25) 4 (19) 0.71
Data regarding visual acuity disorders and visual field defects were missing in 15 and 28 patients, respec-
tively. Weight status could not be determined in 16 patients. Data regarding pituitary hormone deficiencies 
were missing in five patients (GH in four patients, FSH/LH in one patient, TSH in one patient, anterior PH 
in five patients, and complete PH in one patient). Eight patients were too young to reliably assess gonadal 
function. % = percentage; 90Yttrium = 90Yttrium brachytherapy; BMI = body mass index; GTR = gross total 
resection; kg/m2 = kilograms per square metre; n = number; RTx = radiotherapy; STR = subtotal resection; 
w/o = without; yr. = years.
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itself occurred with similar frequencies after initial craniopharyngioma treatment with 
gross total resection, subtotal resection with or without radiotherapy, cyst aspiration, 
and 90Yttrium brachytherapy (P=0.90), as well as in patients with childhood- and adult-
onset disease (P=0.28).
DISCUSSION
In this large single-centre study of patients with craniopharyngioma treated from 1980 
onwards, we cross-sectionally analysed retrospectively collected data on a full spectrum 
of long-term health conditions. After a median follow-up of 13 years since presentation, 
we observed a similar pattern of long-term health effects after initial craniopharyngioma 
treatment with gross total resection, subtotal resection with or without radiotherapy, 
cyst aspiration, and 90Yttrium brachytherapy. In general, long-term health conditions 
were more frequent in patients with childhood- compared with adult-onset craniopha-
ryngioma.
Pituitary hormone deficiencies, visual disturbances, and obesity were the most fre-
quently observed long-term health conditions in our study. This is in concordance with 
other studies that reported prevalence rates of 78-100% for pituitary hormone deficien-
Figure 4.2. Overall survival in patients with craniopharyngioma
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D. Recurrence/progression vs. no recurrence/progression
No recurrence/progression
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A: All patients. B: According to initial craniopharyngioma treatment. C: Patients with childhood- and adult-
onset craniopharyngioma. D: According to recurrence/progression status. 90Yttrium = 90Yttrium brachyther-
apy; GTR = gross total resection; RTx = radiotherapy; STR = subtotal resection; w/o = without.
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cies, 49-87% for visual disturbances, and 27-57% for obesity.10, 20, 22, 23, 26, 28, 30, 32 Notably, 
we observed a relatively high frequency of obstructive sleep apnoea (i.e. 9%) in patients 
with craniopharyngioma. This is considerably higher than the prevalence of obstructive 
sleep apnoea in the Dutch general population, which is estimated to be 1-4%.38 Since 
only patients with suspected sleep disordered breathing were evaluated for obstructive 
sleep apnoea in our study, the observed frequency of 9% may even be an underestima-
tion of the real prevalence of obstructive sleep apnoea in patients with craniopharyn-
gioma. Only a few other studies compared long-term health conditions in patients with 
craniopharyngioma according to initial treatment approach.17, 35-37 In concordance with 
our results, these studies observed no important differences in long-term health effects 
after different initial craniopharyngioma treatment approaches. Lo et al. only observed 
a higher frequency of diabetes insipidus after initial craniopharyngioma treatment with 
neurosurgery compared with craniopharyngioma treatment without neurosurgery in 
123 patients after a median follow-up of 9 years.35 Karavitaki et al. only observed more 
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Figure 4.3. Recurrence-/progression-free survival 
in patients with craniopharyngioma
A: All patients. B: According to initial craniopharyn-
gioma treatment. C: Patients with childhood- and 
adult-onset craniopharyngioma. 90Yttrium = 90Yt-
trium brachytherapy; GTR = gross total resection; 
RTx = radiotherapy; STR = subtotal resection; w/o 
= without.
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visual field defects after initial craniopharyngioma treatment with subtotal resection 
without radiotherapy compared with craniopharyngioma treatment with gross total 
resection or subtotal resection with radiotherapy in 121 patients after a mean follow-
up of 9 years.36 Schoenfeld et al. only observed a higher rate of diabetes insipidus and 
panhypopituitarism after initial craniopharyngioma treatment with gross total resection 
compared with subtotal resection with or without radiotherapy in 122 patients after a 
median follow-up of 5 years.17 Merchant et al. only observed more diabetes insipidus 
and less hypogonadotropic hypogonadism after initial craniopharyngioma treatment 
with gross total resection compared with subtotal resection with radiotherapy in 30 
patients after a median follow-up of 6 years.37
In our study, long-term health conditions seemed to occur more frequently in patients 
with childhood- compared with adult-onset craniopharyngioma. This may be explained 
by differences in tumour characteristics between patients with childhood- and adult-
onset craniopharyngioma already present at diagnosis. In our study, patients with 
childhood-onset craniopharyngioma presented more often with multicystic tumours, 
as well as tumours associated with hydrocephalus and hypothalamic and/or third 
ventricle involvement compared with patients with adult-onset craniopharyngioma. In 
contrast, we observed significantly more cardio- and cerebrovascular events in patients 
with adult- compared with childhood-onset disease. This may be due to the significantly 
older age at follow-up of patients with adult-onset craniopharyngioma. Aging has been 
established as an important risk factor for cardio- and cerebrovascular disease.39 Several 
other studies compared long-term health conditions between patients with childhood- 
and adult-onset craniopharyngioma.28, 30, 36 In concordance with our results, Gautier et 
al. observed a significantly higher prevalence of diabetes insipidus and panhypopitu-
itarism in patients with childhood- compared with adult-onset disease in a cohort of 
171 patients derived from two academic centres in France after a median follow-up of 
12 years.30 In contrast, Kendall-Taylor et al. observed a significantly higher frequency 
of obesity in patients with adult- compared with childhood-onset craniopharyngioma. 
In their study, which included 393 growth hormone-deficient patients from the KIMS 
(Pfizer International Metabolic Database) who were followed for a mean 17 years, 
frequencies of any pituitary hormone deficiency and panhypopituitarism were similar 
between patients with childhood- and adult-onset disease.28 The aforementioned study 
by Karavitaki et al. did not observe any significant differences in long-term health condi-
tions between patients with childhood- and adult-onset craniopharyngioma, except for 
complete dependency for activities of daily living, which was more common in patients 
with adult-onset craniopharyngioma.36
We observed 10-year overall and recurrence-/progression-free survival rates after 
initial craniopharyngioma treatment of 85% and 74%, respectively. This is comparable 
to other studies in patients with craniopharyngioma that reported 10-year overall and 
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recurrence-/progression-free survival rates between 40-95% and 44-76%, respective-
ly.10, 21-25 In our study, overall survival was similar after initial craniopharyngioma treat-
ment with gross total resection, subtotal resection with or without radiotherapy, cyst 
aspiration, and 90Yttrium brachytherapy. However, recurrence-/progression-free survival 
was significantly lower after initial craniopharyngioma treatment with cyst aspiration 
compared with the other therapeutic approaches. Two other studies also investigated 
overall and recurrence-/progression-free survival in patients with craniopharyngioma 
according to initial treatment approach.34, 36 The aforementioned study by Karavitaki et 
al. observed similar overall survival after initial craniopharyngioma treatment with gross 
total resection and subtotal resection with or without radiotherapy. However, recur-
rence-/progression-free survival was significantly lower after initial craniopharyngioma 
treatment with subtotal resection without radiotherapy compared with gross total 
resection or subtotal resection with radiotherapy.36 A recent study by Rao et al. investi-
gated 5-year overall survival in 697 patients with craniopharyngioma registered in the 
United States National Cancer Database. Overall survival was significantly lower after 
subtotal resection without radiotherapy compared with gross total resection or subtotal 
resection with radiotherapy.34 In our study, overall and recurrence-/progression-free sur-
vival were comparable in patients with childhood- and adult-onset craniopharyngioma. 
Other studies observed similar results.24, 30, 36 However, the aforementioned study by Rao 
et al. observed significantly lower overall survival in patients with adult- compared with 
childhood-onset craniopharyngioma.34 Interestingly, patients with craniopharyngioma 
seem to have an increased mortality risk compared with patients with other pituitary 
diseases.21 This might be related to long-term health conditions caused by tumour and 
treatment (e.g. hypopituitarism and hypothalamic dysfunction), as well as to the locally 
aggressive behaviour of craniopharyngiomas and their tendency to recur after treat-
ment.21, 22
In our institution, initial craniopharyngioma treatment became less aggressive over 
time. This is in concordance with other studies.4, 20 We observed significantly lower 
risks of morbid obesity and severe neurological deficits after initial craniopharyngioma 
treatment in more recent decades. In contrast, we observed a significantly higher risk 
of recurrence/progression in patients treated for craniopharyngioma in more recent 
decades.
Strengths of our study include the full spectrum of long-term health conditions 
investigated, as well as the relatively large number of patients treated with 90Yttrium 
brachytherapy assessed. Brachytherapy was first introduced as a treatment for cranio-
pharyngioma in 1952 by Leksell and Liden, and involves the minimally-invasive stereo-
tactic application of beta-emitting isotopes in craniopharyngioma cysts.40 Subsequent 
radiation-induced destruction of epithelial cyst lining results in cyst shrinkage.41 Due to 
the short half-value depth of 90Yttrium in soft tissue, 90Yttrium brachytherapy is not ef-
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fective for solid craniopharyngiomas.42 Only a few other studies investigated long-term 
health conditions after craniopharyngioma treatment with 90Yttrium brachytherapy.42-44 
These studies reported somewhat lower frequencies of long-term health effects com-
pared with our study (55-90% for pituitary hormone deficiencies, 61-90% for visual dis-
turbances, and 51% for obesity). This may be explained by a longer follow-up duration 
after 90Yttrium brachytherapy in our study (22 years vs. 3-12 years in the other studies). 
Besides these strengths, some limitations should be considered when interpreting 
the results of our study. The retrospective nature of data collection may predispose 
to selection bias and missing data. However, due to the rarity of craniopharyngioma 
and the prolonged follow-up duration required to adequately study long-term health 
conditions, it seems unlikely that prospective observational studies with an adequate 
follow-up duration and a sufficient number of patients will become available in the near 
future. In addition, neuroimaging techniques were less sensitive in earlier compared 
with more recent decades. This may have biased the assessment of the degree of cranio-
pharyngioma resection, especially during earlier decades. Furthermore, our results on 
long-term neurocognitive and neuropsychological sequelae should be interpreted with 
caution, as cognitive impairments and behavioral changes were considered present 
when documented in the patient files and have not been formally tested. Moreover, we 
were unable to compare long-term health conditions according to histological subtype 
of craniopharyngioma (i.e. adamantinomatous or papillary), since these data were only 
available in a minority of patients.
In conclusion, our study demonstrates that despite encouraging survival rates, 
long-term health conditions are frequent in patients with craniopharyngioma. Initial 
gross total resection, subtotal resection with or without radiotherapy, cyst aspiration, 
and 90Yttrium brachytherapy result in comparable long-term health effects. Patients 
with childhood-onset craniopharyngioma are generally more affected by long-term 
health conditions than patients with adult-onset disease. Craniopharyngioma should 
be regarded as a chronic condition requiring multidisciplinary management, both at 
diagnosis and during follow-up. Due to the high frequency of endocrine disorders, 
endocrinologists should play a pivotal role in the primary and follow-up care of patients 
with craniopharyngioma. Future studies on craniopharyngioma should focus on modifi-
able risk factors for long-term health conditions, as well as on therapeutic strategies that 
aim to reduce the long-term tumour- and treatment-related morbidity.
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ABSTRACT
Objective: Most studies in patients with craniopharyngioma did not investigate mor-
bidity and mortality relative to the general population, nor evaluated risk factors for 
excess morbidity and mortality. Therefore, the objective of this study was to examine 
excess morbidity and mortality, as well as their determinants in patients with cranio-
pharyngioma.
Design: Hospital-based retrospective cohort study conducted between 1987-2014.
Methods: We included 144 Dutch and 80 Swedish patients with craniopharyngioma 
identified by a computer-based search in the medical records (105 females [47%], 112 
patients with childhood-onset craniopharyngioma [50%], 3153 person-years of follow-
up). Excess morbidity and mortality were analysed using standardized incidence and 
mortality ratios (SIRs and SMRs). Risk factors were evaluated univariably by comparing 
SIRs and SMRs between non-overlapping subgroups.
Results: Patients with craniopharyngioma experienced excess morbidity due to type 
2 diabetes mellitus (SIR 4.4, 95% confidence interval [CI] 2.8-6.8) and cerebral infarc-
tion (SIR 4.9, 95%CI 3.1-8.0) compared to the general population. Risks for malignant 
neoplasms, myocardial infarctions, and fractures were not increased. Patients with cra-
niopharyngioma also had excess total mortality (SMR 2.7, 95%CI 2.0-3.8), and mortality 
due to circulatory (SMR 2.3, 95%CI 1.1-4.5) and respiratory (SMR 6.0, 95%CI 2.5-14.5) 
diseases. Female sex, childhood-onset craniopharyngioma, hydrocephalus, and tumour 
recurrence were identified as risk factors for excess type 2 diabetes mellitus, cerebral 
infarction, and total mortality.
Conclusions: Patients with craniopharyngioma are at increased risk for type 2 diabetes 
mellitus, cerebral infarction, total mortality, and mortality due to circulatory and respira-
tory diseases. Female sex, childhood-onset craniopharyngioma, hydrocephalus, and 
tumour recurrence are important risk factors.
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INTRODUCTION
Craniopharyngiomas are benign epithelial tumours located in the (supra)sellar area 
of the skull that often contain calcifications and fluid-filled cysts. Their locally aggres-
sive behaviour and proximity to critical neurovascular structures (e.g. hypothalamus, 
pituitary, optic nerves, and carotid arteries) characterize them as challenging tumours.1 
Craniopharyngiomas are rare with an estimated incidence rate of 1.7 per million person-
years.2 They affect both children and adults, and have peak incidences between 5-9 
and 40-44 years of age.3 Craniopharyngiomas are generally treated with neurosurgery, 
which is sometimes followed by radiotherapy.1 Despite encouraging 10-year overall sur-
vival rates between 77-93%,2, 4-7 long-term tumour- and treatment-related morbidity is 
common.2, 5-14 Hypopituitarism, visual impairment, and obesity are the most frequently 
observed long-term health conditions in patients with craniopharyngioma.6-11, 14
Although previous studies have examined morbidity and mortality in patients with 
craniopharyngioma, only a few investigated morbidity and mortality in relation to 
the general population. To our knowledge, only one previous study examined excess 
morbidity,2 and only six previous studies investigated excess mortality in patients with 
craniopharyngioma relative to a background population.2, 15-19 The study examining 
excess morbidity observed significantly increased standardized incidence ratios (SIRs) 
for type 2 diabetes mellitus (T2DM), fractures, infections, cerebral infarction, and visual 
impairment.2 The studies that investigated excess mortality reported significantly in-
creased standardized mortality ratios (SMRs) for total mortality between 2.5-9.3.2, 15-19 
Many of these studies were limited by a sample size too small to assess cause-specific 
mortality. The increased risk for morbidity and mortality in patients with craniopharyn-
gioma is likely to be multifactorial, and include tumour- and treatment-related damage 
of critical neurovascular structures, as well as their associated health conditions. To date, 
only three previous studies reported risk factors for excess morbidity and mortality in 
patients with craniopharyngioma.2, 15, 17 These studies evaluated only a few potential risk 
factors but identified female sex, childhood-onset disease, and panhypopituitarism as 
significant determinants of excess morbidity and mortality.
The objective of our study was to examine morbidity and mortality in patients with 
craniopharyngioma in relation to the general population. In addition, the objective was 
to identify risk factors for excess morbidity and mortality in patients with craniopharyn-
gioma.
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MATERIALS AND METHODS
Study population
We performed a hospital-based retrospective cohort study with data from patients 
treated for craniopharyngioma at the Erasmus University Medical Centre (Rotterdam, 
the Netherlands) and the Sahlgrenska University Hospital (Gothenburg, Sweden). We 
conducted our study between 1987-2014 because Swedish general population data on 
morbidity and mortality were only available for this period. To increase the strength of 
our study, we also included patients with craniopharyngioma treated before 1987. These 
patients entered the study on 1st January 1987. A computer-based search in the medical 
records identified 224 patients with craniopharyngioma (144 Dutch and 80 Swedish 
patients) of whom 53 patients (24%) were treated before 1987. The local institutional 
review board of the Erasmus University Medical Centre and the regional ethical review 
board in Gothenburg, Sweden, approved this study. All patients gave their informed 
consent.
Morbidity and mortality
Data on morbidity and mortality in patients with craniopharyngioma were collected from 
the medical records. Data on mortality from the Dutch general population were derived 
from Statistics Netherlands; data on morbidity and mortality from the Swedish general 
population from the Swedish National Patient Registry, the Swedish Cancer Registry, and 
the Swedish National Cause of Death Registry. Data on morbidity from the Dutch gen-
eral population were unavailable. Therefore, we used Swedish general population data 
to examine excess morbidity in Dutch patients with craniopharyngioma. Morbidity and 
cause-specific mortality were categorized according to the International Classification 
of Diseases, Tenth Revision (ICD-10) (see Supplementary data). Malignant neoplasms, 
T2DM, myocardial infarction, cerebral infarction, and fractures were studied as mor-
bidities. Cause-specific mortality was studied for circulatory diseases (ICD-10 chapter 
9) and respiratory diseases (ICD-10 chapter 10). In addition, cause-specific mortality 
was examined for a few particular conditions (i.e. malignant neoplasms, ischemic heart 
disease, and cerebrovascular disease). Baseline, tumour, and treatment characteristics, 
as well as craniopharyngioma recurrence, panhypopituitarism, and weight status at last 
available follow-up visit were studied as risk factors for excess morbidity and mortality. 
Hypothalamic damage was defined as tumour- and/or treatment-related injury to the 
hypothalamus and/or third ventricle as documented in neuroimaging and/or neurosur-
gery reports. Craniopharyngioma recurrence was defined as reappearance or re-growth 
of the tumour after prior treatment. Panhypopituitarism was diagnosed based on formal 
pituitary function testing in all patients. Weight status was classified into obese (i.e. body 
mass index ≥30 kg/m2) and non-obese (i.e. body mass index <30 kg/m2).
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Statistics
Morbidity and mortality were studied as events and compared between patients with 
craniopharyngioma and the general population using SIRs and SMRs. SIRs and SMRs were 
calculated as the ratio of the observed to the expected number of events encountered 
during the study period, as measured in person-years. Corresponding 95% confidence 
intervals (CIs) were calculated assuming a Poisson distribution of the observed number 
of events. Person-years were calculated from the date of study entry to the date of an 
event or end of study (i.e. 31st December 2014). General population data stratified ac-
cording to sex, five-year age group, and one-year calendar period were used to calculate 
the expected number of events. SIRs were calculated depending on whether the patient 
was diagnosed with a specific morbidity on a yearly basis, except for the diagnosis of 
T2DM, which was assessed at the first event only. SIRs and SMRs were not calculated in 
case less than three events were observed. Risk factors for excess morbidity and mortal-
ity were evaluated univariably by comparing SIRs and SMRs between non-overlapping 
subgroups.20 Relevant comparisons were also conducted with the exclusion of patients 
who died within the first six months after their initial craniopharyngioma treatment to 
account for survivorship bias. A P-value <0.05 was considered statistically significant. 
Statistical analyses were conducted using SPSS (version 24) and Stata (version 14).
RESULTS
Patient characteristics
We included 224 patients with craniopharyngioma (105 females [47%]) (Table 5.1). 
Craniopharyngiomas presented <18 years of age (i.e. childhood-onset) in 112 patients 
(50%). Patients were followed-up for a median period of 13 years (interquartile range 
6-21), representing 3153 person-years. Median age at end of study was 42 years (in-
terquartile range 27-59). Growth hormone replacement therapy was used by 78% of 
patients with growth hormone deficiency. Sex steroid replacement therapy was used by 
92% of males and premenopausal females with hypogonadotropic hypogonadism. In 
patients with secondary adrenal insufficiency, the median daily hydrocortisone equiva-
lent dose was 20 milligrams (interquartile range 20-22.5). Patient characteristics were 
similar in females compared to males, except for hypertension (51% vs. 33%; P<0.05) and 
dyslipidaemia (29% vs. 16%; P<0.05).
Excess morbidity 
Excess morbidity and their risk factors in patients with craniopharyngioma are shown in 
Figure 5.1 and Table 5.2, respectively. Twenty patients with craniopharyngioma were di-
agnosed with T2DM compared to the expected number of 4.6, resulting in a significantly 
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Table 5.1. Patient characteristicsa
All patients (n=224) Females (n=105) Males (n=119)
Baseline characteristics
Age at presentation (years)b 20 (9-42) 20 (10-41) 20 (8-42)
Childhood-onset (n [%]) 112 (50) 53 (50) 59 (50) 
Adult-onset (n [%]) 112 (50) 42 (40) 60 (50) 
Follow-up (years)b 13 (6-21) 14 (7-22) 12 (6-21)
Age at end of study (years)b 42 (27-59) 42 (27-57) 41 (26-60)
Tumour characteristics 
Location (n [%])
Intrasellar 5 (2) 1 (1) 4 (4) 
Suprasellar 87 (41) 40 (40) 47 (42) 
Intra-/suprasellar 120 (57) 58 (59) 62 (55) 
Hydrocephalus (n [%]) 62 (28) 32 (31) 30 (26)
Hypothalamic damage (n [%]) 90 (43) 43 (43) 47 (43)
Craniopharyngioma treatment
Neurosurgery (n [%]) 210 (94) 99 (94) 111 (93)
Complete resection 69 (39) 30 (36) 39 (42) 
Incomplete resection 106 (61) 53 (64) 53 (58) 
Radiotherapy (n [%]) 101 (45) 48 (46) 53 (45)
Recurrence (n [%]) 89 (40) 45 (43) 44 (38)
Long-term health conditions
Pituitary hormone deficiencies (n [%]) 215 (96) 100 (95) 115 (97)
GH 180 (83)e 85 (82) 95 (83) 
GH dose (mg/day)b 0.4 (0.3-0.8) 0.5 (0.3-0.8) 0.4 (0.3-0.7) 
FSH/LH 183 (85)f 86 (86) 97 (84) 
TSH 202 (91)g 92 (89) 110 (92) 
ACTH 183 (82)g 83 (79) 100 (84) 
HC equivalent dose (mg/day)b  20 (20-22.5) 20 (16-20) 20 (20-25) 
ADH 141 (63)g 69 (66) 72 (61) 
Panhypopituitarism  114 (51) 58 (55) 56 (48) 
Visual impairment (n [%])c 156 (77) 72 (76) 84 (79)
Obesity (n [%]) 101 (50) 52 (54) 49 (47)
Hypertension (n [%]) 76 (41) 44 (51) 32 (33)
Dyslipidaemia (n [%])d 47 (22) 28 (29) 19 (16)
aEvaluations were based on the number of patients with available data. bMedian (interquartile range). cDe-
fined as a decreased visual acuity after correction for refraction disorder and/or as the presence of a visual 
field defect. dDefined as the use of lipid-lowering drugs. eGrowth hormone replacement therapy was used 
by 141 patients with growth hormone deficiency (78%). fSex steroid replacement therapy was used by 143 
patients with hypogonadotropic hypogonadism (92% of males and premenopausal females). gAll patients 
used hormone replacement therapy. ACTH = adrenocorticotropic hormone; ADH = antidiuretic hormone; 
FSH/LH = follicle stimulating hormone/luteinizing hormone; GH = growth hormone; HC = hydrocortisone; 
mg = milligrams; n = number; TSH = thyroid stimulating hormone.
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increased SIR of 4.4 (95%CI 2.8-6.8). The excess risk for T2DM was significantly higher 
in patients with female sex, childhood-onset craniopharyngioma, hydrocephalus, hy-
pothalamic damage, incomplete tumour resection, radiotherapy, tumour recurrence, 
panhypopituitarism, and obesity. We also observed a significantly increased risk for 
cerebral infarction in patients with craniopharyngioma (SIR 4.9, 95%CI 3.1-8.0). The 
excess risk for cerebral infarction was significantly higher in patients with female sex, 
childhood-onset craniopharyngioma, hydrocephalus, and tumour recurrence. Patients 
Figure 5.1. Excess morbidity and mortality in patients with craniopharyngioma
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Malignant neoplasms
Standardized incidence ratio ± 95%CI
Morbidity in patients with craniopharyngioma
O E SIR (95%CI)
10 11.3 0.9 (0.5-1.6)
7 4.8 1.5 (0.7-3.1)
17 3.4 4.9 (3.1-8.0)
14 11.5 1.2 (0.7-2.1)
a
20 4.6 4.4 (2.8-6.8)
1 5 10 15 20
Cerebrovascular dis ase
Ischemic heart disease
Malignant neoplasms
Respiratory diseases (chapter 10)
Circulatory diseases (chapter 9)
Total mortality
Standardized mortality ratio ± 95%CI
Mortality in patients with craniopharyngioma
O E SMR (95%CI)
34 12.4 2.7 (2.0-3.8)
4 3.5 1.1 (0.4-3.0)
4 0.7 5.8 (2.2-15.5)
4 4.6 0.9 (0.3-2.3)
8 3.5 2.3 (1.1-4.5)
5 0.8 6.0 (2.5-14.5)
Total mortality
Cause-speciﬁc mortality
Particular conditions
ICD-10 chapters
B: Mortality. aObserv d malignant neoplasms included breast cancer (n=1), malignant brain tumour (n=1), 
melanoma (n=1), mesothelioma (n=1), neuro-endocrine tumour of the appendix (n=1), ovarian cancer 
(n=1), pancreatic cancer (n=1), prostate cancer (n=3). CI = confidence interval; E = expected; O = observed; 
SIR = standardized incidence ratio; SMR = standardized mortality ratio; T2DM = type 2 diabetes mellitus.
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with craniopharyngioma had no increased risk for malignant neoplasms, myocardial 
infarction, or fractures.
Excess morbidity was similar in patients treated before and after 1987, except for T2DM 
(SIR 1.8 vs. 5.9; P<0.05) and fractures (SIR 2.2 vs. 0.7; P<0.05). There was no difference 
in excess morbidity between Dutch and Swedish patients (Supplementary Table 5.1). 
To account for survivorship bias, we also evaluated radiotherapy, tumour recurrence, 
panhypopituitarism, and obesity as risk factors for excess morbidity after the exclusion 
of patients who died within the first six months after their initial craniopharyngioma 
treatment (i.e. three patients). This did not significantly affect the results (Supplemen-
tary Table 5.2).
Excess mortality
Excess mortality and risk factors for excess total mortality in patients with craniopha-
ryngioma are shown in Figure 5.1 and Table 5.3, respectively. There were 34 observed 
Table 5.3. Risk factors for excess total mortality in patients with craniopharyngioma 
Risk factors Observed Expected SMR 95%CI P-value
Female 18 3.4 5.3 3.3-8.4
<0.05
Male 16 9.0 1.8 1.1-2.9 
Childhood-onset 13 1.4 9.0 5.3-15.6
<0.05
Adult-onset 21 11.0 1.9 1.2-2.9 
Hydrocephalus 15 1.4 10.5 6.3-17.4
<0.05
No hydrocephalus 19 10.5 1.8 1.2-2.8 
Hypothalamic damagea 16 4.3 3.7 2.3-6.0
0.12
No hypothalamic damage 15 6.9 2.2 1.3-3.6 
Complete resectionb 6 3.5 1.7 0.8-3.9
0.15
Incomplete resection 16 5.0 3.2 2.0-5.2 
Radiotherapy 15 4.8 3.1 1.9-5.2
0.53
No radiotherapy 19 7.6 2.5 1.6-3.9 
Recurrencec 19 3.7 5.1 3.3-8.0
<0.05
No recurrence 14 8.7 1.6 1.0-2.7 
Panhypopituitarismc 15 3.5 4.3 2.6-7.1
<0.05
No panhypopituitarism 18 8.9 2.0 1.3-3.2 
Obesityd 14 4.2 3.3 2.0-5.6
0.08
No obesity 13 7.5 1.7 1.0-3.0 
Treatment <1987 8 3.4 2.4 1.2-4.8
0.64
Treatment ≥1987 26 9.1 2.9 2.0-4.2 
aData missing in three patients who died. bData missing in 12 patients who died. cData missing in one pa-
tient who died. dData missing in seven patients who died. CI = confidence interval; SMR = standardized 
mortality ratio.
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deaths in patients with craniopharyngioma compared to 12.4 expected, resulting in a 
significantly increased SMR for total mortality of 2.7 (95%CI 2.0-3.8). The risk for excess 
total mortality was significantly higher in females compared to males (SMR 5.3 vs. 1.8; 
P<0.05), patients with childhood- compared to adult-onset craniopharyngioma (SMR 
9.0 vs. 1.9; P<0.05), patients with compared to without hydrocephalus (SMR 10.5 vs. 1.8; 
P<0.05), patients with compared to without tumour recurrence (SMR 5.1 vs. 1.6; P<0.05), 
and patients with compared to without panhypopituitarism (SMR 4.3 vs. 2.0; P<0.05). 
There was no difference in excess total mortality between patients treated before and 
after 1987. In addition, excess total mortality was similar in Dutch and Swedish patients 
(Supplementary Table 5.1). The exclusion of the patients who died within the first six 
months after their initial craniopharyngioma treatment did not significantly affect the 
results on risk factors for excess total mortality (Supplementary Table 5.2).
In the analyses on cause-specific mortality, we observed a significantly increased risk 
for mortality due to circulatory diseases (ICD-10 chapter 9) (SMR 2.3, 95%CI 1.1-4.5) and 
respiratory diseases (ICD-10 chapter 10) (SMR 6.0, 95%CI 2.5-14.5). The excess risk for 
mortality due to circulatory diseases was mainly due to cerebrovascular disease. We ob-
served no excess mortality due to malignant neoplasms and ischemic heart disease. The 
low number of observed deaths precluded the reliable assessment of determinants of 
cause-specific mortality. Individual causes of death in patients with craniopharyngioma 
are shown in Supplementary Table 5.3.
DISCUSSION
In this large hospital-based retrospective cohort study, we investigated excess morbid-
ity and mortality in 224 patients with craniopharyngioma after 3153 person-years of 
follow-up. We observed patients with craniopharyngioma to be at significantly increased 
risk for T2DM, cerebral infarction, total mortality, and mortality due to circulatory and 
respiratory diseases relative to the general population. The excess risk for mortality due 
to circulatory diseases was mainly due to a high cerebrovascular mortality. We identified 
female sex, childhood-onset craniopharyngioma, hydrocephalus, hypothalamic dam-
age, incomplete tumour resection, radiotherapy, tumour recurrence, panhypopituita-
rism, and obesity as significant risk factors for excess morbidity and mortality in a series 
of univariable analyses.
Similar to our study, some previous studies investigated morbidity and mortality in 
patients with craniopharyngioma relative to the general population (Table 5.4).2, 15-19 The 
results of these studies are in concordance with our findings regarding the significantly 
increased risk for T2DM, cerebral infarction, total mortality, and mortality due to circula-
tory and respiratory diseases in patients with craniopharyngioma. The increased risk for 
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circulatory diseases in patients with craniopharyngioma seems to be mainly due to an ad-
verse metabolic profile associated with hypothalamic damage and hypopituitarism.14, 21 
Hypothalamic damage may result in acquired leptin and insulin resistance, as well as au-
tonomic nervous system dysfunction, which may altogether promote the development 
of obesity and its associated metabolic derangements.22 The adverse metabolic profile 
associated with hypopituitarism may be due to inadequately treated pituitary hormone 
deficiencies, as well as to currently available hormone replacement regimens that do 
not appropriately simulate hypothalamic-pituitary physiology.23-25 The increased risk for 
respiratory mortality has also been observed in patients with hypopituitarism due to 
other causes,4 and is likely to be due to an increased incidence of severe respiratory tract 
infections. Secondary adrenal insufficiency and glucocorticoid replacement therapy, as 
well as immune dysfunction associated with other pituitary hormone deficiencies seem 
to be responsible for an increased infection risk in patients with hypopituitarism.26 In our 
study, all patients who died from respiratory diseases suffered from secondary adrenal 
insufficiency. In these patients, fatal events were probably at least partly due to adrenal 
crises related to secondary adrenal insufficiency. This is supported by Burman et al., who 
found that adrenal crises in response to acute stress and intercurrent illness contribute 
to death in adult patients with hypopituitarism.27 Patients with craniopharyngioma 
seem to be at increased risk for mortality compared to patients with hypopituitarism 
due to other causes.4 This may be due to craniopharyngioma-specific factors, like a lo-
cally aggressive tumour behaviour, a high recurrence rate, severe hypopituitarism, and a 
high frequency of hypothalamic damage.
We identified female sex, childhood-onset disease, hydrocephalus, tumour recur-
rence, and panhypopituitarism as the most important risk factors for excess morbidity 
and mortality in patients with craniopharyngioma in a series of univariable analyses. 
Although previous studies evaluated only a few potential determinants of excess mor-
bidity and mortality in patients with craniopharyngioma, some of them also observed 
a significantly increased risk for excess morbidity and mortality associated with female 
sex, childhood-onset craniopharyngioma, and panhypopituitarism.2, 15, 17 The reason for 
the increased morbidity and mortality in female compared to male patients with cranio-
pharyngioma is unknown, but sex-specific factors associated with hypopituitarism and 
its management are likely to be involved.4 This is illustrated by studies in patients with 
hypopituitarism due to various causes that also observed a significantly increased risk 
for excess mortality associated with female sex.28 Nielsen et al. suggested that pituitary 
hormone deficiencies may be underdiagnosed in females compared to males due to the 
absence of sex-specific diagnostic tests.29 In their study, they observed a substantially 
lower prevalence of pituitary hormone deficiencies in female compared to male patients 
after surgery for non-functioning pituitary adenoma. In addition, Erfurth et al. reported 
a significantly longer duration of untreated hypopituitarism in female (but not in male) 
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patients with pituitary tumours (including craniopharyngioma) who died of cerebrovas-
cular disease.30 Moreover, some studies suggested that sex-specific differences in the 
pathophysiological states associated with pituitary hormone deficiencies and effects of 
currently available hormone replacement regimens contribute to the increased morbid-
ity and mortality in female compared to male patients with pituitary disease.4, 21, 28
The increased morbidity and mortality in patients with childhood- compared to 
adult-onset craniopharyngioma may be explained by tumour characteristics. Wijnen et 
al. reported that patients with childhood-onset disease present significantly more mul-
ticystic tumours, as well as tumours associated with hydrocephalus and hypothalamic 
damage compared to patients with adult-onset disease.7 Tumour characteristics may 
also explain the significantly increased risk for excess morbidity and mortality associated 
with hydrocephalus and tumour recurrence. Large and aggressive craniopharyngiomas 
that cause hydrocephalus and tend to recur after treatment may induce more tumour- 
and treatment-related brain damage, thereby increasing the risk for excess morbidity 
and mortality.
Radiotherapy is as an important risk factor for cerebrovascular disease.31 Interestingly, 
we observed an equal excess risk for cerebral infarction in patients treated with and 
without radiotherapy. This indicates that other factors, like neurosurgery and an adverse 
metabolic profile associated with hypothalamic damage and hypopituitarism, also 
contribute to the excess risk for cerebral infarction in patients with craniopharyngioma. 
Additionally, our study population may be too young and our follow-up duration too 
short to observe an increased risk for cerebral infarction associated with radiotherapy. 
Previous studies identified an advanced age and a prolonged follow-up duration after 
radiotherapy as important risk factors for radiation-induced cerebrovascular disease.31 
This latter explanation may potentially also apply to the absence of an increased risk for 
myocardial infarction and malignant neoplasms in patients with craniopharyngioma in 
our study.
Our study has several strengths. We investigated morbidity and mortality in patients 
with craniopharyngioma relative to the general population. Additionally, we studied a 
large number of potential risk factors for excess morbidity and mortality. Furthermore, 
through international collaboration, we could establish a large cohort of both patients 
with childhood- and adult-onset craniopharyngioma. The international collabora-
tion also enabled us to replicate our findings in two study populations. Despite these 
strengths, some limitations of our study should be discussed. The (tertiary) hospital-
based setting may induce selection bias of patients with more advanced disease. Ad-
ditionally, we included patients with craniopharyngioma treated before 1987, which 
increased the size of our study population and thereby the strength of our analyses, but 
may have also induced a survivorship bias. However, when we analysed this issue, we did 
not find any survivorship bias, except for T2DM. This indicates that the true excess risk 
126 Chapter 5
for T2DM might be even higher than SIR 4.4 (95%CI 2.8-6.8). Another limitation of our 
study is the use of Swedish general population data to calculate SIRs in Dutch patients 
with craniopharyngioma. Although the Swedish general population has been reported 
to be slightly healthier than the Dutch general population, the difference is minimal.32 
An additional limitation of our study is that we defined hypothalamic damage based on 
data reported in the medical records. Recently, several neuroradiological grading sys-
tems for craniopharyngioma-related hypothalamic damage have been developed.33-36 
Mortini et al. validated some of these classification systems regarding their correlation 
with obesity.37 Unfortunately, due to the retrospective design of our study, we were 
unable to use these classification systems. Future studies are needed to validate these 
grading systems and to investigate their correlation with other symptoms of hypotha-
lamic damage. Furthermore, in our study, data on lifestyle factors and the histological 
subtype of craniopharyngioma were unavailable. Another limitation of our study is that 
the cause of death was unknown in seven patients with craniopharyngioma. Although 
this did not affect the SMR for total mortality, the cause-specific SMRs could have been 
underestimated. Since many patients with craniopharyngioma suffer from growth hor-
mone deficiency and secondary adrenal insufficiency,7 and since these conditions are 
known to be associated with excess circulatory and respiratory mortality,4 it is tempting 
to speculate that mortality due to circulatory, as well as respiratory diseases may have 
been underestimated in our study. In addition, a previous study by Burman et al. has 
shown that deaths due to adrenal crises related to secondary adrenal insufficiency are 
probably underestimated in patients with hypopituitarism as well.27 Moreover, 67 of 
the 80 Swedish patients with craniopharyngioma enrolled in our study also took part 
in a previous study on excess morbidity and mortality in patients with craniopharyn-
gioma.2 This previous population-based study by Olsson et al. was a nationwide study 
that included 307 patients with craniopharyngioma from Sweden. In this study, excess 
morbidity and mortality were investigated using registry-provided data only. Since the 
current study used data derived from the medical records to examine excess morbidity 
and mortality, the results provided in the present study are more accurate and extensive 
compared to the previous study by Olsson et al.2 We were able to study a relatively large 
number of new risk factors for excess morbidity and mortality. In addition, the follow-up 
duration in the current study is considerably longer compared to the previous study 
by Olsson et al. (i.e. median 13 vs. 8 years).2 Lastly, our results on risk factors for excess 
morbidity and mortality should be interpreted cautiously because many determinants 
of excess morbidity and mortality in patients with craniopharyngioma are interrelated 
(e.g. radiotherapy, hypothalamic damage, panhypopituitarism, and obesity).
In conclusion, we observed patients with craniopharyngioma to be at significantly 
increased risk for T2DM, cerebral infarction, total mortality, and mortality due to circu-
latory and respiratory diseases relative to the general population. The excess risk for 
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mortality due to circulatory diseases was mainly due to a high cerebrovascular mortality. 
We identified female sex, childhood-onset disease, hydrocephalus, tumour recurrence, 
and panhypopituitarism as the most important risk factors for excess morbidity and 
mortality in patients with craniopharyngioma in a series of univariable analyses. Since 
excess morbidity and mortality in patients with craniophayrngioma is highly dependent 
on tumour- and treatment-related hypothalamic-pituitary damage, we advocate indi-
vidualized treatment strategies that aim to preserve hypothalamic-pituitary function 
and provide optimal endocrine care.
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SUPPLEMENTARY DATA 
ICD-10 codes for morbidities (ICD-9 codes are shown in parentheses):
Malignant neoplasms: C00-C97 (140-208)
Type 2 diabetes mellitus: E11 (250)
Myocardial infarction: I21 (410)
Cerebral infarction: I63 (430-434, 436-438)
Fractures: S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T14.2 (800.0-800.3, 801.0-
801.3, 802, 803.0-803.3, 804.0-804.3, 805.0-805.7, 806.0-806.7, 807.0-807.6, 808.0-808.5, 
808.8-808.9, 809.0-809.1, 810.0-810.1, 812.0-812.5, 813.0-813.5, 814.0-814.1, 815.0-815.1, 
816.0-816.1, 817.0-817.1, 818.0-818.1, 819.0-819.1, 820.0-820.3, 820.8-820.9, 821.0-
821.3, 822.0-822.1, 823.0-823.3, 824, 825.0-825.3, 826.0-826.1, 827.0-827.1, 828.0-828.1, 
829.0-829.1)
ICD-10 codes for cause-specific mortality (ICD-9 codes are shown in 
parentheses):
Malignant neoplasms: C00-C97 (140-208)
Circulatory diseases (chapter 9): I00-I99 (390-459)
- Ischemic heart disease: I20-I25 (410-414)
- Cerebrovascular disease: I60-I69 (430-438)
Respiratory diseases (chapter 10): J00-J99 (460-519) 
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Supplementary Table 5.1. Excess morbidity and mortality in patients with craniopharyngioma according 
to country of origin
Morbidity Observed Expected SIR/SMR 95%CI P-value
Malignant neoplasms
1.00The Netherlands 6 6.7 0.9 0.4-2.0 
Sweden 4 4.6 0.9 0.3-2.3 
T2DM
0.72The Netherlands 12 2.6 4.7 2.7-8.3 
Sweden 8 2.0 4.0 2.0-8.0 
Myocardial infarction
NCThe Netherlands 5 2.8 1.8 0.7-4.3 
Sweden 2 2.0 NC NC 
Cerebral infarction
0.39The Netherlands 12 2.1 5.7 3.3-10.1 
Sweden 5 1.3 3.7 1.6-9.0 
Fractures
0.76The Netherlands 9 7.0 1.3 0.7-2.5 
Sweden 5 4.5 1.1 0.5-2.7 
Mortality
Total mortality
0.49The Netherlands 24 8.1 3.0 2.0-4.4 
Sweden 10 4.4 2.3 1.2-4.3 
CI = confidence interval; NC = not calculated; SIR = standardized incidence ratio; SMR = standardized mor-
tality ratio; T2DM = type 2 diabetes mellitus.
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Supplementary Table 5.2. Risk factors for excess morbidity and mortality (patients who died ≤6 months 
after their initial craniopharyngioma treatment excluded)
Morbidity Observed Expected SIR/SMR 95%CI P-value
Malignant neoplasms 10 11.3 0.9 0.5-1.7
Radiotherapy 6 5.0 1.2 0.5-2.7
0.32
No radiotherapy 4 6.2 0.6 0.2-1.7 
Recurrence 4 3.8 1.1 0.4-2.8
0.61
No recurrence 6 7.4 0.8 0.4-1.8 
Panhypopituitarism 3 4.2 0.7 0.2-2.2
0.62
No panhypopituitarism 7 7.1 1.0 0.5-2.1 
Obesitya 3 4.8 0.6 0.2-1.9
0.46
No obesity 6 5.8 1.0 0.5-2.3 
T2DM 20 4.6 4.4 2.8-6.8
Radiotherapy 14 2.1 6.8 4.0-11.5
<0.05
No radiotherapy 6 2.5 2.4 1.1-5.3 
Recurrence 10 1.5 6.5 3.5-12.2
<0.05
No recurrence 10 3.0 3.3 1.8-6.2 
Panhypopituitarism 12 1.6 7.3 4.1-12.8
<0.05
No panhypopituitarism 8 2.9 2.7 1.4-5.5 
Obesity 15 1.7 8.8 5.3-14.7
<0.05
No obesity 5 2.6 1.9 0.8-4.7 
Myocardial infarction 6 4.8 1.3 0.6-2.8
Radiotherapy 4 2.1 1.9 0.7-5.0
NC
No radiotherapy 2 2.7 NC NC 
Recurrenceb 3 1.5 2.0 0.6-6.1
NC
No recurrence 2 3.3 NC NC 
Panhypopituitarism 3 1.5 2.1 0.7-6.4
0.29
No panhypopituitarism 3 3.3 0.9 0.3-2.8 
Obesity 4 1.7 2.4 0.9-6.3
NC
No obesity 2 2.9 NC NC 
Cerebral infarction 17 3.4 5.0 3.1-8.0
Radiotherapy 7 1.4 4.9 2.3-10.2
0.97
No radiotherapy 10 2.0 5.0 2.7-9.3 
Recurrencec 9 1.1 8.0 4.2-15.3
<0.05
No recurrence 7 2.3 3.0 1.5-6.4 
Panhypopituitarism 7 1.0 6.9 3.3-14.4
0.29
No panhypopituitarism 10 2.4 4.1 2.2-7.7 
Obesityc 7 1.2 5.6 2.7-11.8
0.70
No obesity 9 2.0 4.6 2.4-8.8 
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Supplementary Table 5.2. Risk factors for excess morbidity and mortality (patients who died ≤6 months 
after their initial craniopharyngioma treatment excluded) (continued)
Morbidity Observed Expected SIR/SMR 95%CI P-value
Fractures 14 11.5 1.2 0.7-2.1
Radiotherapy 5 5.4 0.9 0.4-2.2
0.34
No radiotherapy 9 6.1 1.5 0.8-2.8 
Recurrenced 2 3.9 NC NC
NC
No recurrence 11 7.5 1.5 0.8-2.7 
Panhypopituitarism 6 5.5 1.1 0.5-2.4
0.75
No panhypopituitarism 8 6.0 1.3 0.7-2.7 
Obesityd 5 5.2 1.0 0.4-2.3
0.48
No obesity 8 5.4 1.5 0.7-2.9 
Mortality
Total mortality 31 12.4 2.5 1.8-3.5
Radiotherapy 15 4.8 3.1 1.9-5.2
0.27
No radiotherapy 16 7.6 2.1 1.3-3.4 
Recurrencee 19 3.7 5.1 3.3-8.0
<0.05
No recurrence 11 8.7 1.3 0.7-2.3 
Panhypopituitarisme 15 3.5 4.3 2.6-7.1
<0.05
No panhypopituitarism 15 8.9 1.7 1.1-2.8 
Obesityf 14 4.2 3.3 2.0-5.6
0.08
No obesity 13 7.5 1.7 1.0-3.0 
aData missing in one patient with a malignant neoplasm. bData missing in one patient with a myocardial in-
farction. cData missing in one patient with a cerebral infarction. dData missing in one patient with a fracture. 
eData missing in one patient who died. fData missing in four patients who died. CI = confidence interval; 
NC = not calculated; SIR = standardized incidence ratio; SMR = standardized mortality ratio; T2DM = type 
2 diabetes mellitus.
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Supplementary Table 5.3. Individual causes of death in patients with craniopharyngioma
Sex Age at craniopharyngioma
dx. (yr.)
Cause of death Age at
death (yr.)
Female 2 Cerebral herniation (due to recurrent craniopharyngioma) 4
Female 2 Cerebral herniation (due to recurrent craniopharyngioma) 7
Male 5 Compression of vital brain structures (due to recurrent 
craniopharyngioma) 
28
Female 7 Pneumonia 8
Male 8 Haemorrhagic pancreatitis 12
Female 9 Compression of vital brain structures (due to recurrent 
craniopharyngioma)
18
Female 9 Unknown 29
Female 9 Cerebral haemorrhage 42
Female 12 Cerebral infarction 38
Male 14 Sepsis (in a patient with extensive primary 
craniopharyngioma growth)
25
Male 14 Pneumonia 28
Male 14 Myocardial infarction 43
Male 17 Unknown 28
Male 35 Meningitis 36
Female 35 Unknown 57
Female 36 Non-infective gastro-enteritis (in a patient with extensive 
recurrent craniopharyngioma growth) 
53
Female 40 Cerebral infarction 48
Female 41 Pneumonia 50
Female 41 Myocardial infarction 73
Male 45 Cerebral infarction 67
Female 51 Obesity hypoventilation syndrome 55
Female 54 Unknown 59
Male 54 Lung cancer 78
Male 57 Unknown 65
Male 61 Myocardial infarction 72
Male 62 Prostate cancer 73
Male 63 Compression of vital brain structures (due to primary 
craniopharyngioma)
63
Female 64 Pancreatic cancer 81
Male 67 Myocardial infarction 67
Female 69 Breast cancer 72
Female 69 Unknown 72
Female 72 Unknown 76
Male 77 Pneumonia 80
Male 79 Liver failure 92
dx. = diagnosis; yr. = years.
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ABSTRACT
Objective: Patients with craniopharyngioma are at increased risk for cardio- and cere-
brovascular mortality. The metabolic syndrome (MetS) is an important cardiometabolic 
risk factor, but barely studied in patients with craniopharyngioma. We aimed to investi-
gate the prevalence of and risk factors for the MetS and its components in patients with 
craniopharyngioma.
Design: Cross-sectional study with retrospective data.
Methods: We studied the prevalence of and risk factors for the MetS and its components 
in 110 Dutch (median age 47 years, range 18-92) and 68 Swedish (median age 50 years, 
range 20-81) patients with craniopharyngioma with ≥3 years of follow-up (90 females 
[51%]; 83 patients with childhood-onset craniopharyngioma [47%]; median follow-up 
after craniopharyngioma diagnosis 16 years [range 3-62]). In Dutch patients aged 30-70 
years and Swedish patients aged 45-69 years, we examined the prevalence of the MetS 
and its components relative to the general population.
Results: Sixty-nine of 149 patients with complete data demonstrated the MetS (46%).
Prevalence of the MetS was significantly higher in patients with craniopharyngioma 
compared with the general population (40% vs. 26% [P<0.05] for Dutch patients; 52% 
vs. 15% [P<0.05] for Swedish patients). Multivariable logistic regression analysis identi-
fied visual impairment as a borderline significant predictor of the MetS (OR 2.54, 95%CI 
0.95-6.81; P=0.06) after adjustment for glucocorticoid replacement therapy and follow-
up duration. Age, female sex, tumour location, radiological hypothalamic damage, 
90Yttrium brachytherapy, glucocorticoid replacement therapy, and follow-up duration 
significantly predicted components of the MetS.
Conclusions: Patients with craniopharyngioma are at increased risk for the MetS, espe-
cially patients with visual impairment.
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INTRODUCTION
Craniopharyngiomas are (supra)sellar epithelial tumours that often contain calcifica-
tions and fluid-filled cysts. Despite their benign histology, they are associated with 
significant morbidity due to both tumour and treatment.1 Craniopharyngiomas affect 
children and adults and are predominantly diagnosed between 5-9 and 40-44 years 
of age.2 They are usually treated with neurosurgical excision with or without postop-
erative radiotherapy. Other treatment options include the intracystic appliance of beta-
emitting isotopes or chemotherapeutic substances, as well as stereotactic radiosurgery.1 
Patients with craniopharyngioma are at increased risk for premature mortality.3-6 The 
most important cause of premature mortality in patients with craniopharyngioma is car-
dio- and cerebrovascular disease, with a reported standardized mortality ratio between 
3.2-19.4.4-6 The increased risk for cardio- and cerebrovascular mortality in patients with 
craniopharyngioma is poorly understood but likely to be multifactorial. Tumour- and 
treatment-related damage of critical neurovascular structures (e.g. hypothalamus, 
pituitary, optic nerves, and carotid arteries), as well as their associated morbidities with 
currently available management options (e.g. present hormone replacement regimens 
for hypopituitarism) may be involved.
Studies in the general population identified the metabolic syndrome (MetS) as an 
important risk factor for cardio- and cerebrovascular disease, as well as type 2 diabetes 
mellitus.7 The MetS, which was conceptualized by Reaven in 1988,8 has been associated 
with a two-fold increased risk for cardio- and cerebrovascular disease and a five-fold 
increased risk for type 2 diabetes mellitus.7 During the last two decades, several defini-
tions of the MetS have been proposed.9-14 All these definitions include obesity, insulin 
resistance, dyslipidaemia, and elevated blood pressure as their main components. To 
date, only a few studies assessed the MetS and its components in patients with cra-
niopharyngioma.15-20 Small study populations that mainly consist of children, a lack of 
comparison with the general population, and the evaluation of only a few potential risk 
factors for the MetS and its components are major limitations of these studies.
The objectives of our study were to determine the prevalence of and risk factors 
for the MetS and its components in patients with craniopharyngioma. In a subset of 
patients, we examined the prevalence of the MetS and its components in relation to the 
general population.
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SUBjECTS AND METHODS
Study population
Patients treated for craniopharyngioma at the Erasmus University Medical Centre 
(Rotterdam, the Netherlands) and the Sahlgrenska University Hospital (Gothenburg, 
Sweden) were eligible for participation in this cross-sectional study with retrospective 
data if they were ≥18 years of age at their last follow-up visit, had ≥3 years of follow-
up after craniopharyngioma diagnosis, and presented data on ≥1 component of the 
MetS. A computer-based search in the medical records identified 225 patients with 
craniopharyngioma of whom 178 were eligible (110 Dutch and 68 Swedish patients). 
Craniopharyngiomas were diagnosed <18 years of age (i.e. childhood-onset) in 83 pa-
tients (47%) and ≥18 years of age (i.e. adult-onset) in 95 patients (53%). All patients gave 
their informed consent and were included in the study.
In a subset of patients, we examined the prevalence of the MetS, its components, 
and type 2 diabetes mellitus in relation to the general population. This includes Dutch 
patients aged 30-70 years (n=73) and Swedish patients aged 45-69 years (n=29). Data 
from the Dutch general population were reported in the “Nederland de Maat Genomen” 
(NL de Maat) study;21 data from the Swedish general population in the “Life conditions, 
Stress and Health” (LSH) study.22 In the “NL de Maat” study, 2059 females and 1806 males 
from the Dutch general population, aged 30-70 years, were assessed for cardio- and 
cerebrovascular disease risk factors between 2009-2010.21 The “LSH” study included 505 
females and 502 males from the Swedish general population, aged 45-69 years, who 
were evaluated for cardio- and cerebrovascular disease risk factors between 2003-
2004.22 The local institutional review board of the Erasmus University Medical Centre 
and the regional ethical review board in Gothenburg, Sweden, approved this study.
Data collection
Data on baseline characteristics, tumour characteristics, craniopharyngioma treatment, 
recurrence, and long-term health outcome were collected from the medical records. 
Craniopharyngioma location, hydrocephalus, and radiological hypothalamic damage 
were studied as tumour characteristics. Location was classified as intrasellar, suprasel-
lar, and both intra-/suprasellar. Radiological hypothalamic damage was defined as 
tumour- and/or treatment-related injury to the hypothalamus and/or third ventricle as 
visualized on neuroimaging. Neurosurgery, radiotherapy, and 90Yttrium brachytherapy 
were studied as craniopharyngioma treatment modalities. Recurrence was defined as 
reappearance or re-growth of the craniopharyngioma after prior treatment. The MetS 
and parameters reflecting its components (i.e. body mass index, fasting glucose, triglyc-
erides, high-density lipoprotein [HDL] cholesterol, systolic and diastolic blood pressure), 
presence of and treatment for diabetes mellitus, dyslipidaemia, and hypertension, 
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glycated haemoglobin (HbA1c), cardio- and cerebrovascular morbidity, presence of and 
treatment for hypopituitarism, visual impairment, and current treatment for epilepsy 
and psychiatric illness were studied as conditions reflecting long-term health outcome. 
The MetS was defined according to the Joint Interim Statement of the International 
Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, 
and Blood Institute; American Heart Association; World Heart Federation; International 
Atherosclerosis Society; and International Association for the Study of Obesity (Table 
6.1).14 According to this definition, patients are classified as obese if waist circumfer-
ence is greater than population- and country-specific definitions or if body mass index 
is >30 kg/m2. Because data on waist circumference were unavailable in our patients, we 
classified patients as obese by body mass index only. Pituitary hormone deficiencies 
were diagnosed by formal pituitary function testing in all patients. Growth hormone re-
placement therapy (GHRT) was started based on clinical guidelines and shared decision 
making. Sex steroid replacement therapy was discontinued in females when a physi-
ological menopausal age was reached (i.e. approximately 51 years). Visual impairment 
was defined as a decreased visual acuity after correction for refraction disorders and/or 
as the presence of a visual field defect.
Statistical analysis
Statistical analyses were conducted using the Statistical Package for Social Sciences 
(SPSS 24, Chicago, IL, USA). Evaluations were based on the number of patients with 
available data. Continuous and categorical variables were compared using Student’s 
t-tests and Chi-squared tests, respectively. Non-parametric equivalent tests were used 
when assumptions were not met. Prevalence of the MetS, its components, and type 2 
diabetes mellitus were compared between patients with craniopharyngioma and the 
general population using one-sample proportion tests. Logistic regression analyses were 
performed to identify risk factors for the MetS and its components. Age, sex, age group 
at craniopharyngioma diagnosis, tumour location, hydrocephalus, radiological hypotha-
lamic damage, radiotherapy, 90Yttrium brachytherapy, craniopharyngioma recurrence, 
panhypopituitarism, treatment of growth hormone deficiency (GHD), hypogonadotropic 
Table 6.1. Definition of the MetS14
At least three of the following five criteria:
Body mass index >30 kg/m2
Fasting glucose ≥5.6 mmol/L or drug treatment for increased glucose
Triglycerides ≥1.7 mmol/L or drug treatment for elevated triglycerides
HDL cholesterol <1.0 mmol/L in males and <1.3 mmol/L in females or drug treatment for reduced HDL cholesterol
Blood pressure ≥130/85 mmHg or drug treatment for hypertension
MetS = Metabolic syndrome.
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hypogonadism, secondary adrenal insufficiency, secondary hypothyroidism, and dia-
betes insipidus, as well as visual impairment and treatment for epilepsy and psychiatric 
illness were evaluated as potential risk factors. Variables statistically significant in univari-
able regression (i.e. a P-value <0.05 [two-tailed]) were further evaluated by multivariable 
regression. All multivariable regression analyses were adjusted for follow-up duration.
RESULTS
Patient characteristics
We evaluated 178 patients with craniopharyngioma (90 females [51%]) (Table 6.2). 
Median follow-up after craniopharyngioma diagnosis was 16 years (range 3-62). Median 
age at last follow-up assessment was 47 years (range 18-92) (i.e. median 47 years [range 
18-92] in Dutch patients, and median 50 years [range 20-81] in Swedish patients). Patient 
characteristics were similar in females and males, except for secondary hypothyroidism 
(88% vs. 97%; P<0.05). GHRT was used by 117 patients with GHD (79%). Thirty-five (30%) 
of these patients used GHRT during childhood. Sex steroid replacement therapy was 
used by 122 patients with hypogonadotropic hypogonadism (95% of males and pre-
menopausal females). All premenopausal females on sex steroid replacement therapy 
used regular oral oestrogen-progestin replacement regimens. Three males did not use 
sex steroid replacement therapy due to prostate cancer. All patients with secondary ad-
renal insufficiency, secondary hypothyroidism, and diabetes insipidus were adequately 
treated with hormone replacement therapy. Glucocorticoid replacement therapy was 
used by 145 patients (82%). The median daily hydrocortisone equivalent dose in these 
patients was 20 milligrams (range 5-50). Antiepileptic drugs were used by 15 patients 
(8%); psychiatric drugs (i.e. antipsychotics, antidepressants, or benzodiazepines) by 24 
patients (14%). One patient was known with type 1 diabetes mellitus; another patient 
had gestational diabetes. These two patients were excluded from the analyses on the 
MetS and its components.
Patient characteristics in Dutch compared with Swedish patients with craniopharyngi-
oma, patients with childhood- compared with adult-onset craniopharyngioma, patients 
with treated compared with untreated GHD, and patients with obesity compared to 
patients without obesity are shown in Supplementary Table 6.1.
The MetS and its components
In our study, 69 of 149 patients with complete data demonstrated the MetS (46%) (Table 
6.3). Twenty patients (29%) had three components of the MetS, 30 patients (43%) four 
components, and 14 patients (20%) five components. In five patients with the MetS (7%) 
the exact number of components was unknown. Obesity was present in 84 patients 
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(52%). Increased fasting glucose affected 57 patients (37%); elevated triglycerides 80 
patients (54%). Reduced HDL cholesterol was found in 65 patients (46%); and elevated 
Table 6.2. Patient characteristics
All craniopharyngiomas 
(n=178)
Females
(n=90)
Males
(n=88)
Baseline characteristics
Age at diagnosis (years)a 23 (0-79) 23 (4-73) 24 (0-79)
Childhood-onset (n [%]) 83 (47) 40 (44) 43 (49) 
Adult-onset (n [%]) 95 (53) 50 (56) 45 (51) 
Follow-up since diagnosis (years)a 16 (3-62) 16 (3-62) 18 (3-48)
Age at last follow-up assessment (years)a 47 (18-92) 48 (18-82) 47 (18-92)
Tumour characteristics 
Location (n [%])
Intrasellar 4 (2) 1 (1) 3 (4) 
Suprasellar 67 (40) 34 (41) 33 (40) 
Intra-/suprasellar 95 (57) 49 (58) 46 (52) 
Hydrocephalus (n [%]) 47 (27) 26 (29) 21 (24)
Radiological hypothalamic damage (n [%]) 65 (39) 31 (37) 34 (42)
Craniopharyngioma treatment
Neurosurgery (n [%]) 165 (93) 84 (93) 81 (92)
Radiotherapy (n [%]) 85 (48) 43 (48) 42 (48)
90Yttrium brachytherapy (n [%]) 29 (16) 16 (18) 13 (15)
Recurrence (n [%]) 70 (40) 36 (40) 34 (40)
Long-term health outcome
Pituitary hormone deficiencies (n [%])
GH 148 (85)b 73 (82) 75 (88) 
FSH/LH 155 (88)c 76 (84) 79 (91) 
ACTH 145 (82)d 69 (77) 76 (86) 
TSH 163 (92)d 78 (88) 85 (97) 
ADH 111 (62)d 55 (61) 56 (64) 
Panhypopituitarism 93 (53) 46 (51) 47 (54) 
Visual impairment (n [%]) 126 (78) 63 (77) 63 (80)
Body mass index (kg/m2)a 30.1 (16.9-59.5) 30.4 (20.3-59.5) 30.1 (16.9-49.1)
Treatment for epilepsy (n [%]) 15 (8) 5 (6) 10 (11)
Treatment for psychiatric illness (n [%]) 24 (14) 11 (13) 13 (15)
aMedian (range). bGHRT was used by 117 patients with GHD (79%). cSex steroid replacement therapy was 
used by 122 patients with hypogonadotropic hypogonadism (95% of males and premenopausal females). 
dAll patients were adequately treated with hormone replacement therapy. ACTH = Adrenocorticotropic 
hormone; ADH = Antidiuretic hormone; FSH/LH = Follicle stimulating hormone/luteinizing hormone; GH = 
Growth hormone; GHD = Growth hormone deficiency; GHRT = Growth hormone replacement therapy; kg/
m2 = Kilograms per square metre; n = Number; TSH = Thyroid stimulating hormone.
144 Chapter 6
Ta
bl
e 
6.
3.
 T
he
 M
et
S,
 it
s 
co
m
po
ne
nt
s, 
ty
pe
 2
 d
ia
be
te
s 
m
el
lit
us
, a
nd
 c
ar
di
o-
 a
nd
 c
er
eb
ro
va
sc
ul
ar
 m
or
bi
di
ty
 in
 p
at
ie
nt
s 
w
ith
 c
ra
ni
op
ha
ry
ng
io
m
a
Pa
ti
en
ts
 w
it
h
cr
an
io
ph
ar
yn
gi
om
a
Co
m
pa
ri
so
n 
w
it
h 
ge
ne
ra
l p
op
ul
at
io
n
D
ut
ch
 v
s.
Sw
ed
en
P-
va
lu
e
D
ut
ch
pa
ti
en
ts
c
G
en
er
al
po
pu
la
ti
on
21
P-
va
lu
e
Sw
ed
is
h
pa
ti
en
ts
d
G
en
er
al
po
pu
la
ti
on
22
P-
va
lu
e
M
et
S 
an
d 
it
s 
co
m
po
ne
nt
s
M
et
S
69
/1
49
 (4
6%
)
22
/5
5 
(4
0%
)
29
%
<0
.0
5
15
/2
9 
(5
2%
)
15
%
<0
.0
5
48
%
 v
s. 
44
%
0.
61
O
be
si
ty
 
84
/1
62
 (5
2%
) 
34
/6
3 
(5
4%
) 
13
%
 
<0
.0
5 
14
/2
8 
(5
0%
) 
33
%
 
<0
.0
5 
54
%
 v
s. 
49
%
 
0.
48
 
In
cr
ea
se
d 
fa
st
in
g 
gl
uc
os
e 
57
/1
56
 (3
7%
) 
13
/6
1 
(2
1%
) 
N
A
 
N
A
 
15
/2
9 
(5
2%
) 
N
A
 
N
A
 
29
%
 v
s. 
47
%
 
<0
.0
5 
El
ev
at
ed
 tr
ig
ly
ce
rid
es
 
80
/1
49
 (5
4%
) 
27
/5
6 
(4
8%
) 
N
A
 
N
A
 
18
/2
9 
(6
2%
) 
25
%
 
<0
.0
5 
54
%
 v
s. 
54
%
 
0.
97
 
Re
du
ce
d 
H
D
L 
ch
ol
es
te
ro
l 
65
/1
41
 (4
6%
) 
18
/5
1 
(3
5%
) 
6%
 
<0
.0
5 
16
/2
9 
(5
5%
) 
11
%
 
<0
.0
5 
47
%
 v
s. 
45
%
 
0.
74
 
El
ev
at
ed
 b
lo
od
 p
re
ss
ur
e 
96
/1
72
 (5
6%
) 
44
/6
9 
(6
4%
) 
31
%
 
<0
.0
5 
15
/2
9 
(5
2%
) 
27
%
 
<0
.0
5 
62
%
 v
s. 
47
%
 
0.
06
 
Ty
pe
 2
 d
ia
be
te
s 
m
el
lit
us
 a
nd
 c
ar
di
o-
 a
nd
 c
er
eb
ro
va
sc
ul
ar
 m
or
bi
di
ty
Ty
pe
 2
 d
ia
be
te
s 
m
el
lit
us
24
/1
78
 (1
4%
)
8/
73
 (1
1%
)
5%
<0
.0
5
5/
29
 (1
7%
)
6%
<0
.0
5
15
%
 v
s. 
12
%
0.
60
H
bA
1c
 (m
m
ol
/m
ol
)a,
b
34
 (2
3-
80
)
36
 (2
2-
69
)
N
A
N
A
36
 (2
9-
77
)
N
A
N
A
36
 v
s. 
33
0.
29
M
yo
ca
rd
ia
l i
nf
ar
ct
io
n
6/
17
8 
(3
%
)
4/
73
 (6
%
)
N
A
N
A
0/
29
 (0
%
)
N
A
N
A
6%
 v
s. 
0%
0.
08
Ce
re
br
ov
as
cu
la
r a
cc
id
en
t
15
/1
78
 (8
%
)
4/
73
 (6
%
)
N
A
N
A
1/
29
 (3
%
)
N
A
N
A
9%
 v
s. 
7%
0.
69
a M
ed
ia
n 
(r
an
ge
). 
b D
at
a 
av
ai
la
bl
e 
in
 1
18
 p
at
ie
nt
s. 
c S
ub
se
t o
f D
ut
ch
 p
at
ie
nt
s 
ag
ed
 3
0-
70
 y
ea
rs
. d
Su
bs
et
 o
f S
w
ed
is
h 
pa
tie
nt
s 
ag
ed
 4
5-
69
 y
ea
rs
. D
ut
ch
 =
 D
ut
ch
 p
at
ie
nt
s 
w
ith
 
cr
an
io
ph
ar
yn
gi
om
a;
 H
bA
1c
 =
 G
ly
ca
te
d 
ha
em
og
lo
bi
n;
 H
D
L 
= 
H
ig
h-
de
ns
ity
 li
po
pr
ot
ei
n;
 M
et
S 
= 
M
et
ab
ol
ic
 sy
nd
ro
m
e;
 N
A
 =
 N
ot
 a
va
ila
bl
e;
 S
w
ed
is
h 
= 
Sw
ed
is
h 
pa
tie
nt
s w
ith
 
cr
an
io
ph
ar
yn
gi
om
a.
Metabolic syndrome and craniopharyngioma 145
blood pressure in 96 patients (56%). In the subset of patients who were compared with 
the general population (i.e. Dutch patients aged 30-70 years and Swedish patients aged 
45-69 years), prevalence of the MetS was significantly higher in patients with craniopha-
ryngioma (40% vs. 29% [P<0.05] for Dutch patients; 52% vs. 15% [P<0.05] for Swedish 
patients). Prevalence of obesity, reduced HDL cholesterol, and elevated blood pressure 
were also significantly higher in Dutch and Swedish patients with craniopharyngioma 
compared with the general population. Prevalence of elevated triglycerides could only 
be compared with the general population in Swedish patients with craniopharyngioma. 
In this subgroup, prevalence of elevated triglycerides was significantly higher in patients 
with craniopharyngioma (Table 6.3).
Prevalence of the MetS and its components were similar in Dutch and Swedish patients 
with craniopharyngioma, except for increased fasting glucose, which was significantly 
more common in Swedish compared with Dutch patients (47% vs. 29%; P<0.05) (Table 
6.3). Female patients had a significantly higher prevalence of reduced HDL cholesterol 
(58% vs. 35%; P<0.05) and elevated blood pressure (64% vs. 47%; P<0.05) compared with 
male patients. Elevated blood pressure was significantly more common in patients with 
adult- compared with childhood-onset craniopharyngioma (64% vs. 46%; P<0.05). There 
were no significant differences in the MetS and its components between patients with 
treated and untreated GHD (Table 6.4).
Table 6.4. The MetS, its components, type 2 diabetes mellitus, and cardio- and cerebrovascular morbidity 
in subgroups 
♀ vs. ♂ P-value CO vs. AO P-value GHRT vs.
non-GHRT
P-value
MetS and its components
MetS 54% vs. 40% 0.09 48% vs. 45% 0.71 43% vs. 57% 0.24
Obesity 56% vs. 48% 0.35 59% vs. 45% 0.08 57% vs. 43% 0.19 
Increased fasting glucose 32% vs. 41% 0.26 33% vs. 39% 0.44 33% vs. 40% 0.49 
Elevated triglycerides 59% vs. 49% 0.20 47% vs. 60% 0.12 51% vs. 58% 0.51 
Reduced HDL cholesterol 58% vs. 35% <0.05 51% vs. 42% 0.28 47% vs. 38% 0.47 
Elevated blood pressure 64% vs. 47% <0.05 46% vs. 64% <0.05 52% vs. 67% 0.16 
Type 2 diabetes mellitus and cardio- and cerebrovascular morbidity
Type 2 diabetes mellitus 14% vs. 13% 0.70 11% vs. 16% 0.34 10% vs. 23% 0.08
HbA1c (mmol/mol)a,b 35 vs. 34 0.74 33 vs. 36 0.15 34 vs. 37 0.72
Myocardial infarction 4% vs. 2% 0.68 1% vs. 5% 0.22 2% vs. 7% 0.19
Cerebrovascular accident 9% vs. 8% 0.82 7% vs. 10% 0.59 6% vs. 16% 0.13
aMedian (range). bData available in 118 patients. ♀ = Female; ♂ = Male; AO = Adult-onset craniopharyn-
gioma; CO = Childhood-onset craniopharyngioma; GHRT = Treated growth hormone deficiency; HbA1c 
= Glycated haemoglobin; HDL = High-density lipoprotein; MetS = Metabolic syndrome; Non-GHRT = Un-
treated growth hormone deficiency.
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Risk factors for the MetS and its components in patients with 
craniopharyngioma
Results of the univariable and multivariable logistic regression analyses on risk factors 
for the MetS are shown in Table 6.5. Glucocorticoid replacement therapy (OR 3.27, 95%CI 
1.22-8.74; P<0.05) and visual impairment (OR 2.63, 95%CI 1.11-6.24; P<0.05) were identi-
fied as significant risk factors for the MetS in the univariable analyses. In the multivari-
able analysis, visual impairment was borderline significantly associated with the MetS 
(OR 2.54, 95%CI 0.95-6.81; P=0.06) after adjustment for glucocorticoid replacement 
therapy and follow-up duration. Radiological hypothalamic damage was identified as a 
significant risk factor for obesity (OR 9.86, 95%CI 1.59-61.1; P<0.05) after adjustment for 
age, 90Yttrium brachytherapy, craniopharyngioma recurrence, vasopressin treatment, 
panhypopituitarism, treatment for psychiatric illness, and follow-up duration. A pro-
Table 6.5. Risk factors for the MetS in patients with craniopharyngioma
Parameters
Univariable analysis Multivariable analysisc,d
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Age (in years) 1.01 (0.99-1.03) 0.22
Female sex 1.69 (0.89-3.23) 0.11
Childhood-onset disease 1.10 (0.58-2.09) 0.78
Tumour locationa
Suprasellar 1.15 (0.15-8.71) 0.89   
Intra-/suprasellar 0.70 (0.09-5.20) 0.72   
Hydrocephalus 1.43 (0.69-2.98) 0.34
Radiological hypothalamic damage 1.49 (0.76-2.94) 0.25
Radiotherapy 1.29 (0.68-2.46) 0.43
90Yttrium brachytherapy 2.61 (0.99-6.89) 0.05
Craniopharyngioma recurrence 1.44 (0.74-2.77) 0.28
Panhypopituitarism 1.43 (0.75-2.73) 0.28
Treatment of GHD 0.58 (0.24-1.45) 0.24
Sex steroid replacementb 2.57 (0.26-25.5) 0.42
Glucocorticoid replacement 3.27 (1.22-8.74) <0.05 2.32 (0.80-6.73) 0.12
Thyroid hormone replacement 2.72 (0.53-13.9) 0.23
Vasopressin treatment 1.27 (0.65-2.48) 0.49
Visual impairment 2.63 (1.11-6.24) <0.05 2.54 (0.95-6.81) 0.06
Treatment for epilepsy 0.82 (0.25-2.69) 0.74
Treatment for psychiatric illness 0.46 (0.18-1.19) 0.11
aCompared with intrasellar. bIn males and premenopausal females only. cAnalysis adjusted for follow-up 
duration. dCox & Snell R2=0.06; model χ2=6.87; P=0.08. CI = Confidence interval; GHD = Growth hormone 
deficiency; MetS = Metabolic syndrome.
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longed follow-up duration significantly decreased the risk for increased fasting glucose 
(OR 0.93, 95%CI 0.88-0.97; P<0.05). Intrasellar tumour location significantly protected 
for elevated triglycerides (OR 0.43, 95%CI 0.21-0.88; P<0.05) after adjustment for age 
and follow-up duration. Female sex (OR 3.29, 95%CI 1.35-8.01; P<0.05), 90Yttrium brachy-
therapy (OR 7.87, 95%CI 1.58-39.2; P<0.05), and glucocorticoid replacement therapy 
(OR 4.80, 95%CI 1.12-20.6; P<0.05) were identified as significant risk factors for reduced 
HDL cholesterol after adjustment for hydrocephalus, craniopharyngioma recurrence, 
and follow-up duration. Age (OR 1.06, 95%CI 1.02-1.10; P<0.05) significantly predicted 
elevated blood pressure after adjustment for female sex, childhood-onset craniopha-
ryngioma and follow-up duration.
Since visual impairment was identified as a borderline significant predictor for the 
MetS (i.e. our primary study outcome), we compared baseline, tumour, and treatment 
characteristics, as well as long-term health outcome between patients with and without 
visual impairment (Table 6.6). Craniopharyngioma treatment with 90Yttrium brachyther-
apy (21% vs. 6%; P<0.05) and tumour recurrence (47% vs. 17%; P<0.05) were significantly 
more frequent in patients with compared to without visual impairment.
Type 2 diabetes mellitus and cardio- and cerebrovascular morbidity
In our study, 24 patients (14%) suffered from type 2 diabetes mellitus (Table 6.3). Eleven 
of them received insulin treatment. In the subset of patients who were compared with 
the general population, prevalence of type 2 diabetes mellitus was significantly higher 
in patients with craniopharyngioma (11% vs. 6% [P<0.05] for Dutch patients; 17% vs. 6% 
[P<0.05] for Swedish patients). In our study, six patients with craniopharyngioma (3%) 
experienced a myocardial infarction, and 15 patients (8%) suffered from a cerebrovas-
cular accident. One patient with childhood-onset craniopharyngioma had a myocardial 
infarction at the age of 38 years. In patients with adult-onset craniopharyngioma, the 
median age at myocardial infarction was 53 years (range 32-73 years). Cerebrovascular 
accidents affected six patients with childhood-onset craniopharyngioma at a median 
age of 31 years (range 19-38). The median age of cerebrovascular accident in patients 
with adult-onset craniopharyngioma was 64 years (range 35-77). Prevalence of type 2 
diabetes mellitus, myocardial infarction, and cerebrovascular accident, as well as HbA1c 
levels were similar in Dutch and Swedish patients with craniopharyngioma (Table 6.3), 
as well as in females and males, patients with childhood- and adult-onset craniopharyn-
gioma, and patients with treated and untreated GHD (Table 6.4).
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Table 6.6. Patients with compared to without visual impairment
visual impairment
(n=126)
No visual impairment
(n=35)
P-value
Baseline characteristics
♀ (n [%]) 63 (50) 19 (54)
0.65
♂ (n [%]) 63 (50) 16 (46) 
Age at diagnosis (years)a 26 (0-79) 17 (5-61) 0.26
Childhood-onset (n [%]) 59 (47) 16 (46) 0.91 
Adult-onset (n [%]) 67 (53) 19 (54) 
Follow-up since diagnosis (years)a 16 (3-62) 17 (6-39) 0.49
Age at last follow-up assessment (years)a 48 (18-92) 47 (18-81) 0.71
Tumour characteristics 
Location (n [%]) 0.88
Intrasellar 3 (3) 1 (3) 1.00 
Suprasellar 49 (41) 12 (36) 0.62 
Intra-/suprasellar 67 (56) 20 (61) 0.66 
Hydrocephalus (n [%]) 38 (30) 6 (18) 0.14
Radiological hypothalamic damage (n [%]) 46 (39) 13 (41) 0.84
Craniopharyngioma treatment
Neurosurgery (n [%]) 120 (95) 31 (87) 0.23
Radiotherapy (n [%]) 64 (51) 14 (40) 0.26
90Yttrium brachytherapy (n [%]) 27 (21) 1 (6) <0.05
Recurrence (n [%]) 59 (47) 6 (17) <0.05
Long-term health outcome
Pituitary hormone deficiencies (n [%])
GH 107 (87) 28 (80) 0.30 
FSH/LH 109 (87) 30 (86) 0.78 
ACTH 105 (83) 26 (74) 0.22 
TSH 117 (94) 30 (86) 0.16 
ADH 82 (65) 22 (63) 0.81 
Panhypopituitarism 68 (54) 19 (54) 0.99 
Body mass index (kg/m2)a 30.4 (16.9-59.5) 31.0 (24.6-48.7) 0.47
Treatment for epilepsy (n [%]) 12 (10) 1 (3) 0.30
Treatment for psychiatric illness (n [%]) 15 (12) 6 (17) 0.41
MetS and its components
MetS (n [%]) 56 (52) 9 (29) <0.05
Obesity (n [%]) 60 (53) 19 (54) 0.86
Increased fasting glucose (n [%]) 47 (41) 8 (26) 0.12
Elevated triglycerides (n [%]) 60 (56) 13 (45) 0.30
Reduced HDL cholesterol (n [%]) 52 (51) 10 (35) 0.13
Elevated blood pressure (n [%]) 69 (56) 20 (57) 0.91
aMedian (range). ♀ = Female; ♂ = Male; ACTH = Adrenocorticotropic hormone; ADH = Antidiuretic hor-
mone; FSH/LH = Follicle stimulating hormone/luteinizing hormone; GH = Growth hormone; GHD = Growth 
hormone deficiency; GHRT = Growth hormone replacement therapy; HDL = High-density lipoprotein; kg/
m2 = Kilograms per square metre; MetS = Metabolic syndrome; n = Number; TSH = Thyroid stimulating 
hormone.
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DISCUSSION
We performed the largest study that investigated the MetS and its components in pa-
tients with craniopharyngioma to date. After a median follow-up duration of 16 years, 
almost half of the patients with craniopharyngioma demonstrated the MetS. Accord-
ingly, in a subset of Dutch and Swedish patients who were compared with the general 
population, we found that the MetS was significantly more prevalent than expected. 
Using multivariable logistic regression analyses adjusted for follow-up duration, we 
identified visual impairment, radiological hypothalamic damage, tumour location, 
female sex, 90Yttrium brachytherapy, glucocorticoid replacement therapy, and age as 
significant risk factors for the MetS and its components.
In our study, prevalence of the MetS in patients with craniopharyngioma was 46%. 
Other studies that investigated the MetS in patients with craniopharyngioma observed 
a prevalence between 8-67% (Table 6.7).15-20 This wide variation in prevalence may be 
related to heterogeneity in study populations and difference in definitions used to clas-
sify patients as exhibiting the MetS. In the subset of Dutch and Swedish patients with 
craniopharyngioma who were compared with the general population, we observed a 
significantly higher prevalence of the MetS than expected. This is in concordance with 
three small other studies that also compared the prevalence of the MetS between 
patients with craniopharyngioma and control subjects.15, 17, 18 Studies that investigated 
the MetS in patients with hypopituitarism due to various causes (including craniopha-
ryngioma) did not observe any significant difference in the prevalence of the MetS 
between patients with craniopharyngioma and patients with hypopituitarism due to 
other causes, at least in patients with untreated GHD.18, 23, 24 Profka et al. observed that 
the beneficial metabolic effects of GHRT were less pronounced in patients with cranio-
pharyngioma compared with patients with hypopituitarism due to non-functioning 
pituitary adenoma. In their study, prevalence of the MetS was significantly higher in 
patients with craniopharyngioma compared with patients with non-functioning pitu-
itary adenoma after five years of GHRT (37% vs. 5%; P<0.05).18 
The increased susceptibility for the MetS and its components in patients with cranio-
pharyngioma is likely to be multifactorial. Tumour- and treatment-related damage of im-
portant brain structures, as well as their associated morbidities with currently available 
management options may altogether adversely affect metabolic function. This makes 
it challenging to evaluate risk factors for the MetS and its components. Nevertheless, 
we assessed patients with craniopharyngioma for predictors of an adverse metabolic 
state. Using multivariable logistic regression analyses adjusted for follow-up duration, 
we identified visual impairment as a borderline significant risk factor for the MetS. 
Radiological hypothalamic damage significantly increased the risk for obesity. A pro-
longed follow-up duration significantly decreased the risk for increased fasting glucose. 
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Intrasellar tumour location significantly protected for elevated triglycerides. Female sex, 
90Yttrium brachytherapy, and glucocorticoid replacement therapy were identified as 
significant risk factors for reduced HDL cholesterol. Age significantly predicted elevated 
blood pressure. The increased risk for the MetS associated with visual impairment may 
be due to a negative effect of visual impairment on the ability to participate in physical 
activity. This is illustrated by studies that observed a significantly lower level of physi-
cal activity in patients with craniopharyngioma compared with age-, sex-, and body 
mass index-matched control subjects.25, 26 A lower level of physical activity has been 
associated with an increased risk for the MetS in the general population.27 Differences 
in tumour characteristics between patients with and without visual impairment may 
also contribute to the increased risk for the MetS in patients with visual impairment. 
We found a significantly higher rate of craniopharyngioma recurrence and subsequent 
treatment with 90Yttrium brachytherapy in patients with compared to without visual 
impairment. Craniopharyngioma recurrence and additional treatment may exacerbate 
tumour- and treatment-related brain damage, thereby increasing the risk for the MetS 
and its components.
The increased risk for obesity associated with radiological hypothalamic damage 
may be due to acquired leptin and insulin resistance, as well as autonomic nervous 
system dysfunction. These factors may adversely affect food intake and energy ex-
penditure, thereby promoting obesity.28 An increased risk for obesity in patients with 
craniopharyngioma associated with hypothalamic damage has also been observed in 
other studies.29-32 We observed an increased risk for reduced HDL cholesterol associated 
with female sex. This may be due to currently used oestrogen-progestin replacement 
regimens that do not fully simulate the physiological menstrual cycle.33 This is illustrated 
by a recent study that observed an improved cardiovascular risk profile in premature 
ovarian insufficient females treated with a more physiological transdermal/transvaginal 
oestrogen-progestin replacement regimen compared with a regular oral oestrogen-
progestin replacement regimen.34 In our study, all premenopausal females with hypo-
gonadotropic hypogonadism used a regular oral oestrogen-progestin replacement 
regimen. The increased risk for reduced HDL cholesterol associated with glucocorticoid 
replacement therapy may be due to currently available glucocorticoid replacement regi-
mens that contain relatively high glucocorticoid doses and are administered in patterns 
that do not fully simulate the physiological circadian cortisol rhythm in terms of serum 
level and pulsatility.35 
Some limitations of our study should be considered. Data on waist circumference 
were unavailable. This may have led to an underestimation of the prevalence of the MetS 
and obesity, because those patients with an elevated waist circumference but body 
mass index ≤30 kg/m2 were misclassified as non-obese. However, we anticipate that this 
misclassification is small, since several studies advocated that a body mass index of >30 
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kg/m2 may be used to diagnose obesity as a component of the MetS instead of elevated 
waist circumference.14, 36, 37 Moreover, a recent study by Gierach et al. reported a high and 
significant correlation between body mass index and waist circumference in patients 
with the MetS (R=0.78; P<0.01).38 The “NL de Maat” study and “LSH” study, which were 
used for the comparisons with the general population, classified participants as obese 
by waist circumference.21, 22 Otherwise, there were no substantial differences in the 
criteria used to define the MetS and its components between our study and the “NL de 
Maat” study and “LSH” study. Unfortunately, both the “NL de Maat” study and “LSH” study 
did not report data on increased fasting glucose. Therefore, we were unable to study 
the prevalence of increased fasting glucose in patients with craniopharygioma relative 
to the general population. Another limitation of our study is that we were unable to 
investigate the prevalence of the MetS relative to the general population after adjust-
ment for obesity. Interestingly, when analysing our data, the prevalence of the MetS 
seems to be lower than the prevalence of obesity in patients with craniopharyngioma, 
while in the Dutch general population the prevalence of the MetS seems to be higher 
than the prevalence of obesity. Since visceral adipose tissue-induced insulin resistance 
is postulated to be the principal factor resulting in the MetS and its components,7 this 
indicates that one may expect an even higher prevalence of the MetS in patients with 
craniopharyngioma. Future studies should clarify this issue. Other limitations of our 
study include the unavailability of data on ethnicity, lifestyle factors, histological sub-
type of craniopharyngioma (i.e. adamantinomatous or papillary), and body composition 
measured by dual-energy X-ray absorptiometry (DXA). Body composition measured by 
DXA has been shown to be a better predictor for cardio- and cerebrovascular morbidity 
than body composition measured by anthropometry.39, 40
In conclusion, we observed a high prevalence of the MetS and its components 
in patients with craniopharyngioma. In a subset of Dutch and Swedish patients with 
craniopharyngioma who were compared with the general population, we found that 
the MetS was significantly more prevalent than expected. Using multivariable logistic 
regression analyses adjusted for follow-up duration, we identified visual impairment, ra-
diological hypothalamic damage, tumour location, female sex, 90Yttrium brachytherapy, 
glucocorticoid replacement therapy, and age as significant risk factors for the MetS and 
its components in patients with craniopharyngioma.
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ABSTRACT
Background: Hypothalamic obesity is a devastating consequence of craniopharyn-
gioma. Bariatric surgery could be a promising therapeutic option. However, its efficacy 
and safety in patients with craniopharyngioma-related hypothalamic obesity remain 
largely unknown.
Objectives: We investigated the efficacy of bariatric surgery for inducing weight loss 
in patients with craniopharyngioma-related hypothalamic obesity. Additionally, we 
studied the safety of bariatric surgery regarding its effects on hormone replacement 
therapy for pituitary insufficiency.
Methods: In this retrospective matched case-control study, we compared weight loss 
after bariatric surgery (i.e. Roux-en-Y gastric bypass and sleeve gastrectomy) between 
eight patients with craniopharyngioma-related hypothalamic obesity and 75 controls 
with “common” obesity during two years of follow-up. We validated our results at one 
year of follow-up in a meta-analysis. Additionally, we studied alterations in hormone 
replacement therapy after bariatric surgery in patients with craniopharyngioma.
Results: Mean weight loss after bariatric surgery was 19% vs. 25% (difference -6%, 95% 
CI -14.1 to 4.6; P=0.091) at two years of follow-up in patients with craniopharyngioma-
related hypothalamic obesity compared to control subjects with “common” obesity. 
Mean weight loss was 25% vs. 29% (difference -4%, 95% CI -11.6 to 8.1; P=0.419) after 
Roux-en-Y gastric bypass, and 10% vs. 20% (difference -10%, 95% CI -14.1 to -6.2; P=0.003) 
after sleeve gastrectomy at two years of follow-up in patients with craniopharyngioma-
related hypothalamic obesity vs. control subjects with “common” obesity. Our meta-
analysis demonstrated significant weight loss one year after Roux-en-Y gastric bypass, 
but not after sleeve gastrectomy. Seven patients with craniopharyngioma suffered from 
pituitary insufficiency; three of them required minor adjustments in hormone replace-
ment therapy after bariatric surgery.
Conclusions: Weight loss after Roux-en-Y gastric bypass, but not sleeve gastrectomy, 
was comparable between patients with craniopharyngioma-related hypothalamic 
obesity and control subjects with “common” obesity at two years of follow-up. Bariatric 
surgery seems safe regarding its effects on hormone replacement therapy.
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INTRODUCTION
Craniopharyngiomas are benign epithelial neoplasms located in the sellar and/or su-
prasellar region of the skull that occur in both children and adults. Their treatment gen-
erally consists of neurosurgical excision with or without postoperative radiotherapy.1 
Long-term tumour- and/or treatment-related morbidities, including pituitary hormone 
deficiencies and morbid obesity related to hypothalamic dysfunction, occur frequently 
and may result in premature mortality.2 Hypothalamic obesity and its comorbidities are 
among the most devastating consequences of craniopharyngioma,3 and affect approxi-
mately 55% of the patients.4
Hypothalamic obesity is considered to be an “endogenous” type of obesity, in which 
hypothalamic damage is postulated to result in autonomic nervous system dysfunction, 
as well as acquired leptin and insulin resistance, which altogether adversely affect food 
intake and food satisfaction, metabolism, as well as energy expenditure.5 Therefore, it 
seems to be a distinct entity separated from “exogenous” or “common” obesity, in which 
excessive caloric intake promotes weight gain.6 Hypothalamic dysfunction is a major 
contributor to the morbid obesity commonly observed in patients with craniopharyngi-
oma. However, other factors like familial predisposition for obesity and reduced physical 
activity, which may be related to neurological and visual dysfunction, increased daytime 
sleepiness, and psychological difficulties may also contribute to excessive weight gain.7-9 
Patients with craniopharyngioma-related hypothalamic obesity experience continuous 
weight gain that evolves predominantly during the first year after craniopharyngioma 
treatment.10, 11 Hypothalamic obesity is, similar to “common” obesity,6 largely resistant 
to lifestyle modification.12 In addition, pharmacological treatment strategies show only 
modest results coupled with significant side effects.5 Since bariatric surgery has proven 
to be highly effective in the “common” obese population,13 it has been proposed as a 
therapeutic option for hypothalamic obesity as well.14 However, studies on the efficacy 
and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity 
remain scarce, and do not compare achieved weight loss with matched control subjects.
Since many patients with craniopharyngioma require hormone replacement therapy 
for pituitary hormone deficiencies,2 and bariatric surgery might affect drug absorption 
and bioavailability,15 it is important to consider the effects of bariatric procedures on en-
docrine substitution regimens. This is enforced by differences in pharmacokinetics and 
pharmacodynamics between obese and lean subjects,16 which may reasonably change 
after significant weight loss. Nonetheless, the effects of bariatric surgery on hormone 
replacement therapy have not been addressed extensively in prior studies. Up until now, 
only one small study specifically investigated the absorption of hormone replacement 
therapy in patients with craniopharyngioma after bariatric surgery.17 
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The primary aim of our study was to investigate the efficacy of bariatric surgery for 
inducing weight loss in patients with craniopharyngioma-related hypothalamic obesity. 
As secondary aims, we studied the effects of bariatric surgery on hormone replacement 
therapy and presence of treatment for diabetes mellitus, hypertension, and dyslipidaemia. 
Accordingly, we performed the first matched case-control study that compared bariatric 
surgery-induced weight loss between patients with craniopharyngioma-related hypotha-
lamic obesity and control subjects with “common” obesity. We validated our results on 
bariatric surgery-induced weight loss in patients with craniopharyngioma-related hypo-
thalamic obesity in a meta-analysis. In addition, we investigated the safety of bariatric 
surgery regarding its effects on hormone replacement therapy for pituitary insufficiency. 
As a result, we conducted the first study addressing both the efficacy and safety of bariat-
ric surgery in patients with craniopharyngioma-related hypothalamic obesity.
MATERIALS AND METHODS
Study participants
In this retrospective matched case-control study, we compared bariatric surgery-
induced weight loss between patients with craniopharyngioma-related hypothalamic 
obesity and control subjects with “common” obesity. Patients with craniopharyngioma 
who underwent bariatric surgery were identified by a computer-based search in the 
electronic patient files of the Erasmus University Medical Centre (Rotterdam, the Neth-
erlands), and the Sahlgrenska University Hospital (Gothenburg, Sweden). Eight of such 
patients were identified (four Dutch and four Swedish patients). In the Dutch cases, all 
bariatric procedures had been performed at dedicated regional centres experienced in 
weight-loss surgery. In the Swedish patients, all but one bariatric procedure had been 
performed at the Sahlgrenska University Hospital. In all eight patients, diagnoses of cra-
niopharyngioma were pathology-proven and craniopharyngioma-related hypothalamic 
and/or third ventricle damage was demonstrated by neuroimaging. Pituitary hormone 
deficiencies were diagnosed on the basis of pituitary function testing or complete neu-
rosurgical removal of the pituitary stalk and/or gland.
Patients with craniopharyngioma were individually matched to 6-10 control subjects 
with “common” obesity, which yielded a total of 75 control participants. Control subjects 
were derived from the Scandinavian Obesity Surgery Registry (SOReg), which is a Swed-
ish nationwide registry that includes more than 40 000 individuals treated with bariatric 
surgery from all over the country.18 Matching was based on the type and date of bariatric 
procedure, age, gender, preoperative body mass index, and preoperative morbidity (i.e. 
presence of diabetes mellitus and/or hypertension). Ethical approval was obtained from 
the local institutional review board of the Erasmus University Medical Centre and the 
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regional ethical review board in Gothenburg, Sweden. All patients gave their informed 
consent.
Outcomes of interest
We compared weight loss between patients with craniopharyngioma-related hypotha-
lamic obesity and control subjects with “common” obesity at six weeks, one year, and 
two years of follow-up after bariatric procedure. We validated our results on weight 
loss at one year of follow-up in patients with craniopharyngioma-related hypothalamic 
obesity in a meta-analysis. In addition, we studied bariatric surgery-induced alterations 
in hormone replacement therapy for pituitary insufficiency in patients with craniopha-
ryngioma. Furthermore, we compared presence of treatment for diabetes mellitus, hy-
pertension, and dyslipidaemia between patients with craniopharyngioma and control 
subjects before, as well as one year after bariatric procedure.
Adjustments in the daily recombinant human growth hormone dose, necessary to 
maintain serum insulin-like growth factor I (IGF-I) levels within the age- and sex-adjusted 
reference range, represented the influence of bariatric surgery on growth hormone 
replacement therapy. Adjustments in the daily levothyroxine dose, necessary to main-
tain serum free thyroxine (fT4) levels within the reference range, were used to express 
bariatric surgery-induced alterations in thyroid hormone substitution. Hospital admis-
sions for adrenal crises post- vs. pre-bariatric surgery, as well as adjustments in the daily 
hydrocortisone dose, were used as indicators for bariatric surgery-induced alterations 
in hydrocortisone therapy. Switches in the oestrogen-progestin replacement therapy 
preparation due to signs and symptoms of oestrogen deficiency represented the influ-
ence of bariatric surgery on oestrogen-progestin replacement therapy. The influence of 
bariatric surgery on testosterone replacement therapy was assessed by adjustments in 
the testosterone dose, necessary to keep serum testosterone levels within the reference 
range. Adjustments in the daily desmopressin dose, required to reach an acceptable 
amount of fluid intake and diuresis throughout the day, were used as an indicator for 
bariatric surgery-induced alterations in desmopressin treatment. In addition, changes in 
hormone replacement therapy formulation type due to signs and symptoms of ineffec-
tive endocrine substitution were studied.
Data collection
Relevant clinical data on patient characteristics, medical status, craniopharyngioma 
treatment, bariatric surgery, anthropometry, use of hormone replacement therapy, 
antidiabetic agents, antihypertensive medication, and antihyperlipidemic drugs were 
retrieved from the medical records of the patients with craniopharyngioma. The Scan-
dinavian Obesity Surgery Registry provided the relevant information regarding the 
control subjects.
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Statistics
Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS 24, Chicago, IL, USA) and Review Manager (RevMan version 5.3, The Cochrane 
Collaboration, 2014). Continuous data were represented as mean ± standard deviation 
(SD), or median and range. Categorical data were represented as observed frequen-
cies and percentages. Baseline characteristics were compared between patients with 
craniopharyngioma-related hypothalamic obesity and control subjects with “common” 
obesity by Mann-Whitney U-tests and Fisher’s exact tests for numerical and categorical 
data, respectively. Because of the matched case-control design of our study, weight loss 
was compared between cases and controls using a one-factor generalized randomized 
block design. Two-way analyses of variances were performed, in which the matched 
case-control units were included as blocks. Percentage weight loss at six weeks, one 
year, and two years were considered dependent variables, and either being a patient 
with craniopharyngioma or a control subject as the independent variable. Bootstrapping 
with 1000 replicates was performed since assumptions of two-way analysis of variance 
were not met initially. Presence of treatment for diabetes mellitus, hypertension, and 
dyslipidaemia at one year after bariatric procedure was compared between cases and 
controls using conditional logistic regression. In order to validate our results on bariatric 
surgery-induced weight loss in patients with craniopharyngioma-related hypothalamic 
obesity, we performed a meta-analysis in which we compared body mass index at one 
year of follow-up after bariatric surgery with body mass index at bariatric procedure. We 
included all patients who received a Roux-en-Y gastric bypass or sleeve gastrectomy for 
craniopharyngioma-related hypothalamic obesity with sufficient follow-up data at one 
year after bariatric surgery published previously,19 and added our own eight patients. 
This yielded a total of 20 patients. Data were pooled using the inverse variance method 
with a random-effects model, and mean differences and corresponding 95% confidence 
intervals (CI) were calculated. We estimated statistical heterogeneity between studies 
using the I2 statistic.20 We considered a P-value < 0.05 statistically significant.
RESULTS
Patient characteristics
Characteristics of the patients with craniopharyngioma are shown in Table 7.1. Six 
patients were treated for craniopharyngioma at an age < 18 years and two at an age ≥ 
18 years. Subsequently, all patients developed hypothalamic obesity for which bariatric 
surgery was applied a median 13 years (range 2-26 years) after craniopharyngioma treat-
ment. Five patients received a Roux-en-Y gastric bypass, and three a sleeve gastrectomy. 
One patient underwent a second bariatric procedure (i.e. Roux-en-Y gastric bypass) ap-
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proximately two years after a sleeve gastrectomy due to insufficient weight loss. In this 
patient, only data until the second weight-loss surgery were taken into account.
Baseline characteristics of patients with craniopharyngioma-related hypothalamic 
obesity compared to matched control subjects with “common” obesity are shown in 
Table 7.2. Baseline characteristics were comparable, although patients with craniopha-
ryngioma who underwent sleeve gastrectomy were more likely to use antihypertensive 
medication before bariatric surgery (P=0.033).
Weight loss after bariatric surgery
Weight loss after bariatric surgery in patients with craniopharyngioma-related hypotha-
lamic obesity compared to control subjects with “common” obesity is shown in Figure 
7.1. Mean percentage weight loss after bariatric surgery was 12% vs. 9% (difference 3%, 
95% CI -2.0 to 6.2; P=0.196) at six weeks, 20% vs. 25% (difference -5%, 95% CI -11.7 to 
2.2; P=0.141) at one year, and 19% vs. 25% (difference -6%, 95% CI -14.1 to 4.6; P=0.091) 
at two years of follow-up in patients with craniopharyngioma-related hypothalamic 
obesity compared to control subjects with “common” obesity. After Roux-en-Y gastric 
bypass, mean percentage weight loss was 12% vs. 10% (difference 2%, 95% CI -4.2 to 
8.1; P=0.443) at six weeks, 25% vs. 30% (difference -5%, 95% CI -14.4 to 5.2; P=0.257) 
Table 7.2. 
Characteristic Craniopharyngioma Control
n 8 75
Gender (n [%]) ♂ 1 (12.5)
♀ 7 (87.5)
♂ 9 (12.0)
♀ 66 (88.0)
Bariatric procedure (n [%])
- Roux-en-Y Gastric bypass  5 (62.5) 45 (60.0) 
- Sleeve gastrectomy 3 (37.5) 30 (40.0) 
Mean age at bariatric procedure ± SD (yr.) 33.4 ± 13.6 34.2 ± 12.9
- Roux-en-Y Gastric bypass  32.6 ± 17.3 33.8 ± 16.0 
- Sleeve gastrectomy 34.7 ± 7.0 34.8 ± 6.0 
Mean preoperative BMI ± SD (kg/m2) 43.3 ± 4.1 40.3 ± 4.4
- Roux-en-Y Gastric bypass  43.4 ± 5.2 40.1 ± 3.6 
- Sleeve gastrectomy  43.1 ± 1.9 40.4 ± 4.9 
Preoperative DM (n [%]) 1 (12.5) 6 (8.0)
Preoperative HT (n [%]) 4 (50.0) 13 (17.3)
Preoperative dyslipidaemia (n [%]) 1 (12.5) 2 (2.7)
♂ = male; ♀ = female; % = percentage; BMI = body mass index; DM = treatment for diabetes mellitus; dys-
lipidaemia = treatment for dyslipidaemia; HT = treatment for hypertension; kg/m2 = kilograms per square 
meter; n = number; RYGB = Roux-en-Y gastric bypass; SD = standard deviation; SG = sleeve gastrectomy; 
yr. = years.
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Figure 7.1. Mean percentage weight loss (± bootstrapped standard error) after bariatric surgery in pa-
tients with craniopharyngioma-related hypothalamic obesity compared to control subjects with “common” 
obesity.
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Figure	1		4237	
	4238	
Mean	 percentage	 weight	 loss	 (±	 bootstrapped	 standard	 error)	 after	 bariatric	 surgery	 in	4239	
patients	with	craniopharyngioma-related	hypothalamic	obesity	compared	to	control	subjects	4240	
with	“common”	obesity.	(A)	Both	bariatric	procedures	combined.	(B)	Roux-en-Y	gastric	bypass.	4241	
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at one year, and 25% vs. 29% (difference -4%, 95% CI -11.6 to 8.1; P=0.419) at two 
years of follow-up in patients with craniopharyngioma-related hypothalamic obesity 
vs. control subjects with “common” obesity. Mean percentage weight loss after sleeve 
gastrectomy was 12% vs. 8% (difference 4%, 95% CI -1.3 to 6.9; P=0.117) at six weeks, 
12% vs. 17% (difference - 5%, 95% CI -15.5 to 3.2; P=0.334) at one year, and 10% vs. 20% 
(difference -10%, 95% CI -14.1 to -6.2; P=0.003) at two years of follow-up in patients with 
craniopharyngioma-related hypothalamic obesity vs. control subjects with “common” 
obesity. All but one patient with craniopharyngioma lost weight markedly after bariatric 
surgery. We have no clear explanation for the weight-loss failure in this particular patient 
who underwent a sleeve gastrectomy.
We validated our results on bariatric-surgery induced weight loss in patients with 
craniopharyngioma-related hypothalamic obesity by performing a meta-analysis in 
which we compared body mass index at one year of follow-up after bariatric surgery 
with body mass index at bariatric procedure (Figure 7.2). We observed significant weight 
loss after bariatric surgery (mean 8.78, 95% CI 2.60 to 14.95 kg/m2). Although Roux-en-Y 
gastric bypass resulted in significant weight loss (mean 11.10, 95% CI 2.32 to 19.88 kg/
m2), sleeve gastrectomy was less effective (mean 6.50, 95% CI -2.18 to 15.18 kg/m2).
Effects of bariatric surgery on hormone replacement therapy 
Effects of bariatric surgery on hormone replacement therapy are shown in Table 7.3. 
Seven of eight patients with craniopharyngioma used hormone replacement therapy for 
pituitary insufficiency. In the patients using growth hormone replacement, serum IGF-I 
levels declined during the first year after bariatric surgery in all but one patient (data 
not shown). In two patients, this enforced a minor increase in the daily recombinant hu-
man growth hormone dose. The daily levothyroxine dose was reduced in three patients 
during the first twelve months after bariatric surgery. No patients were admitted to the 
hospital for adrenal crisis pre- or post-bariatric procedure. In addition, no adjustments 
in the daily hydrocortisone dose were necessary. One patient switched from oestradiol 2 
mg/dydrogesteron 10 mg oestrogen-progestin replacement to ethinyloestradiol 30 μg/
levonorgestrel 150 μg approximately two months after bariatric procedure; five months 
later she switched to ethinyloestradiol 50 μg/levonorgestrel 125 μg. No adjustments in 
Figure 7.2. Forest plot on the mean difference in body mass index at one year of follow-up after bariatric 
surgery compared to body mass index at bariatric procedure in patients with craniopharyngioma-related 
hypothalamic obesity. BMI = body mass index; kg/m2 = kilograms per square meter.
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Figure	2	4244	
	4245	
Forest	plot	on	the	mean	difference	in	body	mass	index	at	one	year	of	follow-up	after	bariatric	4246	
surgery	 compared	 to	 body	 mass	 index	 at	 bariatric	 procedure	 in	 patients	 with	4247	
craniopharyngioma-related	hypothalamic	obesity.	BMI	=	body	mass	index;	kg/m2	=	kilograms	4248	
per	square	m ter.		 	4249	
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the prescribed testosterone replacement therapy were required after bariatric surgery. 
In two of six patients using desmopressin, the daily dose had to be slightly increased 
after bariatric surgery. No patient required any change in formulation type of endocrine 
substitution therapy.
Diabetes mellitus, hypertension, and dyslipidaemia
Presence of treatment for diabetes mellitus, hypertension, and dyslipidaemia before, 
as well as one year after bariatric surgery in patients with craniopharyngioma-related 
hypothalamic obesity compared to control subjects with “common” obesity is shown 
in Table 7.4. At one year of follow-up after bariatric surgery, there were no significant 
differences in the use of antidiabetic, antihypertensive, and antihyperlipidemic agents 
between cases and controls. Presence of treatment for diabetes mellitus, hypertension, 
and dyslipidaemia in patients with craniopharyngioma before and one year after bariat-
ric surgery was 12.5% vs. 0%, 50.0% vs. 25.0%, and 12.5% vs. 12.5%, respectively.
DISCUSSION
This matched case-control study is the first to address two of the most important 
clinical questions on bariatric surgery for craniopharyngioma-related hypothalamic 
obesity: does bariatric surgery results in sufficient weight loss, and is bariatric surgery 
Table 7.4. 
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Diabetes mellitus: n (%)
- Before BS 1 (12.5) 6 (8.0) NS 1 (20.0) 6 (13.3) NS 0 0 NS 
- 1 yr. FU 0 2 (2.7) NS 0 2 (4.4) NS 0 0 NS 
Hypertension: n (%)
- Before BS 4 (50.0) 13 (17.3) NS 2 (40.0) 11 (24.4) NS 2 (66.7) 2 (6.7) 0.021 
- 1 yr. FU 2 (25.0) 17 (22.7) NS 1 (20.0) 14 (31.1) NS 1 (33.3) 3 (10.0) NS 
Dyslipidaemia: n (%)
- Before BS 1 (12.5) 2 (2.7) NS 0 1 (2.2) NS 1 (33.3) 1 (3.3) NS 
- 1 yr. FU 1 (12.5) 0 NS 0 0 NS 1 (33.3) 0 NS 
% = percentage; BS = bariatric surgery; FU = follow-up; n = number; NS = not significant; RYGB = Roux-en-Y 
gastric bypass; SG = sleeve gastrectomy; yr. = years.
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safe regarding its effects on hormone replacement therapy for pituitary insufficiency? 
We compared bariatric surgery-induced weight loss between patients with craniopha-
ryngioma-related hypothalamic obesity and extensively matched control subjects with 
“common” obesity. Additionally, we validated our results on weight loss in patients with 
craniopharyngioma-related hypothalamic obesity in a meta-analysis. Moreover, we in-
vestigated the effects of bariatric surgery on hormone replacement therapy for pituitary 
insufficiency. At two years of follow-up, weight loss after Roux-en-Y gastric bypass, but 
not sleeve gastrectomy, was comparable between patients with craniopharyngioma-
related hypothalamic obesity and control subjects with “common” obesity. Accordingly, 
our meta-analysis revealed significant weight loss after Roux-en-Y gastric bypass at one 
year of follow-up after bariatric surgery in patients with craniopharyngioma-related 
hypothalamic obesity; sleeve gastrectomy was less effective. Minor adjustments in 
hormone replacement therapy were required in three of seven patients with craniopha-
ryngioma.
One other case-control study compared weight loss after bariatric surgery between 
patients with craniopharyngioma-related hypothalamic obesity and control subjects 
with “common” obesity. In this retrospective non-matched study, Weismann et al. in-
cluded nine patients with craniopharyngioma and 143 control subjects. In their study, 
two patients with craniopharyngioma received a Roux-en-Y gastric bypass, and four a 
sleeve gastrectomy.21 In concordance with our results, weight loss after bariatric surgery 
was only comparable between cases and controls in the subset of patients who received 
a Roux-en-Y gastric bypass. In the study by Weismann et al., control subjects were 
significantly older and presented more pronounced metabolic disturbances at baseline 
compared to patients with craniopharyngioma.21 In the present study, we validated our 
results on bariatric surgery-induced weight loss in patients with craniopharyngioma-
related hypothalamic obesity by performing a meta-analysis. Consequently, we updated 
a previous meta-analysis by Bretault et al.19 This prior meta-analysis studied weight loss 
at six months and one year of follow-up after bariatric surgery and could not demon-
strate significant weight loss after Roux-en-Y gastric bypass or sleeve gastrectomy.
At the moment, it is still largely unknown by what exact mechanisms bariatric proce-
dures establish their effects. Alterations in eating behaviour and energy homeostasis due 
to a combination of changes in gut hormone and autonomous nervous system signalling 
are thought to be responsible for weight loss and improved glycaemic control. Bariatric 
surgery-induced alterations in blood bile acid concentrations and gut microbiota may 
also contribute to weight decline.22 Hypothalamic structures, like the ventromedial nu-
cleus, arcuate nucleus, paraventricular nucleus, lateral hypothalamic area, dorsomedial 
nucleus, dorsal hypothalamic area, supraoptic nucleus, and suprachiasmatic nucleus are 
key regulators in balancing feeding behaviour and energy expenditure by integrating 
gut hormone and autonomous nervous system signalling.5, 23 Craniopharyngiomas and/
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or their treatment may damage these important brain structures, thereby resulting 
in autonomic nervous system dysfunction and acquired leptin and insulin resistance, 
which subsequently adversely alter food intake and food satisfaction, metabolism, as 
well as energy expenditure.5 This could diminish the efficacy of bariatric procedures 
like Roux-en-Y gastric bypass and sleeve gastrectomy, which may rely, at least partly, 
on intact hypothalamic function for their beneficial effects.24 However, we observed a 
weight loss similar to control subjects with “common” obesity in most of our patients 
with craniopharyngioma-related hypothalamic obesity after bariatric surgery. This may 
be explained by the observation that brain circuits and gut hormone receptors thought 
to be important in exerting beneficial effects of bariatric procedures are not only found 
in the hypothalamus, but in other brain regions probably not affected by the craniopha-
ryngioma and/or its treatment as well.24 Consequently, weight-loss-promoting changes 
in gut hormone and autonomous nervous system signalling can probably still exert 
some of their beneficial effects in patients with craniopharyngioma-related hypotha-
lamic obesity.
Bariatric procedures potentially influence drug absorption and bioavailability.15 In ad-
dition, pharmacokinetics and pharmacodynamics, which are different in obese and lean 
subjects,16 may reasonably change following weight loss, possibly resulting in altered 
drug dose requirements. Therefore, it is important to consider the effects of bariatric 
surgery on hormone replacement therapy for pituitary insufficiency in patients with cra-
niopharyngioma. In our study, seven patients with craniopharyngioma used endocrine 
substitution regimens. Bariatric surgery did not seem to affect hormone replacement 
therapy significantly, although one might expect lower levothyroxine requirements 
due to the bariatric surgery-induced weight loss.25 Therefore, it seems likely that the 
absorption of some hormones might be decreased. Other studies addressing bariatric 
surgery-induced alterations in hormone replacement therapy are scarce. A recent study 
by Wolf et al. reported no significant changes in the administered daily recombinant 
human growth hormone, levothyroxine, hydrocortisone, and desmopressin dose in four 
patients with craniopharyngioma at 13-65 months of follow-up after gastric bypass 
compared to baseline. In addition, no adrenal crises were observed. An oral thyroid/
hydrocortisone absorption test, which was performed in one patient after bariatric sur-
gery, revealed adequate drug absorption.17 Given the bariatric surgery-induced weight 
loss, the hydrocortisone need is expected to be reduced. Therefore, using the same hy-
drocortisone dose after compared to before bariatric surgery may induce steroid-related 
side-effects like weight gain, unless the bioavailability of hydrocortisone is reduced.26 
However, this has not been systematically studied.
At one year of follow-up after bariatric surgery, there were no significant differences 
in the use of antidiabetic, antihypertensive, and antihyperlipidemic agents between pa-
tients with craniopharyngioma-related hypothalamic obesity and control subjects with 
Bariatric surgery for hypothalamic obesity 175
“common” obesity. In patients with craniopharyngioma, the presence of treatment for 
diabetes mellitus and hypertension declined at one year of follow-up after bariatric sur-
gery compared to baseline, while the use of hypolipidemic medication remained equal. 
In the aforementioned study by Bretault et al., 31.6% of patients with craniopharyngio-
ma-related hypothalamic obesity were diabetic at bariatric procedure. This declined to 
8.3% at one year of follow-up. One patient required antihypertensive medication before 
bariatric surgery. No data on antihyperlipidemic drugs were available.19 
Our study has some limitations. Since craniopharyngioma is a rare disease, and only 
a minority of patients with craniopharyngioma is likely to have undergone bariatric 
surgery, it is hard to obtain a large sample size, even with international collaboration. In 
an attempt to overcome this issue, we performed a meta-analysis to validate our results 
on bariatric surgery-induced weight loss in patients with craniopharyngioma-related 
hypothalamic obesity. However, due to the relatively small number of patients, results 
of statistical analyses have to be interpreted cautiously. In addition, we were unable to 
report perioperative and postoperative complications of bariatric surgery in all patients 
with craniopharyngioma. Only data from the Swedish patients were available on this 
subject, in whom only one patient suffered from postoperative abdominal pain during 
the first six weeks after sleeve gastrectomy. In the study by Weismann et al., the occur-
rence of postoperative problems after bariatric surgery (i.e. abdominal pain, vomiting, 
and reflux) was similar in patients with craniopharyngioma-related hypothalamic obe-
sity and control subjects with “common” obesity.21
In conclusion, our observations suggest that bariatric surgery, in particular with Roux-
en-Y gastric bypass, might be an effective therapeutic option for craniopharyngioma-
related hypothalamic obesity without significant side-effects on hormone replacement 
therapy for pituitary insufficiency. However, careful drug monitoring is still advised, 
especially for levothyroxine and hydrocortisone. Larger, international, well-designed 
studies are needed to receive more efficacy and safety data regarding the therapeutic 
potential of bariatric surgery for craniopharyngioma-related hypothalamic obesity. 
Such studies should have an adequate follow-up duration and should compare weight 
loss between patients and matched control subjects.
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GENERAL DISCUSSION AND CONCLUSIONS
During the past decades, cancer survival increased substantially in both children and 
adults.1-4 This resulted in an increased awareness of and insight in long-term consequences 
of cancer and its treatment.5-10 Accordingly, a high prevalence of chronic health conditions 
has been reported in childhood and adult cancer survivors, particularly due to endocrine 
and metabolic disorders.11-18 Research on long-term consequences of cancer and its treat-
ment focused predominantly on individuals with a malignant tumour. This is illustrated 
by the recently started studies from the Late Effects of Childhood Cancer task force of the 
Dutch Childhood Oncology Group (DCOG-LATER).19 However, some benign neoplasms, 
including craniopharyngiomas, may also cause substantial long-term health effects.
The aim of this thesis was to examine long-term endocrine and metabolic conditions, 
as well as their determinants in patients treated for cancer with a special focus on 
patients treated for craniopharyngioma. We found that not only patients treated for a 
malignant tumour, but also patients treated for a benign neoplasm (i.e. craniopharyn-
gioma), experience a high frequency of long-term endocrine and metabolic disorders. In 
patients with craniopharyngioma, such disorders are mainly due to tumour- and treat-
ment-related damage of critical neurovascular structures (e.g. hypothalamus, pituitary, 
optic nerves, carotid arteries), as well as their associated morbidities (e.g. obesity related 
to hypopituitarism). We identified the metabolic syndrome (MetS) and its components 
as important long-term health conditions in patients with craniopharyngioma, likely to 
be largely responsible for the excessive morbidity and mortality due to type 2 diabetes 
mellitus (T2DM) and circulatory diseases in this patient population. At last, we demon-
strated that bariatric surgery may be an effective and safe therapy for obesity in patients 
with craniopharyngioma. The main findings of this thesis are summarized in Figure 8.1.
kEY POINT:
The aim of this thesis was to examine long-term endocrine and metabolic conditions, 
as well as their determinants in patients treated for cancer with a special focus on 
patients treated for craniopharyngioma.
Long-term endocrine and metabolic consequences of cancer and its treatment
The development of a subsequent neoplasm is an important long-term health condi-
tion after cancer treatment.20 Endocrine-related cancers are among the most common 
secondary tumours in both childhood and adult cancer survivors.4, 21 In Chapter 2, we 
reviewed the literature on risk factors for subsequent endocrine-related cancer in child-
hood cancer survivors. Thereby, we focused on secondary neoplasms of the breast and 
thyroid.
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We identified the potential harmful effects of oestrogen-progestin replacement ther-
apy on radiation-induced breast cancer development in premature ovarian insufficient 
childhood cancer survivors as the most important area for future research. Several stud-
ies reported a protective effect of premature ovarian insufficiency on radiation-induced 
breast cancer development.22-26 Accordingly, concerns have raised regarding the safety 
of oestrogen-progestin replacement therapy. However, although available evidence is 
weak, no clear detrimental effect of oestrogen-progestin replacement therapy on the 
risk for radiation-induced breast cancer development in premature ovarian insufficient 
childhood cancer survivors has been demonstrated.27 Since untreated premature ovarian 
insufficiency is associated with significant side effects,28 the use of oestrogen-progestin 
replacement therapy should not be discouraged in premature ovarian insufficient child-
hood cancer survivors treated with chest irradiation until clear harmful effects have been 
demonstrated. Future studies are needed to ascertain the safety of oestrogen-progestin 
replacement therapy. Meanwhile, oestrogen-progestin replacement therapy could be 
prescribed based on shared decision-making.
The MetS is another important long-term health condition in cancer survivors.29-31 
It can be defined as a constellation of obesity, insulin resistance, dyslipidaemia, and 
elevated blood pressure,32 and has been associated with a two-fold increased risk for 
cardio- and cerebrovascular disease, as well as a five-fold increased risk for T2DM.33 An 
Figure 8.1. Main findings of this thesis
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unhealthy lifestyle with insufficient physical activity seems an important risk factor for 
the MetS.34, 35 Accordingly, in Chapter 3, we studied daily life physical activity in sur-
vivors of nephroblastoma and neuroblastoma. Thereby, we performed one of the first 
studies that investigated physical activity relative to a non-cancer control group using a 
validated questionnaire.36
We observed a significantly lower level of physical activity in male neuroblastoma 
survivors compared to male control subjects. Female neuroblastoma survivors and male 
and female nephroblastoma survivors had similar physical activity levels compared 
to control subjects. Our results concerning male neuroblastoma survivors confirmed 
the results of a previous study by Ness et al. that investigated physical activity using 
a non-validated questionnaire.37 Other studies in childhood cancer survivors reported 
particularly low levels of physical activity in individuals treated for brain cancer and os-
teosarcoma.38, 39 Most studies in adult cancer survivors focused on individuals treated for 
breast and colorectal cancer.39 Consistent with a low level of physical activity, survivors 
of these malignancies demonstrate a high prevalence of the MetS.29, 30, 40, 41
Our results indicate that physical inactivity contributes to the development of the 
MetS in childhood cancer survivors. Therefore, we advocate a healthy lifestyle with 
sufficient exercise; all the more because sufficient physical activity has been shown to 
ameliorate the MetS in childhood and adult cancer survivors.42 Future studies should use 
objective methods to measure physical activity.43 In addition, lifestyle interventions that 
aim to increase exercise should be developed and evaluated.
kEY POINTS:
The potential harmful effects of oestrogen-progestin replacement therapy on radia-
tion-induced breast cancer development in premature ovarian insufficient childhood 
cancer survivors is an important area for future research.
An unhealthy lifestyle with insufficient physical activity seems to contribute to the 
development of the MetS in childhood cancer survivors. Lifestyle interventions that 
aim to increase exercise should be developed and evaluated.
Long-term endocrine and metabolic consequences in patients with 
craniopharyngioma
Not only malignant tumours, but also benign neoplasms, may result in significant long-
term tumour- and treatment-related morbidities. An important example of such a be-
nign neoplasm is craniopharyngioma. In Chapter 4, we investigated long-term health 
conditions in a large single-centre cohort of patients treated for craniopharyngioma. We 
observed pituitary hormone deficiencies, visual impairment, and obesity to be the most 
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common long-term health effects in 98%, 75%, and 56% of the patients, respectively. 
Our results confirm previous studies on long-term sequelae of craniopharyngioma treat-
ment.44-49 In patients with craniopharyngioma, long-term health conditions are mainly 
due to tumour- and treatment-related damage of critical neurovascular structures and 
their associated morbidities.50 
Modern craniopharyngioma treatment aims to minimize long-term tumour- and 
treatment-related sequelae while providing adequate survival and disease control.51 Al-
though there is consensus about the fact that hypothalamic and optic functions should 
be preserved, it remains unknown whether the optimal treatment strategy should be 
aggressive or more conservative. Accordingly, in Chapter 4, we examined long-term se-
quelae of craniopharyngioma treatment according to the initial therapeutic approach. 
Thereby, we performed one of the first studies that evaluated long-term health effects of 
craniopharyngioma treatment with 90Yttrium brachytherapy and cyst drainage.
After a median follow-up period of 13 years, we observed a similar spectrum of 
long-term health conditions in patients treated with gross total resection, subtotal 
resection with or without radiotherapy, 90Yttrium brachytherapy, and cyst drainage. 
Recurrence-free survival was significantly lower after cyst drainage compared to the 
other treatment strategies. Our results confirm previous studies,45, 52, 53 and indicate that 
long-term tumour- and treatment-related health effects are frequent in patients with 
craniopharyngioma, irrespective of the initial treatment strategy.
When interpreting our results, it is important to recognize that the treatment of cra-
niopharyngiomas is predominantly individualized based on tumour and patient charac-
teristics. Therefore, selection bias may have, at least in part, affected our findings. Ideally, 
a multi-institutional prospective randomized trial should be performed to determine 
the optimal initial craniopharyngioma treatment strategy. Such a trial should not only 
study endocrine and metabolic endpoints, but also other conditions like neurological 
deficits, neurocognitive and neurobehavioral dysfunction, and quality of life.
In Chapter 4, we also performed one of the first studies that examined long-term 
health conditions in patients with craniopharyngioma according to the age at diagnosis. 
We observed a significantly higher frequency of pituitary hormone deficiencies, morbid 
obesity, epilepsy, and psychiatric conditions in patients with childhood- compared to 
adult-onset craniopharyngioma. In addition, we demonstrated that these findings are, 
at least partly, likely to be due to differences in tumour characteristics already present at 
diagnosis. Our results are in concordance with a previous study by Gautier et al.46
We observed significantly more multicystic tumours, as well as tumours associated 
with hydrocephalus and hypothalamic damage in patients with childhood- compared 
to adult-onset craniopharyngioma. Gautier et al. observed significantly more suprasellar 
tumours with intrasellar extension, as well as a trend towards larger tumours in patients 
with childhood-onset disease.46 These results indicate that craniopharyngiomas in chil-
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dren are diagnosed when significant progression of the tumour has already occurred. In-
deed, Müller et al. reported that most children with craniopharyngioma already present 
a reduced growth rate 7.5 years before diagnosis.54 Physicians should be more vigilant 
of the possibility of a craniopharyngioma in children with growth failure. Future studies 
should identify other features that may lead to a prompter diagnosis of craniopharyn-
gioma in children, as well as investigate other factors that may explain the significantly 
higher frequency of long-term health conditions in patients with childhood- compared 
to adult-onset craniopharyngioma.
kEY POINTS:
In patients with craniopharyngioma, long-term health conditions are mainly due to 
tumour- and treatment-related damage of critical neurovascular structures and their 
associated conditions. Pituitary hormone deficiencies, visual impairment, and obesity 
are the most common long-term health effects.
Long-term tumour- and treatment-related health conditions are frequent in patients 
with craniopharyngioma, irrespective of their initial treatment strategy.
Long-term health effects are generally more common in patients with childhood- 
compared to adult-onset craniopharyngioma. This seems, at least partly, to be due to 
differences in tumour characteristics already present at diagnosis.
Studies that evaluate long-term health conditions relative to a control population may 
more reliably identify excess morbidity and mortality than studies that directly examine 
long-term health effects.55 Accordingly, in Chapter 5, we performed one of the first 
studies that investigated morbidity and mortality in patients with craniopharyngioma 
relative to the general population. We studied a large cohort of Dutch and Swedish 
patients with craniopharyngioma and evaluated many risk factors for excess morbidity 
and mortality.
We observed patients with craniopharyngioma to have a significantly increased risk 
for morbidity due to T2DM and cerebral infarction, as well as total mortality and mor-
tality due to circulatory and respiratory diseases. We identified female sex, childhood-
onset craniopharyngioma, hydrocephalus, tumour recurrence, and panhypopituitarism 
as important risk factors for excess morbidity and mortality. Our results confirm previous 
studies,56-61 and indicate that patients with craniopharyngioma experience excessive 
morbidity and mortality relative to the general population.
As indicated above, the increased risk for morbidity and mortality in patients with cra-
niopharyngioma may be explained by tumour- and treatment-related damage of critical 
neurovascular structures, as well as their associated conditions. Hypothalamic damage 
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may result in acquired leptin and insulin resistance, as well as in autonomic nervous 
system dysfunction, which may altogether adversely affect food intake, metabolism, 
and energy expenditure, thereby promoting obesity and its associated metabolic 
derangements.62 Hypopituitarism adversely affects metabolism due to inadequately 
treated pituitary hormone deficiencies and currently available hormone replacement 
regimens that do not appropriately simulate hypothalamic-pituitary physiology.63 This 
latter explanation may also apply to the excessive morbidity and mortality associated 
with female sex,64 and indicates that currently available sex hormone replacement regi-
mens could be improved. New hormone replacement regimens that better mimic the 
physiological situation should be developed.
Although many potential risk factors for morbidity and mortality in patients with 
craniopharyngioma are interrelated, hypothalamic damage and hypopituitarism seem 
to be the principal factors resulting in an adverse health status. Therefore, craniopharyn-
gioma treatment should aim to preserve hypothalamic and pituitary functions and pro-
vide optimal endocrine care. To date, most studies in patients with craniopharyngioma 
used neuroimaging to define hypothalamic involvement without considering clinical 
features of hypothalamic dysfunction. Although several classification systems for hypo-
thalamic involvement have been developed,65-68 most of them lack proper validation 
and are, therefore, not used in clinical practice. Recently, Mortini et al. validated some 
of these classification systems regarding their correlation with obesity.69 Future studies 
should use these validated classification systems and investigate their correlation with 
other clinical features of hypothalamic dysfunction.
Radiotherapy is an important risk factor for the development of cerebrovascular 
disease.70 However, none of the studies that examined excess morbidity and mortal-
ity in patients with craniopharyngioma (including ours) observed an increased risk for 
cerebrovascular disease associated with radiotherapy. This indicates that other factors, 
like neurosurgery and metabolic disturbances due to hypothalamic damage and hypo-
pituitarism, also contribute to the development of cerebrovascular disease in patients 
with craniopharyngioma. In addition, available studies may have included patients too 
young with a follow-up duration too short to already observe an increased risk for cere-
brovascular disease associated with radiotherapy. Future studies should have a longer 
follow-up duration.
Patients with craniopharyngioma are at increased risk for mortality compared to pa-
tients with hypopituitarism due to other causes.57, 60 Although the underlying reason is 
unknown, craniopharyngioma-specific factors (e.g. hypothalamic damage, severe hypopi-
tuitarism, a locally aggressive tumour behaviour with a high recurrence rate) are likely to 
be involved.71 Future studies are needed to gain insight into this issue. Such studies should 
compare patients with craniopharyngioma to a control population with hypopituitarism 
due to other causes and should also investigate cause-specific mortality.
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kEY POINTS:
Patients with craniopharyngioma are at increased risk for morbidity due to T2DM 
and cerebral infarction, as well as total mortality and mortality due circulatory and 
respiratory diseases.
Craniopharyngioma treatment should aim to preserve hypothalamic and pituitary 
functions and provide optimal endocrine care.
The MetS and its components in patients with craniopharyngioma
As discussed above, obesity is an important long-term health condition in patients with 
craniopharyngioma. Obesity is often associated with other metabolic abnormalities, like 
those constituting the MetS.33 In Chapter 6, we performed the largest study to date 
that investigated the MetS and its components in patients with craniopharyngioma. In 
a combined cohort of Dutch and Swedish patients, we examined the prevalence of and 
risk factors for the MetS and its components relative to the general population.
We observed the MetS and its components to be significantly more common in pa-
tients with craniopharyngioma. After a median follow-up period of 16 years, almost half 
of the patients with craniopharyngioma demonstrated the MetS. We identified visual 
impairment as the most important risk factor for the MetS. Hypothalamic damage, fol-
low-up duration, tumour location, female sex, 90Yttrium brachytherapy, glucocorticoid 
replacement therapy, and age significantly predicted components. Our results confirm 
previous studies that investigated the MetS in patients with craniopharyngioma.58, 72-74
The discussion on the increased risk for morbidity and mortality in patients with 
craniopharyngioma above, may also apply to the high prevalence of the MetS and its 
components. Visual impairment may contribute to the MetS due to a negative effect on 
physical activity. Several studies reported a significantly lower level of physical activ-
ity in patients with craniopharyngioma compared to age-, sex-, and body mass index-
matched control subjects.75, 76 This indicates that insufficient physical activity does not 
only contribute to the development of the MetS in individuals treated for a malignant 
tumour, but also in individuals treated for a benign neoplasm (i.e. craniopharyngioma).
Although patients with craniopharyngioma are at increased risk for mortality com-
pared to patients with hypopituitarism due to other causes,57, 60 and mortality in both 
patients with craniopharyngioma and patients with hypopituitarism due to other causes 
is predominantly circulatory,71 the prevalence of the MetS has been reported to be simi-
lar.74, 77, 78 This striking finding may be explained by the fact that studies reporting this 
issue investigated the MetS before commencement of growth hormone replacement 
therapy (GHRT). Profka et al. demonstrated that after five years of GHRT, the MetS is 
significantly more prevalent in patients with craniopharyngioma compared to patients 
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with hypopituitarism due other causes.74 The higher prevalence of the MetS in patients 
with craniopharyngioma may be due to a high frequency of hypothalamic damage. 
Recent studies in rodents demonstrated that hypothalamic growth hormone signalling 
plays an important role in the central regulation of metabolism.79, 80 Future studies that 
compare the prevalence of the MetS between patients with craniopharyngioma and 
patients with hypopituitarism due to other causes should include patients who are 
adequately substituted with hormone replacement therapy.
The data above suggest that the MetS may be largely responsible for the excess mor-
bidity and mortality due to T2DM and circulatory diseases in patients with craniopha-
ryngioma. The high prevalence of the MetS warrants regular screening and appropriate 
treatment. Future studies should investigate interventions that aim to reduce the preva-
lence of the MetS and its components. Such studies should preferably focus on obesity, 
since visceral adipose tissue-induced insulin resistance seems to be the principal factor 
resulting in the MetS and its components.33 
kEY POINTS:
The MetS is significantly more common in patients with craniopharyngioma com-
pared to the general population. After 16 years of follow-up since craniopharyngioma 
diagnosis, almost half of the patients demonstrate the MetS.
The high prevalence of the MetS in patients with craniopharyngioma seems to be 
due to hypothalamic damage and hypopituitarism, as well as visual impairment.
The MetS may be largely responsible for the excess morbidity and mortality due to 
T2DM and circulatory diseases in patients with craniopharyngioma.
Bariatric surgery as an intervention for craniopharyngioma-related obesity
As discussed above, obesity is a major problem in patients with craniopharyngioma. It 
contributes to the high prevalence of the MetS and subsequent excess morbidity and 
mortality due to T2DM and circulatory diseases, and it has been identified as the most 
important predictor of a worse quality of life.44, 81-84 Treatment of obesity in patients 
with craniopharyngioma is difficult. Intensive lifestyle modification only slows weight 
gain,85, 86 while currently available pharmacotherapies result in minimal weight loss 
coupled with significant side effects.62, 87 Therefore, in Chapter 7, we studied bariatric 
surgery as a therapy for craniopharyngioma-related obesity in a combined cohort of 
Dutch and Swedish patients. Thereby, we performed the first matched case-control 
study that evaluated the efficacy and safety of two bariatric procedures (i.e. Roux-en-Y 
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gastric bypass and sleeve gastrectomy) in patients with craniopharyngioma. We vali-
dated our results in a meta-analysis.
After two years of follow-up, weight loss after bariatric surgery was comparable 
between patients with craniopharyngioma and control subjects with common obesity. 
Roux-en-Y gastric bypass resulted in similar weight loss, while weight loss after sleeve 
gastrectomy was significantly lower in patients with craniopharyngioma. Our meta-
analysis confirmed these findings. Both bariatric procedures seemed safe regarding their 
effects on hormone replacement therapy. A previous meta-analysis evaluated weight 
loss after two other bariatric procedures (i.e. laparoscopic adjustable gastric banding 
and biliopancreatic diversion with duodenal switch).88 Laparoscopic adjustable gastric 
banding did not result in significant weight loss, while weight loss after biliopancreatic 
diversion with duodenal switch could not be reliably analysed due to the low number of 
patients. Similar to our study, two other reports showed that gastric bypass and sleeve 
gastrectomy in patients with craniopharyngioma seemed safe regarding their effects on 
hormone replacement therapy.89, 90 
The exact mechanisms by which bariatric procedures result in weight loss remain 
largely unknown. Alterations in eating behaviour and metabolism due to changes in gut 
hormone and autonomous nervous system signalling are postulated to be involved.91 
The hypothalamus plays a key role in integrating gut hormone and autonomous nervous 
system signalling.92 Since patients with craniopharyngioma often demonstrate hypo-
thalamic damage, the effectiveness of bariatric surgery has been questioned. However, 
as our findings indicate, weight loss after bariatric surgery may be comparable to control 
subjects with common obesity. This may be explained by the fact that brain circuits and 
gut hormone receptors responsible for the beneficial effects of bariatric procedures are 
not only found in the hypothalamus, but in other brain regions as well.92, 93
Although our results are retrospective and limited by a small study population and 
short duration of follow-up, they suggest that bariatric surgery, especially with Roux-
en-Y gastric bypass, may be an effective and safe therapy for craniopharyngioma-related 
obesity. However, careful drug monitoring is still advised. Future studies are needed that 
prospectively evaluate the efficacy and safety of bariatric procedures in larger cohorts 
of patients with craniopharyngioma after a longer duration of follow-up. Such studies 
should preferably have a randomized controlled design, and use pharmacokinetic and 
pharmacodynamic parameters to investigate the effects of bariatric procedures on hor-
mone replacement therapy. In addition, such studies should examine other potential 
complications of bariatric surgery, like nutrient deficiencies and surgical-related prob-
lems. Moreover, the effects of bariatric procedures on the MetS, T2DM, and cardio- and 
cerebrovascular disease should be investigated, as studies in the general population 
reported a significantly lower prevalence of these conditions after bariatric surgery.94-97
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Another important aspect to consider in the bariatric surgical treatment of patients 
with craniopharyngioma is the timing of the intervention. Obesity develops predomi-
nantly during the first twelve years after craniopharyngioma treatment.98 In this twelve 
years, the most significant weight gain occurs during the first year.99 Accordingly, one 
might argue that early intervention with bariatric surgery may prevent severe weight 
gain. Thereby, it is important to consider that approximately 30% of craniopharyngiomas 
present in children and adolescents.100 Although bariatric surgery has been proven to 
be effective in adolescents with common obesity,101 there are considerable ethical and 
moral concerns.102, 103 Currently, there is insufficient evidence to recommend bariatric 
surgery for obesity in paediatric patients with craniopharyngioma.
kEY POINT:
Bariatric surgery, especially with Roux-en-Y gastric bypass, seems to be an effective 
and safe therapy for craniopharyngioma-related hypothalamic obesity. However, fu-
ture studies are needed to prospectively evaluate the efficacy and safety of bariatric 
procedures in larger cohorts of patients after a longer duration of follow-up.
Future perspectives for patients with craniopharyngioma
As discussed above, the ideal craniopharyngioma treatment strategy should aim to 
preserve hypothalamic and pituitary functions and provide optimal endocrine care. 
Recent advances in the treatment of craniopharyngiomas (e.g. endoscopic endonasal 
tumour resection, proton therapy, targeted drug therapy) allow a more precise tumour 
treatment whereby sparing healthy surrounding tissues.104-111 Therefore, these promis-
ing therapies may result in similar or even better treatment outcomes coupled with less 
long-term toxicities. However, their place in the craniopharyngioma treatment arma-
mentarium still needs to be determined.
Glucagon-like peptide-1 (GLP-1) is one of the gut hormones responsible for weight 
loss after bariatric surgery.91, 92 Recently, GLP-1 receptor agonists have become avail-
able.112 Although these agents were originally developed and approved for the treat-
ment of T2DM,113 one of them (i.e. liraglutide) has now also been approved as a therapy 
for obesity.114 Several case reports and series described that these agents may also 
induce significant weight loss in patients with craniopharyngioma.115, 116 Pharmaco-
therapies based on other gut hormones (i.e. ghrelin, peptide YY, and cholecystokinin) 
are under development.117-119 Future studies should determine the therapeutic potential 
of these promising agents that may eventually replace bariatric surgery as a therapy for 
craniopharyngioma-related obesity.
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CONCLUSION
To date, more than 32.5 million individuals in the world are long-term survivors of be-
nign and malignant neoplasms.120 Due to ongoing improvements in cancer treatment 
and care,121 this number is anticipated to increase. The findings from this thesis illustrate 
the importance of continuous research and follow-up care of this patient population. 
Unfortunately, patients with craniopharyngioma are not included in the recently started 
DCOG-LATER studies.19 Due to the rarity of craniopharyngiomas, as well as their broad 
spectrum of long-term sequelae, multidisciplinary care in expert centres and multi-
institutional research collaboration is recommended. Therefore, we were very privileged 
with the international collaboration with the Sahlgrenska University Hospital in Gothen-
burg, Sweden. For future studies, these collaborations should be extended.
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CREATIVE COMMONS CORPORATION IS NOT A LAW FIRM AND DOES NOT PROVIDE LEGAL SERVICES. 
DISTRIBUTION OF THIS LICENSE DOES NOT CREATE AN ATTORNEY-CLIENT RELATIONSHIP. CREATIVE COM-
MONS PROVIDES THIS INFORMATION ON AN “AS-IS” BASIS. CREATIVE COMMONS MAKES NO WARRANTIES 
REGARDING THE INFORMATION PROVIDED, AND DISCLAIMS LIABILITY FOR DAMAGES RESULTING FROM 
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License
THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS OF THIS CREATIVE COMMONS PUBLIC 
LICENSE (“CCPL” OR “LICENSE”). THE WORK IS PROTECTED BY COPYRIGHT AND/OR OTHER APPLICABLE 
LAW. ANY USE OF THE WORK OTHER THAN AS AUTHORIZED UNDER THIS LICENSE OR COPYRIGHT LAW IS 
PROHIBITED.
BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU ACCEPT AND AGREE TO BE BOUND BY 
THE TERMS OF THIS LICENSE. TO THE EXTENT THIS LICENSE MAY BE CONSIDERED TO BE A CONTRACT, THE 
LICENSOR GRANTS YOU THE RIGHTS CONTAINED HERE IN CONSIDERATION OF YOUR ACCEPTANCE OF 
SUCH TERMS AND CONDITIONS.
1. Definitions
 “Adaptation” means a work based upon the Work, or upon the Work and other pre-existing works, such 
as a translation, adaptation, derivative work, arrangement of music or other alterations of a liter-
ary or artistic work, or phonogram or performance and includes cinematographic adaptations 
or any other form in which the Work may be recast, transformed, or adapted including in any 
form recognizably derived from the original, except that a work that constitutes a Collection will 
not be considered an Adaptation for the purpose of this License. For the avoidance of doubt, 
where the Work is a musical work, performance or phonogram, the synchronization of the Work 
in timed-relation with a moving image (“synching”) will be considered an Adaptation for the 
purpose of this License.
 “Collection” means a collection of literary or artistic works, such as encyclopedias and anthologies, or 
performances, phonograms or broadcasts, or other works or subject matter other than works 
listed in Section 1(f ) below, which, by reason of the selection and arrangement of their contents, 
constitute intellectual creations, in which the Work is included in its entirety in unmodified form 
along with one or more other contributions, each constituting separate and independent works 
in themselves, which together are assembled into a collective whole. A work that constitutes 
a Collection will not be considered an Adaptation (as defined below) for the purposes of this 
License.
 “Creative Commons Compatible License” means a license that is listed at https://creativecommons.
org/compatiblelicenses that has been approved by Creative Commons as being essentially 
equivalent to this License, including, at a minimum, because that license: (i) contains terms 
that have the same purpose, meaning and effect as the License Elements of this License; and, 
(ii) explicitly permits the relicensing of adaptations of works made available under that license 
under this License or a Creative Commons jurisdiction license with the same License Elements as 
this License.
 “Distribute” means to make available to the public the original and copies of the Work or Adaptation, as 
appropriate, through sale or other transfer of ownership.
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 “License Elements” means the following high-level license attributes as selected by Licensor and indi-
cated in the title of this License: Attribution, ShareAlike.
 “Licensor” means the individual, individuals, entity or entities that offer(s) the Work under the terms of 
this License.
 “Original Author” means, in the case of a literary or artistic work, the individual, individuals, entity or 
entities who created the Work or if no individual or entity can be identified, the publisher; and 
in addition (i) in the case of a performance the actors, singers, musicians, dancers, and other 
persons who act, sing, deliver, declaim, play in, interpret or otherwise perform literary or artistic 
works or expressions of folklore; (ii) in the case of a phonogram the producer being the person 
or legal entity who first fixes the sounds of a performance or other sounds; and, (iii) in the case of 
broadcasts, the organization that transmits the broadcast.
 “Work” means the literary and/or artistic work offered under the terms of this License including without 
limitation any production in the literary, scientific and artistic domain, whatever may be the mode 
or form of its expression including digital form, such as a book, pamphlet and other writing; a 
lecture, address, sermon or other work of the same nature; a dramatic or dramatico-musical work; 
a choreographic work or entertainment in dumb show; a musical composition with or without 
words; a cinematographic work to which are assimilated works expressed by a process analogous 
to cinematography; a work of drawing, painting, architecture, sculpture, engraving or lithog-
raphy; a photographic work to which are assimilated works expressed by a process analogous 
to photography; a work of applied art; an illustration, map, plan, sketch or three-dimensional 
work relative to geography, topography, architecture or science; a performance; a broadcast; a 
phonogram; a compilation of data to the extent it is protected as a copyrightable work; or a work 
performed by a variety or circus performer to the extent it is not otherwise considered a literary 
or artistic work.
 “You” means an individual or entity exercising rights under this License who has not previously violated 
the terms of this License with respect to the Work, or who has received express permission from 
the Licensor to exercise rights under this License despite a previous violation.
 “Publicly Perform” means to perform public recitations of the Work and to communicate to the public 
those public recitations, by any means or process, including by wire or wireless means or public 
digital performances; to make available to the public Works in such a way that members of the 
public may access these Works from a place and at a place individually chosen by them; to per-
form the Work to the public by any means or process and the communication to the public of the 
performances of the Work, including by public digital performance; to broadcast and rebroadcast 
the Work by any means including signs, sounds or images.
 “Reproduce” means to make copies of the Work by any means including without limitation by sound 
or visual recordings and the right of fixation and reproducing fixations of the Work, including 
storage of a protected performance or phonogram in digital form or other electronic medium.
2. Fair Dealing Rights. Nothing in this License is intended to reduce, limit, or restrict any uses free from 
copyright or rights arising from limitations or exceptions that are provided for in connection with the 
copyright protection under copyright law or other applicable laws.
3. License Grant. Subject to the terms and conditions of this License, Licensor hereby grants You a 
worldwide, royalty-free, non-exclusive, perpetual (for the duration of the applicable copyright) license to 
exercise the rights in the Work as stated below:
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 a. to Reproduce the Work, to incorporate the Work into one or more Collections, and to Reproduce 
the Work as incorporated in the Collections;
 b. to create and Reproduce Adaptations provided that any such Adaptation, including any transla-
tion in any medium, takes reasonable steps to clearly label, demarcate or otherwise identify that 
changes were made to the original Work. For example, a translation could be marked “The original 
work was translated from English to Spanish,” or a modification could indicate “The original work 
has been modified.”;
 c. to Distribute and Publicly Perform the Work including as incorporated in Collections; and,
 d. to Distribute and Publicly Perform Adaptations.
 e. For the avoidance of doubt:
  i.  Non-waivable Compulsory License Schemes. In those jurisdictions in which the right to 
collect royalties through any statutory or compulsory licensing scheme cannot be waived, 
the Licensor reserves the exclusive right to collect such royalties for any exercise by You of the 
rights granted under this License;
  ii.  Waivable Compulsory License Schemes. In those jurisdictions in which the right to collect 
royalties through any statutory or compulsory licensing scheme can be waived, the Licensor 
waives the exclusive right to collect such royalties for any exercise by You of the rights granted 
under this License; and,
  iii.  voluntary License Schemes. The Licensor waives the right to collect royalties, whether indi-
vidually or, in the event that the Licensor is a member of a collecting society that administers 
voluntary licensing schemes, via that society, from any exercise by You of the rights granted 
under this License.
The above rights may be exercised in all media and formats whether now known or hereafter devised. 
The above rights include the right to make such modifications as are technically necessary to exercise 
the rights in other media and formats. Subject to Section 8(f ), all rights not expressly granted by Licensor 
are hereby reserved.
4. Restrictions. The license granted in Section 3 above is expressly made subject to and limited by the 
following restrictions:
 a. You may Distribute or Publicly Perform the Work only under the terms of this License. You must 
include a copy of, or the Uniform Resource Identifier (URI) for, this License with every copy of the 
Work You Distribute or Publicly Perform. You may not offer or impose any terms on the Work that 
restrict the terms of this License or the ability of the recipient of the Work to exercise the rights 
granted to that recipient under the terms of the License. You may not sublicense the Work. You 
must keep intact all notices that refer to this License and to the disclaimer of warranties with ev-
ery copy of the Work You Distribute or Publicly Perform. When You Distribute or Publicly Perform 
the Work, You may not impose any effective technological measures on the Work that restrict the 
ability of a recipient of the Work from You to exercise the rights granted to that recipient under 
the terms of the License. This Section 4(a) applies to the Work as incorporated in a Collection, but 
this does not require the Collection apart from the Work itself to be made subject to the terms 
of this License. If You create a Collection, upon notice from any Licensor You must, to the extent 
practicable, remove from the Collection any credit as required by Section 4(c), as requested. If You 
create an Adaptation, upon notice from any Licensor You must, to the extent practicable, remove 
from the Adaptation any credit as required by Section 4(c), as requested.
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 b. You may Distribute or Publicly Perform an Adaptation only under the terms of: (i) this License; (ii) 
a later version of this License with the same License Elements as this License; (iii) a Creative Com-
mons jurisdiction license (either this or a later license version) that contains the same License 
Elements as this License (e.g., Attribution-ShareAlike 3.0 US)); (iv) a Creative Commons Compat-
ible License. If you license the Adaptation under one of the licenses mentioned in (iv), you must 
comply with the terms of that license. If you license the Adaptation under the terms of any of the 
licenses mentioned in (i), (ii) or (iii) (the “Applicable License”), you must comply with the terms of 
the Applicable License generally and the following provisions: (I) You must include a copy of, or 
the URI for, the Applicable License with every copy of each Adaptation You Distribute or Publicly 
Perform; (II) You may not offer or impose any terms on the Adaptation that restrict the terms 
of the Applicable License or the ability of the recipient of the Adaptation to exercise the rights 
granted to that recipient under the terms of the Applicable License; (III) You must keep intact 
all notices that refer to the Applicable License and to the disclaimer of warranties with every 
copy of the Work as included in the Adaptation You Distribute or Publicly Perform; (IV) when You 
Distribute or Publicly Perform the Adaptation, You may not impose any effective technological 
measures on the Adaptation that restrict the ability of a recipient of the Adaptation from You 
to exercise the rights granted to that recipient under the terms of the Applicable License. This 
Section 4(b) applies to the Adaptation as incorporated in a Collection, but this does not require 
the Collection apart from the Adaptation itself to be made subject to the terms of the Applicable 
License.
 c. If You Distribute, or Publicly Perform the Work or any Adaptations or Collections, You must, 
unless a request has been made pursuant to Section 4(a), keep intact all copyright notices for 
the Work and provide, reasonable to the medium or means You are utilizing: (i) the name of the 
Original Author (or pseudonym, if applicable) if supplied, and/or if the Original Author and/or 
Licensor designate another party or parties (e.g., a sponsor institute, publishing entity, journal) 
for attribution (“Attribution Parties”) in Licensor’s copyright notice, terms of service or by other 
reasonable means, the name of such party or parties; (ii) the title of the Work if supplied; (iii) to 
the extent reasonably practicable, the URI, if any, that Licensor specifies to be associated with 
the Work, unless such URI does not refer to the copyright notice or licensing information for the 
Work; and (iv) , consistent with Ssection 3(b), in the case of an Adaptation, a credit identifying 
the use of the Work in the Adaptation (e.g., “French translation of the Work by Original Author,” or 
“Screenplay based on original Work by Original Author”). The credit required by this Section 4(c) 
may be implemented in any reasonable manner; provided, however, that in the case of a Adapta-
tion or Collection, at a minimum such credit will appear, if a credit for all contributing authors of 
the Adaptation or Collection appears, then as part of these credits and in a manner at least as 
prominent as the credits for the other contributing authors. For the avoidance of doubt, You may 
only use the credit required by this Section for the purpose of attribution in the manner set out 
above and, by exercising Your rights under this License, You may not implicitly or explicitly as-
sert or imply any connection with, sponsorship or endorsement by the Original Author, Licensor 
and/or Attribution Parties, as appropriate, of You or Your use of the Work, without the separate, 
express prior written permission of the Original Author, Licensor and/or Attribution Parties.
 d. Except as otherwise agreed in writing by the Licensor or as may be otherwise permitted by ap-
plicable law, if You Reproduce, Distribute or Publicly Perform the Work either by itself or as part 
of any Adaptations or Collections, You must not distort, mutilate, modify or take other deroga-
tory action in relation to the Work which would be prejudicial to the Original Author’s honor or 
reputation. Licensor agrees that in those jurisdictions (e.g. Japan), in which any exercise of the 
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right granted in Section 3(b) of this License (the right to make Adaptations) would be deemed to 
be a distortion, mutilation, modification or other derogatory action prejudicial to the Original Au-
thor’s honor and reputation, the Licensor will waive or not assert, as appropriate, this Section, to 
the fullest extent permitted by the applicable national law, to enable You to reasonably exercise 
Your right under Section 3(b) of this License (right to make Adaptations) but not otherwise.
5. Representations, Warranties and Disclaimer
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN WRITING, LICENSOR OFFERS THE WORK 
AS-IS AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE WORK, EX-
PRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF TITLE, 
MERCHANTIBILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF 
LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OF ABSENCE OF ERRORS, WHETHER OR NOT 
DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO 
SUCH EXCLUSION MAY NOT APPLY TO YOU.
6. Limitation on Liability.
EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, IN NO EVENT WILL LICENSOR BE LIABLE TO YOU 
ON ANY LEGAL THEORY FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY 
DAMAGES ARISING OUT OF THIS LICENSE OR THE USE OF THE WORK, EVEN IF LICENSOR HAS BEEN AD-
VISED OF THE POSSIBILITY OF SUCH DAMAGES.
7. Termination
 a. This License and the rights granted hereunder will terminate automatically upon any breach by 
You of the terms of this License. Individuals or entities who have received Adaptations or Collec-
tions from You under this License, however, will not have their licenses terminated provided such 
individuals or entities remain in full compliance with those licenses. Sections 1, 2, 5, 6, 7, and 8 
will survive any termination of this License.
 b. Subject to the above terms and conditions, the license granted here is perpetual (for the duration 
of the applicable copyright in the Work). Notwithstanding the above, Licensor reserves the right 
to release the Work under different license terms or to stop distributing the Work at any time; 
provided, however that any such election will not serve to withdraw this License (or any other 
license that has been, or is required to be, granted under the terms of this License), and this 
License will continue in full force and effect unless terminated as stated above.
8. Miscellaneous
 a. Each time You Distribute or Publicly Perform the Work or a Collection, the Licensor offers to the 
recipient a license to the Work on the same terms and conditions as the license granted to You 
under this License.
 b. Each time You Distribute or Publicly Perform an Adaptation, Licensor offers to the recipient a 
license to the original Work on the same terms and conditions as the license granted to You under 
this License.
 c. If any provision of this License is invalid or unenforceable under applicable law, it shall not affect 
the validity or enforceability of the remainder of the terms of this License, and without further 
action by the parties to this agreement, such provision shall be reformed to the minimum extent 
necessary to make such provision valid and enforceable.
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 d. No term or provision of this License shall be deemed waived and no breach consented to unless 
such waiver or consent shall be in writing and signed by the party to be charged with such waiver 
or consent.
 e. This License constitutes the entire agreement between the parties with respect to the Work 
licensed here. There are no understandings, agreements or representations with respect to 
the Work not specified here. Licensor shall not be bound by any additional provisions that may 
appear in any communication from You. This License may not be modified without the mutual 
written agreement of the Licensor and You.
 f. The rights granted under, and the subject matter referenced, in this License were drafted utilizing 
the terminology of the Berne Convention for the Protection of Literary and Artistic Works (as 
amended on September 28, 1979), the Rome Convention of 1961, the WIPO Copyright Treaty of 
1996, the WIPO Performances and Phonograms Treaty of 1996 and the Universal Copyright Con-
vention (as revised on July 24, 1971). These rights and subject matter take effect in the relevant 
jurisdiction in which the License terms are sought to be enforced according to the corresponding 
provisions of the implementation of those treaty provisions in the applicable national law. If the 
standard suite of rights granted under applicable copyright law includes additional rights not 
granted under this License, such additional rights are deemed to be included in the License; this 
License is not intended to restrict the license of any rights under applicable law.
Creative Commons Notice
Creative Commons is not a party to this License, and makes no warranty whatsoever in connection with 
the Work. Creative Commons will not be liable to You or any party on any legal theory for any damages 
whatsoever, including without limitation any general, special, incidental or consequential damages aris-
ing in connection to this license. Notwithstanding the foregoing two (2) sentences, if Creative Commons 
has expressly identified itself as the Licensor hereunder, it shall have all rights and obligations of Licensor.
Except for the limited purpose of indicating to the public that the Work is licensed under the CCPL, 
Creative Commons does not authorize the use by either party of the trademark “Creative Commons” 
or any related trademark or logo of Creative Commons without the prior written consent of Creative 
Commons. Any permitted use will be in compliance with Creative Commons’ then-current trademark 
usage guidelines, as may be published on its website or otherwise made available upon request from 
time to time. For the avoidance of doubt, this trademark restriction does not form part of the License.
Creative Commons may be contacted at https://creativecommons.org/.
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SUMMARY
Cancer survival increased substantially during the past decades. Accordingly, long-term 
consequences of cancer and its treatment have become increasingly important. A high 
prevalence of chronic health effects has been reported in both childhood and adult 
cancer survivors (Chapter 1). The aim of this thesis was to examine long-term endocrine 
and metabolic conditions, as well as their determinants in patients treated for cancer 
with a special focus on patients treated for craniopharyngioma.
Long-term endocrine and metabolic consequences of cancer and its treatment
The development of a subsequent neoplasm is an important long-term health condition 
in cancer survivors. We reviewed the literature on risk factors for subsequent endocrine-
related cancer in childhood cancer survivors. Thereby, we focused on secondary tumors 
of the breast and thyroid (Chapter 2). We identified the potential harmful effects of 
estrogen-progestin replacement therapy on radiation-induced breast cancer develop-
ment as the most important area for future research.
The metabolic syndrome is also a common long-term health effect in cancer survivors. 
An unhealthy lifestyle with insufficient physical activity seems an important risk factor. 
Therefore, we studied daily life physical activity in survivors of nephroblastoma and neu-
roblastoma relative to a control group not treated for cancer (Chapter 3). We observed a 
significantly lower level of physical activity in male neuroblastoma survivors compared 
to male control subjects. Female neuroblastoma survivors and male and female nephro-
blastoma survivors showed similar physical activity levels compared to control subjects.
Long-term endocrine and metabolic consequences in patients with 
craniopharyngioma
Craniopharyngiomas are benign intracranial neoplasms that affect children and adults. 
They may cause significant long-term tumor- and treatment-related morbidities. We 
studied long-term sequelae of various initial craniopharyngioma treatment strategies 
in both patients with childhood- and adult-onset craniopharyngioma (Chapter 4). 
Pituitary hormone deficiencies, visual impairment, and obesity were the most common 
long-term health conditions. 90Yttrium brachytherapy and cyst drainage resulted in 
similar long-term health effects as gross total resection and subtotal resection with or 
without radiotherapy. Recurrence-free survival was significantly lower after cyst drain-
age. Patients with childhood-onset disease showed a significantly higher prevalence 
of pituitary hormone deficiencies, morbid obesity, epilepsy, and psychiatric conditions 
compared to patients with adult-onset disease.
In addition, we investigated morbidity and mortality in Dutch and Swedish patients 
with craniopharyngioma relative to the general population (Chapter 5). We observed 
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excess morbidity due to type 2 diabetes mellitus and cerebral infarction, as well as excess 
total mortality and mortality due to circulatory and respiratory diseases. We identified 
hypothalamic and pituitary damage as the principal determinants.
The metabolic syndrome and its components in patients with 
craniopharyngioma
We studied the metabolic syndrome and its components in Dutch and Swedish patients 
with craniopharyngioma (Chapter 6). The metabolic syndrome and its components 
were significantly more common in patients with craniopharyngioma compared to 
the general population. In addition to hypothalamic and pituitary damage, visual im-
pairment was identified as an important risk factor. Excess morbidity and mortality in 
patients with craniopharyngioma may be mainly driven by the metabolic syndrome.
Bariatric surgery as an intervention for craniopharyngioma-related obesity
We investigated the efficacy and safety of bariatric surgery in Dutch and Swedish 
patients with craniopharyngioma relative to matched control subjects with common 
obesity (Chapter 7). After two years of follow-up, weight loss was comparable between 
patients with craniopharyngioma and control subjects with common obesity. Roux-en-Y 
gastric bypass, but not sleeve gastrectomy, resulted in similar weight loss. Both bariatric 
procedures seemed safe regarding their effects on hormone replacement therapy.
Conclusion and future perspectives
Not only patients with a malignant tumor, but also patients with a benign neoplasm (i.e. 
craniopharyngioma) are at risk for long-term tumor- and treatment-related endocrine 
and metabolic conditions (Chapter 8). Due to the rarity of a disease like craniopharyngi-
oma, centralization of care is recommended, as well as multi-institutional collaboration 
in research. Our international collaboration with the Sahlgrenska University Hospital in 
Gothenburg, Sweden, should be extended for future studies.
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SAMENvATTING
De overleving van kanker is de afgelopen decennia sterk verbeterd. Hierdoor wordt er 
meer aandacht besteed aan de lange termijn gevolgen van kanker en de bijbehorende 
behandeling. Eerdere onderzoeken hebben aangetoond dat overlevenden van kanker 
vaak last hebben van aandoeningen die een laat gevolg zijn van de eerdere kanker 
en bijbehorende behandeling (Hoofdstuk 1). Het doel van dit proefschrift was om 
(risicofactoren voor) endocriene en metabole lange termijn gevolgen van kanker en 
de behandeling van kanker vast te stellen. Hierbij werd speciaal aandacht besteed aan 
mensen met een craniopharyngioom.
Endocriene en metabole gevolgen van kanker en de behandeling van kanker
Een belangrijk lange termijn gevolg van de behandeling van kanker is het ontstaan van 
nieuwe tumoren. Wij hebben een overzichtsartikel gemaakt waarin wij risicofactoren 
beschrijven voor het ontstaan van nieuwe tumoren bij overlevenden van kinderkanker 
(Hoofdstuk 2). Hierbij hebben wij speciaal aandacht besteed aan borstkanker en schild-
klierkanker. Uit onze studie bleek dat er meer onderzoek nodig is naar het mogelijk 
risicoverhogend effect van hormonale suppletietherapie op borstkanker bij vrouwen 
die bestraald zijn op de borstregio.
Het metabool syndroom is een vaak voorkomende aandoening bij overlevenden van 
kanker. Een ongezonde levensstijl met een gebrek aan lichamelijke activiteit lijkt een be-
langrijke risicofactor. Daarom hebben wij lichamelijke activiteit onderzocht bij mensen 
die op de kinderleeftijd zijn behandeld voor een nier- of bijniertumor (Hoofdstuk 3). 
Mannen die voor een bijniertumor behandeld zijn, bleken significant minder actief dan 
controlepersonen. Vrouwen die voor een bijniertumor behandeld zijn, evenals mannen 
en vrouwen die voor een niertumor behandeld zijn, bleken even actief als controleper-
sonen.
Endocriene en metabole gevolgen van craniopharyngiomen
Craniopharyngiomen zijn goedaardige hersentumoren die zowel bij kinderen als 
volwassenen voorkomen. Lange termijn problemen veroorzaakt door de tumor en 
bijbehorende behandeling komen vaak voor. Wij hebben lange termijn gevolgen van 
verschillende behandelingen van craniopharyngiomen onderzocht. Tevens hebben wij 
deze lange termijn gevolgen vergeleken tussen mensen die zich als kind en volwassene 
presenteerden met een craniopharyngioom (Hoofdstuk 4). In ons onderzoek waren 
hormoonuitval, problemen met het zicht en obesitas de meest voorkomende lange 
termijn problemen. Behandeling middels operatie, bestraling, 90Yttrium brachytherapie 
en cysteaspiratie resulteerden in dezelfde lange termijn problemen. De kans op een 
recidieftumor was significant groter na behandeling met cysteaspiratie. Mensen die op 
212 Chapter 9
de kinderleeftijd gediagnosticeerd zijn met een craniopharyngioom hadden significant 
vaker last van hormoonuitval, morbide obesitas, epilepsie en psychiatrische aandoenin-
gen.
Ook hebben wij lange termijn problemen vergeleken tussen mensen die behandeld 
zijn voor een craniopharyngioom en de algemene bevolking (Hoofdstuk 5). Mensen die 
behandeld zijn voor een craniopharyngioom hadden significant vaker last van ouder-
domssuikerziekte en herseninfarcten. Ook stierven zij significant vaker aan cardio- en 
cerebrovasculaire, alsmede respiratoire aandoeningen. Schade aan de hypothalamus en 
hypofyse bleek de belangrijkste risicofactor voor morbiditeit en mortaliteit.
Het metabool syndroom en zijn componenten bij craniopharyngioompatiënten 
Wij hebben het metabool syndroom en zijn componenten onderzocht bij mensen die 
behandeld zijn voor een craniopharyngioom (Hoofdstuk 6). Het metabool syndroom 
en zijn componenten kwamen significant vaker voor in vergelijking met de algemene 
bevolking. Naast schade aan de hypothalamus en hypofyse bleek een verminderd zicht 
een belangrijke risicofactor voor het metabool syndroom. Het metabool syndroom lijkt 
een belangrijke oorzaak te zijn voor het vaker voorkomen van morbiditeit en mortaliteit 
bij mensen met een craniopharyngioom.
Bariatrische chirurgie als behandeling van obesitas bij 
craniopharyngioompatiënten
Hypothalame schade is de belangrijkste oorzaak van obesitas bij mensen met een 
craniopharyngioom. Hierdoor is het bijzonder moeilijk om af te vallen middels een 
dieet en lichamelijke activiteit. Medicijnen die gewichtsverlies bevorderen zijn ook niet 
effectief. Daarom hebben wij de effectiviteit en veiligheid van bariatrische chirurgie 
onderzocht (Hoofdstuk 7). Twee jaar na bariatrische chirurgie middels een “Roux-en-Y 
gastric bypass” bleken mensen met een craniopharyngioom even veel af te vallen als 
controlepersonen zonder een craniopharyngioom. Het gewichtsverlies na een “sleeve 
gastrectomy” was significant minder bij patiënten met een craniopharyngioom. Beide 
operaties bleken veilig betreffende hun effecten op hormonale suppletietherapie.
Conclusie en aanbevelingen voor toekomstig onderzoek
Endocriene en metabole lange termijn gevolgen van kanker en de behandeling 
van kanker komen vaak voor, zowel bij mensen met een maligne als benigne tumor 
(Hoofdstuk 8). Omdat craniopharyngiomen zeldzaam zijn, zijn centralisatie van zorg 
en multi-institutionele samenwerking in onderzoek onontbeerlijk. Daarom zijn wij voor 
dit proefschrift een samenwerkingsverband aangegaan met de Sahlgrenska universiteit 
in Göteborg, Zweden. Voor toekomstig onderzoek dient deze samenwerking te worden 
uitgebreid.
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